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Summary 
 
Prion diseases are fatal neurodegenerative disorders that have the particularity of 
being caused by an infectious proteinaceous agent. The main player in this disease 
is a structural modification of the endogenous non-pathogenic prion protein (PrPC), 
termed PrPSc. Though PrPC is widely expressed in the body and highly conserved in 
mammals, its physiological function remains elusive. Moreover, Prnp-/- mice devoid of 
PrP have no strong evident phenotype, apart from being completely resistant to prion 
diseases. Interestingly, many PrPC mutants with deletions around the α-cleavage site 
of PrPC are highly toxic when expressed in transgenic mice and this toxicity is 
rescued by coexpression of wild-type PrPC. One of the main mysteries in the prion 
field is the elucidation of the molecular mechanisms that drive not only the toxicity of 
PrPSc, but also the pathology caused by these PrPC deletion mutants.  
To understand the principles behind PrP-dependent toxicity, first a model was 
conceptualized, which aimed to integrate and unify the largest possible set of 
experimental evidences already available in the literature. The goal was to conceive 
a framework that congregates a putative function of PrPC, as well as the pathological 
features of prion diseases and of prionopathies caused by PrPC deletion mutants. 
From all possible models considered, the most parsimonic one established that α-
cleavage of the PrPC central domain is crucial for regulating PrPC function and for 
explaining PrP-dependent toxicity. The model was also based on a main set of 
assumptions, which are that internalization of uncleaved PrPC contributes to cell 
activation, and that miss-regulation of this process results in cell over-activation and 
consequent cell death. Therefore, I decided to study these two paradigms, which are 
the α-cleavage, and the toxicity due to the putative cell hyper-activation derived from 
PrPC miss-regulation.  
Concerning α-cleavage, the main grounds sustaining its importance are that both 
PrPSc and all toxic PrPC deletion mutants have a strong impairment on α-cleavage. In 
this project I tried to identify the PrPC domains neighbouring the α-cleavage site, 
which play a role in mediating this proteolysis.  Assessment of the α-cleavage rate of 
a large number of PrPC mutants designed in this study revealed that neither 
substitution of the amino-acid residues at the cleavage site, replacement or inversion 
of the charged residues, mutation of the palindromic region, nor exchange of the 
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hydrophobic amino-acids, had major effects on the degree of α-cleavage. Also, short 
deletions at the cleavage site had only a mild effect on PrPC proteolysis. However, an 
increase in the size of the deletion resulted in a gradual decrease of α-cleavage rate, 
which was virtually blocked in the deletion mutant PrPΔ(106-119). These results suggest 
that cleavage of PrPC is largely sequence independent, which is an uncommon 
feature that can find parallelism with the proteolytic plasticity of the γ-secretase. 
To investigate the second paradigm, that PrPC is a modulator of cell activation, and 
that miss-regulation of its function can result in cell death, the impact of PrPC on 
lymphocyte activation and positive and negative selection of lymphocytes was 
assessed. This study suggested that PrPC is strongly up-regulated in activated T-
cells, and that it is found at high quantities in activated lymphocytes, in cells 
undergoing positive selection, and in populations that traditionally have high reactivity 
to antigens, like regulatory T-cells and marginal zone B-cells. An alteration of the 
lymphocytic homeostasis in mice deficient of or overexpressing PrPC was also 
observed. This alteration could be explained by a deletion of the transgenic cells with 
high levels of PrPC during the negative selection of auto-reactive cells, and by an 
arrest in development due to anergy of Prnp-/- lymphocytes. In addition, it was shown 
that the costimulatory CD3 molecule is down-regulated in circulating T-cells from 
PrPC-overexpressing mice, probably in order to re-establish the activation threshold, 
which might have been decreased due to the high presence of PrPC. Finally, I 
showed that PrPC overexpression partially rescues the impairment on development of 
CD4 T-cells in mice devoid of MHC class II, which is essential for providing an 
activatory signal to these cells. 
Taken together, here I propose a unifying model for PrP function and PrP-
dependent toxicity, assessed the main assumption, and studied the principles 
governing α-cleavage, which is the main mechanism of this model. 
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Zusammenfassung 
 
Prionenkrankungen sind fatale neurodegenerative Erkrankungen, deren 
Besonderheit es ist, ein infektiöses Protein als Ursache zu haben. Der 
Hauptverursacher dieser Erkrankung ist eine strukturell missgefaltete Version des 
endogenen, nicht-pathogenen Prionenproteins (PrPC), genannt PrPSc. Obwohl PrPC 
praktisch im gesamten Organismus vorkommt und die Sequenz in Säugetieren stark 
konserviert ist, blieb die Frage der physiologischen Funktion bisher ungelöst. 
Überdies haben Prnp-/- Mäuse ohne das Prion-Protein keinen stark ausgeprägten 
Phänotyp - ausser dass sie komplett resistent gegen Prionen-Erkrankung sind. 
Interessanterweise sind viele PrP-Mutationen mit einer Deletion in der Nähe der -
Schnittstelle von PrPC extrem toxisch, wenn sie in transgenen Mäusen exprimiert 
werden. Diese Toxizität wird aber bei gleichzeitiger Expression von PrPC 
aufgehoben. Eines der grossen Mysterien im Bereich der Prionen bleibt die 
Aufklärung der molekularen Mechanismen, die der Toxizität von PrPSc wie auch der 
Deletionsmutanten von PrPC zugrunde liegen. 
Um die Prinzipien, die hinter der PrP-abhängigen Toxizität stehen, zu beleuchten, 
entwarf ich ein Modell, das möglichst viele bereits publizierter experimenteller 
Beweise integriert. Das Ziel war ein Model, der sowohl die mögliche Funktion von 
PrPC, wie auch die pathologischen Charakteristika von übertragbarer 
Prionenerkrankungen und der Deletionsmutanten erklärt. Das plausibelste Model 
wäre, dass die -Schnittstelle in der zentralen Domäne des Prion-Proteins essentiell 
für die Funktion des Proteins ist. Die Konsequenz wäre, dass eine Fehl-Regulation 
der proteolytischen Spaltung eine konstante Internalisation von aktivem PrP zur 
Folge hat, was eine Erhöhung des Aktivierungsstatus der Zelle hat und 
schlussendlich den Zelltod auslöst. Daraufhin beschloss ich, die  Spaltung an der α-
Schnittstelle und die Toxizität, die möglicherweise von der Hyperaktivierung, 
aufgrund einer PrPC-Fehlregulation verursacht wird, zu untersuchen. 
Dass die -Spaltung tatsächlich äusserst wichtig ist, wird dadurch unterstützt, dass 
sowohl PrPSc, als auch alle toxischen PrPC Mutanten eine ausgeprägte 
Beeinträchtigung der -Spaltung aufweisen. Mein Ziel war die Identifikation von PrPC 
Domänen, die die -Spaltung ermöglichen, und ihre Charakteristika zu 
determinieren. Ich habe deswegen eine Vielzahl von PrPC Mutanten kreiert und ihre 
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proteolytische Aktivität analysiert. Weder die Substitution von Aminosäurenresten an 
der Schnittstelle, der Austausch oder die Ladungsumkehr von basischen 
Aminosäuren, Mutation der palindromischen Region oder der Austausch der 
hydrophobischen Aminosäuren hatten einen grossen Einfluss auf die Spaltung. Auch 
kleinere Deletionen um die Spaltungstelle resultierten in geringer Beeinträchtigung 
des Spaltunsprozesses. Das Entfernen grösserer Bereiche hingegen reduzierte die 
-Spaltungsrate. Im Falle der Deletionsmutante PrPΔ(106-119) tratt praktisch keine 
Spaltung mehr auf. Daraus schliesse ich, dass die Spaltung von PrPC grösstenteils 
sequenzunabhängig ist, was mit der proteolytischen Aktivität der -Sekretase 
verglichen werden kann.  
Um das zweite Paradigma, PrPC als Modulator der Zellaktivität, beziehungsweise die 
Fehlregulation seiner Funktion die zum Zelltod führen kann, zu studieren, habe ich 
die Entwicklung von Lymphozyten untersucht. Ich analysierte die Expression von 
PrPC während der Lymphocyten-Aktivierung, und der positiven und negativen 
Selektion von Lymphozyten. Dabei stellte ich eine starke Hochregulation von PrPC in 
aktivierten T Zellen fest. Ausserdem konnte ich erhöhte PrP-Werte auf aktivierten 
Lymphozyten, und während der positiven Selektion, und in reaktiven Populationen 
wie zum Beispiel regulatorischen T Zellen oder B Zellen der Marginalzone 
nachweisen. Bei der Analyse von Prnp-/- und PrP überexprimierenden Mäusen, 
konnte ich Veränderungen in der Homeostase der Lymphozytenpopulationen 
feststellen. Ein Grund dafür könnte die Deletion von Zellen mit übermässiger PrPC 
Expression, während der negativen Selektion von autoreaktiven Zellen, sein. Prnp-/- 
Lymphozyten hingegen reifen aufgrund von Aktivitätsmangel nicht vollständig. 
Ausserdem konnte ich zeigen, dass das Co-Stimulationsmolekül CD3 in 
zirkulierenden T Zellen von PrPC überexprimierenden Mäusen runterreguliert wird, 
möglicherweise um einen ausgeglichenen Aktivitätszustand der Zelle herstellen zu 
können, welcher durch die grosse Menge an PrPC reduziert ist. Schliesslich konnte 
ich zeigen, dass die Überexpression von PrPC partiell die Beeinträchtigung der 
Entwicklung von CD4 positiven T Zellen verbessern kann. Dafür analysierte ich MHC 
class II defiziente Mäuse.  MHC class II ist wichtig für die Zellaktivierung während der 
Entwicklung. MHC II defizienten Mäusen fehlen daher CD4 positive Zellen.  
Zusammenfassend haben ich hiermit ein Modell entwickelt, das PrP-Funktion und 
PrP-induzierte Toxizität miteinander vereint, konnte dessen Grundannahmen 
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bestätigen, und die -Spaltung eingehend charakterisieren, welche laut unserer 
Hypothese der Hauptmechanismus ist. 
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Abbreviations 
 
aa amino acid 
ADAM a desintegrin and metalloprotease domain 
APC antigen-presenting cell 
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BCR B-cell receptor 
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CNS central nervous system 
Con A concanavalin A 
CR complement receptor 
CWD chronic wasting disease 
Da Daltons 
DC dendritic cell 
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Dpl Doppel 
EGFP enhanced green fluorescent protein 
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ETP early T lineage precursors 
  10
FCS fetal calf serum 
FDC follicular dendritic cell 
FFI fatal familial insomnia 
FO Folicular B-cells 
Fr fraction 
GFP green fluorescent protein 
GPI glycosylphosphatidylinositol 
GSS Gerstmann-Sträussler-Scheinker syndrome 
HC hydrophobic core 
HLA human leukocyte antigen 
HRP horseradish peroxidase 
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IL interleukin 
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MHC Major Histocompatibility complex 
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N2 N-proximal product of β-cleavage 
OR octarepeats 
ORF open reading frame 
PBS phosphate buffered saline 
PK proteinase K 
PMA 12-O-Tetradecanoylphorbol-13-acetate 
Pre-B Pre B-cells 
Prnd murine doppel gene 
Prnp murine PrP gene 
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Pro-B pro B-cells 
PrP prion protein 
PrPase putative protease complex involved in α-cleavage of PrPC 
PrPC cellular isoform of the prion protein 
PrPSc pathological isoform of the prion protein 
SP single positive 
T transitional B-cells 
TCR T-cell receptor 
TdT terminal deoxynucleotidyl transferase 
TME transmissible mink encaphalopathy 
T-reg regulatory T-cell 
TSE Transmissible spongiform encephalopathy 
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w.o. weeks old 
Wt wild-type 
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1. Introduction 
1.1. Prion diseases 
1.1.1. Definition of prion diseases 
 
The term “Prion” was first created in 1982 by Prusiner (Prusiner 1982) to 
characterize a proteinaceous and infectious particle. Therefore, “Prion Diseases” 
refers to all infectious diseases caused by a nucleic-acid free, self replicating 
proteinaceous agent. And this is the fundamental postulate of the protein-only 
hypothesis (Griffith 1967; Prusiner 1982). However, it is still arguable if this infectious 
agent is completely devoid of nucleic acids and even if this can ever be proved 
(Adams 1991; Aguzzi and Weissmann 1997; Deleault et al. 2003). 
Data available until now strongly suggests that the transmissible agent of all prion 
diseases in mammals is mainly composed of the toxic isoform of the cellular prion 
protein (PrPC), named PrPSc, and its infectivity and toxicity depended on PrPC 
expression (Büeler et al. 1993; Brandner et al. 1996a). And because these diseases 
also share the feature of being transmissible spongiform encephalopaties (TSE), the 
term Prion Diseases has now been popularly associated with transmissible diseases 
that have PrPSc as the infectious agent. And this is the definition of “Prion Diseases” I 
will use in this Dissertation. It is however important to note that there have been 
growing laboratorial examples of other proteinaceous agents that can form infectious 
aggregates in mice (Lundmark et al. 2002; Kane et al. 2000; Walker et al. 2002; Xing 
et al. 2001) and that can even show amyloid strain properties (Xing et al. 2002).  
There is also another group of fatal diseases that result from mutations on Prnp 
gene, which encodes for PrPC (Aguzzi et al. 2008a). These diseases are not 
infectious, and therefore the term “Prion Diseases” is not applicable. For this reason 
in this Dissertation I will designate them “prionopathies”. 
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1.1.2. Animal prion diseases 
 
There are several described animal prion diseases. From the natural occurring 
prion diseases, the origin is still poorly understood, and it is still not clear which 
diseases had a sporadic origin and which ones resulted from species barrier and 
further adaptation of the infectious agent. 
The earliest recorded descriptions of a prion disease refer to scrapie in sheep and 
date from the mid 18th century (Aguzzi 2006; Schneider et al. 2008). This name 
referred to the clinical behaviour shown by sick animals, which scraped or bit areas 
affected by pruritus (Lampert et al. 1972). The described disease lead to animal 
death in 3 to 6 months (Cuille and Chelle 1939) and appeared to be acquired by oral-
digestive route (Hadlow et al. 1982). However, and unlike other prion diseases, 
sheep scrapie is considered to be not transmissible to humans (Chatelain et al. 1981; 
Smith and Bradley 2003). 
Other examples of animal prion diseases include Transmissible Mink 
Encephalopathy (TME) which is a rare prion disease identified in minks  in the 1940s 
(Hadlow 1999) and transmissible to many other mammal species (Marsh et al. 1969; 
Eckroade et al. 1973). Likewise, Chronic Wasting Disease (CWD) is another fatal 
prion disease, first identified in the late 1960s in deer (Williams and Young 1980) and 
later in elk (Williams and Young 1982). Unlike the other most common prion diseases 
in animals, where the manifestation of the disease is strongly characterized by 
neurological disabilities, in CWD the clinical signs are more predominantly described 
as loss of body condition and emanation, and there is a strong component of 
horizontal transmission through saliva and other secreta or excrements (Sigurdson 
2008). 
Probably the most dramatic animal TSE is bovine spongiform encephalopathy 
(BSE). It was first reported in United Kingdom in 1985, and was suggested that it 
originated from meet and bone food preparations from scrapie infected carcasses or 
a rare sporadic occurrence of the disease in cattle (Smith and Bradley 2003), 
although other hypothesis are also considered (Colchester and Colchester 2005). 
This disease is transmissible to Humans upon contaminated food intake, and is 
unvariably fatal. The recent world outbreak of an until recently undiscribed disease, 
also added to the current importance and public awareness about this TSE. 
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1.1.3. Human prion diseases 
 
The first descriptions of human prion diseases where done in the 1920s by 
Creutzfeldt and Jakob (Creutzfeldt 1920; Jakob 1921) and therefore named 
Creutzfeldt-Jakob Disease (CJD). Though very studied because of its particular 
infectious characteristics, the incidence of this disease is rare, with a global incidence 
of one to two new occurrences per million people per annum. The most frequent form 
is the sporadic CJD (sCJD), representing about 75-85% of all human prion cases 
(Brandel et al. 2000); (http://www.cjd.ed.ac.uk/figures.htm) and generally only 
manifests itself during adulthood (in the 45-75 year old group), and results in death 
commonly within 6 months after the onset of the clinical manifestations (Collinge 
1997). This disease arises through rare spontaneous misfolding of PrPC into an 
amyloid form, or through somatic mutations in Prnp gene and its incidence is 
positively correlated with homozygosity at the polymorphic codon 129 of Prnp, which 
encodes either for methionine or valine (Aguzzi et al. 2007a).  
Another group of human prion diseases are familial forms which account for around 
10% of prion cases in Europe (www.eurocjd.ed.ac.uk). These are heterogeneous 
diseases acquired through genetic mutations in Prnp gene. Although the clinic 
distinction between these diseases is not clear (Collinge et al. 1992), genetically they 
are mainly divided into familial CJD (fCJD), which is clinically similar to sCJD, 
Gerstmann-Sträussler-Scheinker disease (GSS) (Gerstmann et al. 1935), frequently 
associated with PrP P101L mutation, and Fatal Familial Insomnia (FFI) mainly 
connected with the D178N substitution (Medori et al. 1992). From these familial 
cases, fCJD is the most common one, with many attributed hereditary Prnp 
mutations (Gambetti et al. 2003). 
Kuru disease (Gajdusek and Zigas 1959; Berndt 1981), means shiver or shake in 
Fore language, was the first case of a human to human transmission of a prion 
disease. It was an epidemic circumscribed to the Fore natives in Papua New Guinea, 
supposedly transmitted through cannibalism (Goldfarb 2002). 
The disease that generated highest awareness among the public for the past few 
years is the variant form of CJD (vCJD). First described in 1996 (Will et al. 1996) it 
had an earlier onset of disease and a longer clinical course, if compared to other 
human TSEs. This new disease was later linked to consumption of BSE infected 
bovine material (Collinge and Rossor 1996; Weissmann and Aguzzi 1997).  
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A big clinical challenge is related with the various cases of CJD acquired by 
iatrogenic exposure to human infected material (iCJD), mainly during transplants of 
cornea (Duffy et al. 1974), dura mater (Thadani et al. 1988), or growth hormone 
purified from human cadavers (Lazarus 1985). Moreover, the reports about 
secondary transmissions of prions in blood transfusions (Llewelyn et al. 2004; Peden 
et al. 2004; Wroe et al. 2006) increased the awareness to the dangerous of the 
spread of CJD in clinical procedures.  These reports stress the need of improvement 
of diagnostic tools for screening CJD-infected material in donors. 
 
1.1.4. PrPSc as the prion transmission agent 
The first successful proofs of transmission of scrapie were obtained by Cuillé and 
Chelle (Cuille and Chelle 1939). They were the firsts to perform inoculation 
experiments in a controlled way and in a time frame long enough to allow them to 
obtain positive results. The theory that scrapie was caused by a “slow virus” became 
gradually popular. However, it is important to take in consideration the fact that at the 
time of those experiments the definition of virus was attributed to an infectious agent 
that could turn on its own synthesis and replication, which did not imply that a virus 
should contain nucleic acids. This aspect of the nucleic acid issue was addressed by 
Alper and colleagues in an experiment that showed that strong UV treatment did not 
inactivate the infectious agent. The conclusion was that the scrapie infectious agent 
could not contain more than a 800bp nucleic acid fragment (Alper et al. 1966), 
speculating that the replicating agent should have a polysaccharide nature (Alper et 
al. 1967; Field 1966). Following several studies and theories, Prusiner published the 
Nobel Prize winning “protein only” hypothesis (Prusiner 1982). This theory postulated 
that the nature of the scrapie infectious agent was proteic. And it went further, by 
proposing the “heretical” notion that it was uniquely composed of a protein with self 
replicating properties, denominated “prion”, which stood for “proteinaceous 
infectious”. But it was only after the identification of the PrPSc (Bolton et al. 1982; 
Prusiner et al. 1983), and the description of the normal PrPC (Oesch et al. 1985; 
Basler et al. 1986), that the work hypothesis of the mathematician Griffith started to 
have public relevance (Griffith 1967). Indeed he was the first one to propose a 
consistent model describing the scrapie agent as a protein. But his model went 
further than Prusiner’s, because all explanations Griffith proposed implied that the 
prion protein had to be host encoded. He speculated that the scrapie agent is a seed 
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of modified protein, and that the native host encoded protein attaches to this seed, 
which eventually grows and divides itself into new seeds. Though this model was 
published 15 years before the publication of the Nobel Prize awarded protein-only 
hypothesis (Prusiner 1982), it had stronger assumptions that are now very close to 
the currently accepted principles. PrPC is protease sensitive, detergent soluble, host 
encoded and its expression is independent of scrapie infection (Oesch et al. 1985; 
Basler et al. 1986). In contrast,  PrPSc is the protease resistant core that is 
specifically associated with prion disease (Meyer et al. 1986). 
The next phase of prion research started with experiments focusing on PrPC 
transgenic mice. Scott and coworkers showed a positive correlation between prion 
incubation time and transgenic PrPC expression (Scott et al. 1989). Later on, it was 
discovered that Prnp0/0 mice, devoid of PrPC, were resistant to scrapie and did not 
propagate its infectivity (Büeler et al. 1993; Prusiner et al. 1993; Sailer et al. 1994). 
But the most important evidence for the role of PrPC in prion diseases was the finding 
that Prnp0/0 brain tissue was healthy and did not propagate prions, even when in 
contact with scrapie infected brain graft (Brandner et al. 1996a); and that PrPC was 
determinant for the spread of infectivity (Brandner et al. 1996b). 
The remaining supporting research for the protein only hypothesis arose with the 
controversial experiment that claimed the conversion of recombinant PrPC fibers into 
synthetic mammalian prions (Legname et al. 2004; Couzin 2004), and also the 
amplification in vitro of PrPSc in healthy brain homogenates by protein misfolding 
cyclic amplification (PMCA) (Castilla et al. 2005; Saa et al. 2006). The latest 
advances in generating PrPSc in vitro from a synthetic non infectious material were 
provided with the still arguable results from de novo generation of scrapie using PrPC 
and a mixture of lipids and a synthetic polyanion (Deleault et al. 2007; Aguzzi et al. 
2008a). Despite these efforts, it is believed that it is scientifically impossible to 
disprove that a virus, and not PrPSc, is the true scrapie infectious agent (Aguzzi and 
Weissmann 1997) and therefore to prove the protein only hypothesis. 
 
1.1.5. PrPC conversion into PrPSc 
 
Structural studies on PrP molecule suggest that around 40% of PrPC molecule is 
organized in an α-helical structure, and 3% in β-sheet conformation (Pan et al. 1993). 
In contrast, PrPSc has a β-sheet content of about 40%, and 30% α-helix (Pan et al. 
 1993; Safar et al. 1993). Given these two distinct structural forms of the same 
protein, there are intriguing questions to be asked: How does this transition from 
PrPC to PrPSc occur? What is the driving force for this sudden β-sheet conformation 
acquisition? Is it an all or nothing effect of is there a stable intermediate 
conformation? 
There were many studies performed with PrP fibrils, aiming to structurally describe 
the transition of PrPC into PrPSc (Stohr et al. 2008), but these studies are far from 
being clarifying. This is because it is still debatable if these fibrils are infectious 
(Couzin 2004; Aguzzi et al. 2008a), and also due to the fact that only part of the 
structure of PrPC is known (Riek et al. 1996; Hornemann et al. 1997; Knaus et al. 
2001). There are however two main theoretical models for PrPC conversion into PrPSc 
(Figure 1.1) (Weissmann 1999).  
 
 
Figure 1.1: Main conceptual models for conversion of PrPC into PrPSc.  A) The Refolding Model; 
B) The Seeding Model. Adapted from (Aguzzi and Sigurdson 2004). 
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The refolding model proposes that there is a high energy barrier between the PrPC 
and the PrPSc conformations and that the former only converts into the later upon 
interaction with PrPSc, who serves as a template (Figure 1.1 A). It also requires the 
help of a chaperone and an energy source, in order to support the partial unfolding of 
PrPC and refolding into PrPSc (Prusiner 1991). This process should be repeated in a 
slow passed way, until large PrPSc aggregates are formed. 
In contrast, the seeding model, proposes that PrPC conformation coexists in 
equilibrium with the PrPSc conformation or with one of its precursors. It assumes that 
this PrPSc structure is unstable and is stabilized only when aggregated in an 
oligomeric form that functions as a seed. It also proposes that the formation of this 
seed is a very rare event, because it demands the presence of a substantial number 
of molecules, but when it is formed, monomeric PrPSc units are added on a fast pace 
and result in the formation of big fibrils that eventually break and generate new 
seeds. This model is the one that appears to be supported by most of the 
experimental data (Gajdusek 1988; Brown and Gajdusek 1991; Jarrett and Lansbury 
1993), however this question is still far from being resolved (Aguzzi and Sigurdson 
2004), and there is the possibility that the biological aggregation of PrPC into PrPSc 
works in an intermediate form between these two models. 
 
1.1.6. Prion strains 
 
 Like viruses and other pathogens, the property of having different strains is also 
attributed to prions. This has been suggested already, before the proposition of the 
protein only hypothesis (Griffith 1967; Prusiner 1982), and resulted from studies 
where inoculations of different scrapie isolates were done into inbreed animals 
(Pattison and Millson 1961; Dickinson and Meikle 1971; Bruce and Dickinson 1987). 
These strains could be characterized by their specific clinical, biochemical and 
histopathological features in genetically identical hosts. Along with these properties, 
prion stains have also specific host tropisms, lymphotropic or neurotropic (Aguzzi 
2004; Aguzzi et al. 2007b), differential infectivity to other species (Caughey 2003), 
and most importantly, these individual strain qualities are very stable upon serial 
passage in inbreed animals (Aguzzi et al. 2007a). 
Because in all infectious entities, strain specifications are phenotypes coded by 
their genomes, it has also been suggested that prion structural properties are 
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specified by a nucleic portion that is part o the prion (Bruce and Dickinson 1987), by 
a host gene (Weissmann 1991), or some sort of host structure defining non-nucleic-
acid component (Prusiner 1991), but so far there is little evidence supporting these 
explanations. The alternative and currently more plausible model is the existence of 
PrPSc seeds with diverse strain specific conformations, acting as templates for de 
novo folding of PrPC into PrPSc (Bruce et al. 1991). Though the explanation for the 
formation of these distinct seeds remains elusive and little is known about the biology 
of prion strains, advances have been made in their typing. More recently, this typing 
has been mainly done using biochemical methods that function as a read out for the 
structure of prions. The most popular classification was based on the PrPSc 
fragments and proportion of its abundance upon PK treatment (Collinge et al. 1996; 
Parchi et al. 1996; Aguzzi et al. 2007a) and it was found that this strain typing has a 
good match with the clinical histopathological data (Parchi et al. 1999). But more 
recently a new advance has been made, using luminescent conjugated 
polyelectrolytes (LCPs). These particles appear to bind differentially to prion strains 
and to emit a wavelength spectrum that can be a finger-print of a polymeric 
aggregate (Nilsson et al. 2005; Sigurdson et al. 2007). 
 
1.1.7. Pathological features of prions 
 
The main pathological features of prion diseases are neuronal loss, vacuolation, 
reactive astrocytosis, and microgliosis (Crozet et al. 2008). In addition, PrP 
aggregates are frequently present mainly in white matter brain areas such as corpus 
callosum or the fibre tracts of striatum (Taraboulos et al. 1992a; Bendheim et al. 
1992), and these aggregates have generally a high degree of proteinase K (PK) 
resistance (Prusiner 1982; Aguzzi et al. 2007b). The early effects of prion 
pathogenesis are dependent on the availability of PrPC, because PrPSc is not toxic to 
Prnp-/- tissue (Brandner et al. 1996a; Brandner et al. 1996b), and the depletion of 
host PrPC expression in a scrapie infection context prevents disease and reverses 
spongiosis (Mallucci et al. 2003) and the early cognitive deficits (Mallucci et al. 2007). 
Among the referred early effects of prion pathogenesis, there occurs mainly 
synaptic loss (Cunningham et al. 2003), dendritic atrophy (Jamieson et al. 2001), and 
neuronal impairment with loss of GABAergic neurons and alteration of 
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neurotransmitters (Goudsmit et al. 1981; Diez et al. 2007; Bassant et al. 1986), which 
consequently result in neurocognitive deficit (Bareggi et al. 2003; Fraser et al. 2003).  
 
1.2. Characterization of PrPC 
1.2.1. Genetic characterization of PrPC 
 
The PrPC coding gene is Prnp, localized at the short arm of chromosome 20 in 
humans, and in the homologous region of chromosome 2 in the mouse (Sparkes et 
al. 1986). This gene is present and conserved in mammals, and in all cases its open 
reading frame (ORF) is contained within a single exon (Basler et al. 1986; Westaway 
et al. 1987), which in turn excludes the possibility of existence of alternative RNA 
splicing events. In hamsters the 5’-noncoding region contains an intron with about 10 
kb, and the ORF and 3’ untranslated region are in exon 2 (Basler et al. 1986). Mouse 
and sheep Prnp has another exon in the 5’ noncoding region, and exon 3 is 
analogous to the hamster exon 2 (Westaway et al. 1991; Westaway et al. 1994a). 
About the promoter regions, the specific delimitation of these domains is not known 
and no TATA-box was found, but upstream the ORF these are GC-rich repeats that 
are believed to participate in promoting the Prnp transcription. 
In terms of gene conservation, PrPC sequence shows a high degree of 
conservation within mammals (Figure 1.2.) and similar prion proteins were also 
identified in other vertebrates such as fish (Suzuki et al. 2002; Rivera-Milla et al. 
2003), birds (Gabriel et al. 1992), reptiles (Simonic et al. 2000) and amphibians 
(Strumbo et al. 2001), but never found in invertebrates (Aguzzi et al. 2008a). Though 
the sequence identity between all these non-mammalian PrPC molecules is limited, 
their structure appears to be highly conserved (Aguzzi et al. 2008a). Globally this 
suggests for an important function of PrPC, particularly in mammals, where the 
conservation is higher. However, this does not appear to be in accordance with 
experimental data (Büeler et al. 1992). 
 
 
 
  
Figure 1.2: Protein sequence alignment of PrP from multiple mammals. Short lines show identical 
residues and asterisks indicate deletions. The protein residues that differ from Human PrP are 
indicated explicitly. Adapted from (Wu et al. 2006b). 
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 1.2.2. Characterization of the structure of PrPC 
 
The PrPC molecule is a GPI-linked extracellular membrane protein (Stahl et al. 
1987) localized in cholesterol-rich lipid rafts of the cellular membrane (Taraboulos et 
al. 1995; Kaneko et al. 1997a). It is composed by a C-proximal globular domain 
containing 3 α-helices and 2 short β-sheets, and a N-proximal flexible domain, with 
an until now unresolved structure (Riek et al. 1996) (Figure 1.3). The N-terminus 
contains a signal sequence that is cleaved in endoplasmatic reticulum (ER), followed 
by a short charged domain that is reported to be important for PrPC internalization 
(Sunyach et al. 2003). Between amino acids (aa) 51-91 in mouse sequence, there is 
a series of 5 charged octarepeat sequences (OR), that where reported to interact 
with Cu2+ (Miura et al. 1999; Viles et al. 1999). It follows a small charged cluster (CC) 
and a large hydrophobic core (HC), which together form the central domain (CD). 
Between this cluster and hydrophobic core, PrPC is frequently cleaved, around the 
residues 110K↓H111 in human sequence or 109K↓H110 in mouse sequence (Chen 
et al. 1995), designated as the α-cleavage and the α-cleavage site respectively 
(Mange et al. 2004). This cleavage has been speculated to be a key regulator of PrP 
function or malfunction (Jimenez-Huete et al. 1998; Checler and Vincent 2002). 
There is also another important cleavage site, designated as β-cleavage site (Mange 
et al. 2004), localised several residues upstream (Caughey et al. 1989; Chen et al. 
1995). The C-proximal portion of PrPC is tighten by a disulfide bond and has 
glycosylation sites (Liao et al. 1986; Kretzschmar et al. 1986; Haraguchi et al. 1989). 
In the C-terminal part there is a sequence that is cleaved to give rise to a glycosyl 
phosphatidyl inositol (GPI) anchor (Stahl et al. 1987). Together, unprocessed murine 
PrPC is 254 aa long, and is later metabolised into a 209 aa long protein, with 25KDa, 
which can also be increased by 6 or 12KDa, depending if the molecule is un- mono- 
or diglycosylated respectively. 
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Figure 1.3: Structure of PrPC molecule. A) Schematic representation of mouse PrPC sequence, with 
representation of the main PrP domains: SP, signal peptide; OR, octarepeats; CC, charged cluster; 
HC, hydrophobic core; H1, helix 1; H2, helix 2; H3, helix 3; GPIp, GPI anchor signal peptide. Yellow 
stars indicate the glycosylation sites at aa180 and 196. Adapted from (Linden et al. 2008). B) NMR 
structure of human PrPC. yellow dots represent a region with flexible unresolved structure. Adapted 
from (Zahn et al. 2000). 
_________________________________________________________________________________ 
 
1.2.3. General PrP expression profiles 
 
The principal compartment for PrPC expression is the brain, especially in the grey 
matter where it is mainly prominent in neurons (Taraboulos et al. 1992a), but it also 
present in high levels in astrocytes and oligodendrocytes (Büeler et al. 1992). 
In the periphery, PrPC is also widely expressed, with higher evidence in the 
lymphatic tissues particularly in cells like Follicular Dendritic Cells (FDCs) (Ford et al. 
2002; Kranich et al. 2008), heart, skeletal muscle, kidney, lungs and gut (Ford et al. 
2002). Moreover, PrPC expression can be strongly increased by inflammatory 
conditions (Heikenwalder et al. 2005), suggesting that virtually PrPC can be highly 
expressed in any tissue. 
 
1.2.4. Biosynthesis and trafficking of PrPC 
 
PrPC synthesis is targeted to the ER, by its N-terminal 22aa long signal sequence, 
which is later cleaved.  After synthesis, the protein travels through the Golgi 
(Taraboulos et al. 1992b) to the lipid rafts at the cell membrane (Taraboulos et al. 
1995; Kaneko et al. 1997a). Before that, the protein is folded and post-tranlatedly 
modified with the formation of a disulfide bond, the adjunction of a GPI anchor (Stahl 
et al. 1987) and the possible addition of N-linked oligosaccharide chains (Haraguchi 
et al. 1989). In the membrane, PrPC is internalized within few minutes (Sunyach et al. 
2003) and in few hours cycles between the cell surface and the endocytic 
compartment (Caughey et al. 1989; Shyng et al. 1993). The internalization appears 
to occur via clathrin-coated pits and vesicles (Shyng et al. 1994; Laine et al. 2001), or 
by caveosomes in non neuronal cells (Peters et al. 2003), or by other mechanisms 
like bulk flow into endocytic organelles within 16-18h time (Morris et al. 2006). Inside 
the cell, PrPC has been found in many organelles (Campana et al. 2005), but most 
likely it goes to recycling endosomes (Sunyach et al. 2003). During all these 
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processes, PrPC can be shedded by α or β cleavage, with a  reported rate of about 
1% cleavage per hour (Shyng et al. 1993), or by cleavage in the GPI anchor 
(Borchelt et al. 1990). The sub-cellular localization of α and β cleavage has still not 
been clarified, although reports suggested that it occurs in an acidified endocytic 
compartment (Shyng et al. 1993).  
 
1.2.5. The physiological function of PrPC 
 
The biggest mystery in the prion field is the reason why a protein ubiquitously 
expressed in the body (Ford et al. 2002), strongly expressed in neurons (Taraboulos 
et al. 1992a), with homologs proteins within the general vertebrate taxon (Aguzzi et 
al. 2008a), highly conserved in mammals (Wu et al. 2006a), has a yet non major 
assigned physiological function. Moreover, it is still very puzzling the discovery that 
Prnp-/- mice do not present any major phenotype (Büeler et al. 1992), apart from 
being completely resistant to PrPSc infection (Büeler et al. 1993). However, there 
have been many minor phenotypes attributed to Prnp-/- mice, and many interacting 
partners assigned to PrPC molecule (Aguzzi et al. 2008a).  
As physiological functions assigned to PrPC, many studies were performed, 
suggesting various putative functions for PrPC. In the nervous system it have been 
proposed roles of PrPC in processes such as central nervous system (CNS) 
development (Steele et al. 2006), spatial outgrowth of neuritis and neuronal survival 
(Chen et al. 2003; Santuccione et al. 2005), synaptic transmission and reorganization 
of neuronal circuitry (Colling et al. 1997; Le Pichon et al. 2009), maintenance of Ca2+ 
-activated K+ currents CA1 pyramidal cells (Colling et al. 1996; Fuhrmann et al. 2006) 
and modulation of long-term potentiation (Collinge et al. 1994; Manson et al. 1995; 
Whittington et al. 1995). It has also been implicated both as anti-apoptotic (Zanata et 
al. 2002; Meslin et al. 2007) and pro-apoptotic agent (Paitel et al. 2003), as well as 
being reactive to oxidative stress (Brown et al. 1999a) and being able to reduce 
neuronal excitability and glutamate excitotoxicity (Khosravani et al. 2008). In addition, 
it has been also suggested a link between PrPC and resistance to epileptic seizures 
(Walz et al. 1999) and brain injury (Marciano et al. 2004), brain ischemia (Shyu et al. 
2005; Weise et al. 2006), attenuation of neuroinflamation (Tsutsui et al. 2008), 
neuroprotection (Chiarini et al. 2002), circadian rhythms and patterns (Tobler et al. 
1996), memory formation and cognition (Coitinho et al. 2003; Criado et al. 2005), 
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locomotor activity during exploration of a new environment (Roesler et al. 1999), 
olfaction (Le Pichon et al. 2009), neuromuscular physiology (Nico et al. 2005) and 
anxiety generation in stress situations. 
PrPC has also been associated with immune function, namely in supporting self-
renewal of hematopoietic stem cells (HSC) (Zhang et al. 2006), early activation in 
splenocytes (Mazzoni et al. 2005), down-regulation of  phagocytosis by macrophages 
(de Almeida et al. 2005), modulation of T-cell development (Jouvin-Marche et al. 
2006), T-cell activation (Mattei et al. 2004) and T-cell immune responsiveness 
(Bainbridge and Walker 2005; Ballerini et al. 2006). 
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2. A unifying model for the physiological function of PrPC 
and toxicity of PrPSc, Dpl and PrPC deletion mutants 
2.1. Introduction 
2.1.1. PrP mutations and toxicity 
 
The era of experimental prionopathies started with the generation of PrPC deficient 
mice. In the cases where the genetic ablation was restricted to the Prnp ORF, the 
knock-out mice were found normal with no altered phenotype (Büeler et al. 1992; 
Manson et al. 1994), but when large portions of the ORF flanking regions were 
deleted, mice suffered from Purkinje cell degeneration, which resulted in ataxia 
(Sakaguchi et al. 1996; Moore et al. 1999; Rossi et al. 2001). This phenotype was 
later attributed to an accidental over-expression of Prnd in the brain, a gene 16Kb 
downstream of Prnp that coded for the PrP-like protein Doppel (Dpl) (Moore et al. 
1999; Rossi et al. 2001). Similarly to Prnp, Prnd is conserved in mammals, with about 
25% genetic identity with the globular structured C-proximal half of PrPC, which is 
reflected by their similar structure (Silverman et al. 2000; Lu et al. 2000; Mo et al. 
2001). Dpl is highly expressed in embryogenesis, in brain of newborn mice (Li et al. 
2000), in the testis and heart (Moore et al. 1999), suggesting that this toxic protein in 
adult brain is important for brain development and other physiological processes. 
Interestingly, mice where PrPC expression was transgenically replaced by Dpl-like 
PrPC molecules also developed ataxia, cerebellar granule cell loss and a widespread 
white matter disease (Shmerling et al. 1998; Radovanovic et al. 2005). These 
molecules were truncated versions of PrPC (PrPΔ32-134 and PrPΔ32-121), with deletion of 
all the N-proximal flexible part, except the N-terminal small charged amino-acids that 
were claimed to play a role in directing PrPC internalization (Sunyach et al. 2003). 
Like Dpl, these mutants were composed by an intact globular domain membrane 
attached by a C-terminal GPI anchor, and with a short positively charged N-terminus, 
and their toxicity was rescued in a dose dependent manner of PrPC expression. 
However, transgenic mice bearing shorter deletions in PrPC (PrPΔ32-106, PrPΔ32-93 and 
PrPΔ32-80) showed no major toxicity in Prnp-/- background when transgenically 
expressed (Fischer et al. 1996; Shmerling et al. 1998). Moreover, PrPC mutants with 
shorter deletions that encompassed the hydrophobic core region (HC) and the 
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charged cluster (CC) (PrPΔ94-134 and PrPΔ105-125) were strongly pathogenic in the 
absence of normal PrPC, and like in the other cases, this toxicity was directly 
correlated with mutant transgene expression, and inversely correlated with PrPC 
coexpression (Baumann et al. 2007; Li et al. 2007). However, shorter deletions in 
these regions (PrPΔ114-121 and PrPΔ104-114) did not appear to be toxic (Baumann et al. 
2007; Hegde et al. 1998). More interestingly, transgenic mice with high over-
expression of PrPC also showed neuromuscular toxicity at very old age, although the 
circumstances were not clearly resolved (Westaway et al. 1994b). 
 
2.1.2. Mechanistic models for neurotoxicity of PrPC deletion mutants 
 
Many models have been postulated which aimed to explain the mechanisms of 
toxicity of PrPC deletion mutants, but the speculative degree of all of them is very 
high, due to lack of experimental evidences. 
One of the first models that aimed to explain the neurotoxicity of PrPC deletion 
mutants has come from Shmerling and colleagues. They proposed that there is a 
ligand for PrPC that transmits a survival signal when bound to PrPC. In addition, they 
also speculated that there is a molecule that mimics the PrPC domain responsible for 
interacting with its ligand which then replaces PrPC in transmitting the survival signal 
in Prnp-/- mice. Finally, Shmerling and coworkers propose that the reason why these 
PrPC mutants render toxicity in Prnp-/- background is because they out-compete the 
PrPC-replacing molecule in binding to its ligand, but are unable to provide the survival 
signal due to the deletion (Shmerling et al. 1998). 
Other models arose with the generation of more deletions in the CC and HC domains 
(Baumann et al. 2007; Li et al. 2007). One of them, the model from Li (Li et al. 2007), 
proposed that the binding of PrPC with its ligand provides a protective signal to the 
cell, and for this signal it is necessary a region within the CC and HC. When this 
signal is not present, the result of the binding is toxicity. This damage allegedly 
depends on the stability of the binding, which is assured by the other PrPC domains, 
with especial relevance to the N-proximal ones. 
Baumann proposed an alternative explanation, based on studies where not only PrPC 
was coexpressed with its deletion mutants, but also when two deletion mutants were 
coexpressed. In these experiments PrPΔ114-121 rendered toxicity only when 
coexpressed with PrPΔ94-134, but partially rescued the toxicity of PrPΔ32-134 (Baumann 
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et al. 2007). This model assumed that PrPC and its ligand only function in a dimmeric 
form (Priola et al. 1995). It further proposed that the dimerized ligand is stabilized by 
its binding to dimerized PrPC resulting into a survival signal. However, in absence of 
PrPC, the ligand is unstable, which results in a mild toxic signal. This toxicity is 
allegedly further enhanced if the ligand is stabilized by binding to a dominant 
negative deletion mutant of PrPC (Baumann et al. 2007). 
Another approach to the physiological mechanism for the toxicity of PrPC deletion 
mutants was proposed by Hegde and colleagues (Hegde et al. 1998). They proposed 
that the HC domain of PrPC can cross the ER membrane (Hegde and Lingappa 
1997), and therefore the C-proximal domain or the N-proximal domain can be in the 
lumen. They also proposed that toxicity is generated in conditions when the C-
proximal domain of PrPC stays in the lumen, which they suggested that happens as a 
function of the hydrophobicity of the HC region. 
 
2.1.3. Proteolytic processing of PrPC 
 
The exact localization of α-cleavage site is not yet completely resolved. Studies 
with PrPC human brain detected two western blot bands close to each other. These 
bands were assumed to be the C-proximal product of α-cleavage (C1). 
Radiosequencing of these bands revealed cleavage sites of 110-111KH↓M112 and 
109-110LK↓H111 for each of the two bands (Chen et al. 1995), which corresponds to 
110H↓V111 and 109K↓H110 in the murine aa sequence. However, it is questionable 
that such western blot format would have sufficient resolution to distinguish 
differences of one amino-acid, which would be 155 Da for a histidine residue. Later, it 
was shown that 3F4 antibody, which recognises the human 108-111 epitope of PrP 
(Bolton et al. 1991; Rogers et al. 1991), does not detect any product of α-cleavage, 
thus suggesting that the cleavage site is within those residues (Jimenez-Huete et al. 
1998). Also, in vitro experiments incubating recombinant mouse protein with 
plasminogen detected a C1 product of PrPC that was identified as starting at aa 110-
111HV from mouse sequence (Kornblatt et al. 2003), suggesting that cleavage 
probably occurred at 109K↓H110. There is another important cleavage, which is 
more prominent in PrPSc. It occurs in the OR region (Caughey et al. 1989; Chen et al. 
1995; Mange et al. 2004) and is designated β-cleavage (Mange et al. 2004). 
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The proteases involved in these cleavages are not known and there has been high 
speculation about this topic. Nevertheless, most studies point to an effect of 
metalloproteinases in proteolytic processing or PrPC. For example, Jimenez-Huete 
(Jimenez-Huete et al. 1998) showed a 75% cleavage inhibition, using 5mM EDTA, 
and this effect could be rescued by adding Cu2+ and Fe2+, indicating that proteolysis 
of PrPC could be mediated by Cu2+ and Fe2+ dependent metalloproteases. Also, in 
vitro studies involving over-expression of this class of enzymes suggested that 
ADAM10 (ADAM: A Desintegrin And Metalloprotease domain), ADAM17, and 
probably ADAM9 would play a role in PrPC cleavage (Vincent et al. 2001; Cisse et al. 
2005). However, other studies strongly challenged this data by showing that 10uM of 
EDTA had absolutely no effect on α-cleavage (Shyng et al. 1993). In contrast, 10uM 
of the serine protease inhibitor aprotinin substantially reduced C1 generation (Shyng 
et al. 1993). Also other molecules like plasminogen (Kornblatt et al. 2003) and protein 
kinase C (Vincent et al. 2000) have been suggested as important factors for PrPC α-
cleavage, and calpain for β-cleavage (Yadavalli et al. 2004).  Another study in post-
mortem individuals showed a positive correlation between ADAM10 expression and 
percentage of α-cleavage (Laffont-Proust et al. 2005). However the group only 
detected the protease in four samples and the specificity of this correlation it was not 
assessed. 
 
2.1.4. α-cleavage of PrPC and toxicity of prion diseases and 
prionopathies 
 
Studies on proteolytic processing of PrPC and PrPSc have shown that while the 
former mainly accumulates C1 cleavage fragment, the latter is cleaved much more 
upstream, in the β-cleavage site, generating a larger C-proximal product (C2) 
(Jimenez-Huete et al. 1998).  The reason for this difference in cleavage resides in the 
fact that C1 cleavage site is part of the PK-resistant core of PrPSc (Caughey et al. 
1989; Chen et al. 1995) and that the β-cleavage site is flanking this core (Caughey et 
al. 1989). However, it is interesting to observe that mice expressing only a deletion 
mutant form of PrPC resembling the C1, as PrPΔ23-134 and PrPΔ23-121, can not replicate 
PrPSc (Shmerling et al. 1998; Aguzzi et al. 2008a). An obvious suggestion that arises 
from these observations is that enhancement of α-cleavage in vivo could be a way to 
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diminish the availability of full-length PrPC for conversion into PrPSc. More 
interestingly is the observation that PrPC transgenic mutants that have a strong 
impairment of α-cleavage and C1 generation often show toxicity (Shmerling et al. 
1998; Baumann et al. 2007; Fischer et al. 1996; Li et al. 2007). This toxicity is 
dependent of the transgene expression, and can be rescued in a dose dependent 
manner by coexpression of normal PrPC, which is normally cleaved and produces a 
normal C1 fragment. Together this suggests a correlation between inhibition of α-
cleavage and generation of toxicity. 
 
2.2. Description of the model 
 
There have been already many conceptual models that aimed to explain the 
mechanisms of toxicity of PrPC mutants (Li et al. 2007; Baumann et al. 2007; Hegde 
et al. 1998; Shmerling et al. 1998), and many more for toxicity of prions (Aguzzi et al. 
2008b; Aguzzi et al. 2008a). But until now, little importance has been given to the 
hypothetical role of α-cleavage of PrPC as the main player in PrPC regulation and 
toxicity. In this section I suggest a complementary or alternative explanation to the 
various models that have been proposed until now.  
The main focus is the α-cleavage of PrPC. The model assumes that PrPC is a 
modulator of cell activation, as it has been suggested by others (Aguzzi et al. 2008a; 
Hu et al. 2008; Zomosa-Signoret et al. 2008; Mazzoni et al. 2005). In addition, it is 
also assumed that the charged amino-acids localized at the N-terminus of the mature 
PrPC molecule are important for its localization in a specific membrane environment, 
which should have an impact on the routes of trafficking of PrPC and on its function 
(Sunyach et al. 2003; Shyng et al. 1995; Nunziante et al. 2003; Taylor et al. 2005). 
Therefore, the cleaved C1 fragment would be devoid of this N-terminus charged 
domain, and for this reason it should have a different trafficking route, comparing to 
full length PrPC (Figure 2.1 A), as it was already shown in the N2a cell culture system 
(Nunziante et al. 2003). 
Thus, assuming that the globular domain of PrPC provides an activation signal when 
internalized by the coat-pit endocytic pathway targeted by the charged aa in the N-
terminus of PrPC (Sunyach et al. 2003; Shyng et al. 1995; Taylor et al. 2005), the α-
cleavage of PrPC would be a way to separate the supposed C1 signalling domain 
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from the N-terminus internalization domain. Therefore, cleavage of PrPC could be an 
efficient way to inhibit internalization of the globular domain of PrPC, as suggested by 
others (Nunziante et al. 2003; Sunyach et al. 2003), and to consequently regulate the 
cell activation role of PrPC (Aguzzi et al. 2008a; Hu et al. 2008; Zomosa-Signoret et 
al. 2008; Mazzoni et al. 2005) (Figure 2.1 A). 
 
2.2.1. Model predictions: the case of prionopathies caused by Dpl and 
PrPC deletion mutants 
 
The molecular pattern in PrPC deletion mutants that in vivo rendered the most 
dramatic toxic effect is a large deletion in the adjacent areas of α-cleavage site, 
including mainly the CC and the HD domains (Baumann et al. 2007; Li et al. 2007). 
Mutants bearing these deletions completely abrogated PrPC cleavage, (Baumann et 
al. 2007) and resulted in a very strong neonatal toxicity. The proposed model 
explains these surprising results by predicting that PrPC mutants, that have an intact 
effector globular domain and N-terminus charged domain, are constantly internalized 
through the coated-pit endocytic pathway and thereby provide a constant activatory 
signal (Figure 2.1 B). The lack of regulation of this activation should result in strong 
toxicity. 
Assuming that PrPC mutants and the cleaved N1 fragment compete for the same 
internalization ligand, it is expectable that the toxic effect of the formers can be 
rescued by coexpression of cleavable PrPC, in a dose dependent manner. Indeed, 
the limiting factor of specific ligands of coated-pit mediated endocytic pathways has 
already been observed with other molecules (Kaplan and Ward 1990; Ward and 
Kaplan 1990), and if this holds true for PrPC, it is likely that coexpression of toxic 
PrPC mutant and normal PrPC would result in competition of both molecules for the 
same ligand. This would finally contravene the toxic effect of the mutant. 
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Figure 2.1: Models for PrP-related toxicity. A) Cleavage of PrPC modulates its function: The N-
terminus polybasic domain of PrPC interacts with a coated-pit endocytic ligand (Sunyach et al. 2003; 
Shyng et al. 1995; Nunziante et al. 2003; Taylor et al. 2005), leading to its internalization. When the 
full length PrPC is endocytosed through the coated-pit dependent pathway, the C-proximal globular 
domain provides an activation signal. On the other hand, the cleaved N1 competes with PrPC for the 
internalization ligand and has no effect when endocytosed. Without the N-terminal charges, the C-
proximal domain is internalized through an alternative pathway (Nunziante et al. 2003; Sunyach et al. 
2003) and provides no activation. This model represents the cellular physiological conditions. B) 
Situation with PrPΔ94-134 (Baumann et al. 2007) and PrPΔ105-125 (Li et al. 2007) in Prnp0/0 background. 
These deletions in the α-cleavage site region inhibit the cleavage, and therefore the full-length form is 
continuously internalized, providing continuous activation signals, which results in strong toxicity, in 
spite of their low expression. C) Situation with PrPΔ32-134 (Shmerling et al. 1998) and Dpl (Moore et al. 
1999) in Prnp0/0 background: These molecules have an N-terminus polybasic domain attached to the 
globular domain. In these conditions cleavage is abrogated and the total protein is constantly 
internalized via the polybasic-binding ligand responsible for coated-pit mediated endocytosis. This 
provides a constant activation signal, which is not very strong, due to binding instability derived from 
the inexistence of the big portion of the N-proximal domain. (Continues on next page) 
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D) Situation in scenario of coexpression of the very toxic PrPΔ94-134 (red) with the mildly toxic PrP114-121 
(yellow) in Prnp0/0 background (Baumann et al. 2007). PrPΔ94-134 is uncleaved and is quickly 
internalized providing activatory signals. Due to the low expression of this protein, its endocytic ligands 
are below saturating conditions. The α-cleavage of PrP114-121 is impaired and therefore many full-length 
molecules interact with the free polybasic-binding ligand responsible for coated-pit mediated 
endocytosis, resulting in a toxic effect additive to the one of PrPΔ94-134. E) Situation of coexpression of 
the fairly toxic PrPΔ32-134 (orange) with the mildly toxic PrP114-121 (yellow) in Prnp0/0 background 
(Baumann et al. 2007). PrPΔ32-134 is uncleaved (Shmerling et al. 1998) and is internalized by 
interaction with its N-terminus polybasic-binding ligand responsible for coated-pit mediated 
endocytosis, providing a constant activation signal. The high expression of PrPΔ32-134 (Shmerling et al. 
1998) saturates the availability of free ligands. When coexpressed with PrP114-121, whose cleavage is 
partially impaired (Baumann et al. 2007), its binding with the N-terminus polybasic binding protein is 
outcompeted, due to the instability of this interaction, which resulted from the deletion of a big portion 
of the N-proximal domain. This competition partially rescues the toxicity of PrPΔ32-134. F) Situation of 
PrPSc infection (orange triangle). The α-cleavage of PrPSc is abrogated (Caughey et al. 1989; Chen et 
al. 1995), resulting in accumulation of uncleaved PrPSc molecules in the membrane, which compete 
with cleavable PrPC and N1 for the N-terminus polybasic binding protein, and therefore increases the 
rate of coated-pit mediated endocytosis of full-length PrPC. This will increase the amount of activatory 
signals and will result in toxicity. G) Situation of strong over-expression of PrPC. When the degree of 
overexpression of PrPC is extremely high (Westaway et al. 1994b), it can result in the saturation of the 
α-cleaving proteases, and therefore increase the amount of full-length PrPC coated-pit mediated 
endocytosis, in comparison with the intake of N1. This can increase the activation status of the cell 
and finally result in toxicity. 
___________________________________________________________________ 
 
There is an alternative mechanism to the one referred above, which is not 
exclusive, and may even work together with the afore-mentioned one. This is based 
on the assumption that the α-cleavage products C1 or N1 transmit an inhibitory signal 
opposite to the one of full-length PrPC. The result would be that the cleavable form of 
PrPC would inhibit dose dependently the toxicity of the PrPC uncleavable mutants. 
This phenomenon of the cleavage product having the opposite function of the full 
length form of the protein is widely known, especially in the context of the 
complement proteins (Muller-Eberhard et al. 1969; Manderson et al. 2004), and is a 
system that provides a good explanation for the absence of phenotype of Prnp-/- mice 
(Büeler et al. 1992).  
There are other two important toxic molecules: PrPΔ32-134 (Shmerling et al. 1998) 
and Dpl (Moore et al. 1999; Rossi et al. 2001). These are PrP-like proteins, with a 
GPI-linked globular domain and with the N-proximal domain restricted to an N-
terminus polybasic domain (Shmerling et al. 1998; Mo et al. 2001). These show 
milder toxicity than the ones referred previously, whose deletions are restricted to the 
CC and the HD domains (Baumann et al. 2007; Li et al. 2007; Shmerling et al. 1998; 
Moore et al. 1999) (Figure 2.1 C). The reason for this difference in toxicity may 
possibly result from the fact that molecules with a very short N-proximal tail may have 
a more unstable binding between N-terminal polybasic domain and its ligand 
responsible for coated-pit dependent endocytosis. 
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On the other hand, the observation that expression of the truncation of the globular 
domain of PrPC linked to the GPI anchor (PrPΔ141-131) results in cell toxicity when 
coexpressed with PrPC (C. Bridel and A. Aguzzi, unpublished data), can be explained 
by an aggregation of the mutant molecule with PrPC, which is expectable given the 
high amyloid propensity of the HC of PrPC (Kourie 2001). Such an aggregation could 
inhibit the α-cleavage and therefore diminish the generation of N1 product. This 
would lead to a toxic phenotype, dose dependently of PrPC expression. 
 
2.2.2. Model predictions: a more parsimonic explanation for Baumann’s 
effect 
 
This model can also provide a more parsimonic clarification of Baumann’s effect 
(Baumann et al. 2007) than the one provided in that publication. Baumann based his 
model on a mutant-ligand affinity hierarchy and on dimmeric property of those 
molecules, in order to explain the finding that the expression of a PrPΔ114-121 was 
innocuous in the presence or absence of full-length PrPC, but enhanced the toxicity of 
PrPΔ94-134, which had low expression (Baumann et al. 2007), and diminished that of 
PrPΔ32-134, which was highly expressed (Shmerling et al. 1998).  
According to the model I propose here, the simple assumption that in the paradigm 
of the low expressed PrPΔ94-134 there is no saturation of the ligand for the coated-pit 
mediated endocytic pathway, allows the deduction that coexpression of another 
deletion mutant with partial inhibition of α-cleavage (Baumann et al. 2007), which is 
not sufficient to generate a toxic phenotype per se, would add to the toxicity of 
PrPΔ94-134 (Figure 2.1. D). On the other hand, assuming that the high expression of 
PrPΔ32-134 saturates all the internalization ligands, it is expectable that coexpression 
with this PrPC deletion form, along with the low toxic mutant PrPΔ114-121 and with 
some of its N1 cleavage products, results in a competition for the ligand, and 
therefore would partially impair the toxicity of PrPΔ32-134 (Figure 2.1 E). 
This line of thought can equally be applied to explain the phenotype of secreted 
PrPC, PrPΔ232-254, which is a mutant that lacks the GPI anchor (Chesebro et al. 2005). 
According to unpublished data from F. Baumann, B. Chesebro and A. Aguzzi, this 
construct has no influence in toxicity of PrPΔ94-134 in a Prnp-/- background, but partially 
rescues toxicity of PrPΔ32-134 in absence of normal PrPC expression. F. Baumann and 
  36
A. Aguzzi showed that PrPΔ94-134,232-254, which is an anchorless form of the highly 
toxic form PrPΔ94-134, shows no phenotype when transgenically expressed in Prnp-/- 
mice (F. Baumann and A. Aguzzi, unpublished results), strongly suggesting that PrPC 
needs to be membrane attached in order to be functional. This therefore implies that 
the anchorless PrPΔ232-254 should not be functional if internalized. Thus, PrPΔ232-254 
may probably compete with PrPΔ32-134 for the limiting protein responsible for induction 
of coated-pit dependent endocytosis, which binds the PrP N-terminus polybasic 
sequence. In addition, PrPΔ232-254 may be cleaved outside the cell (Walmsley et al. 
2008), and though a cleavage outside the cell membrane should not be very effective 
in terms of correct localization of its products, these generated N1 fragments could 
be the competitors with PrPΔ32-134 for the internalization ligand. But independently if it 
is the full length secreted PrPΔ232-254, or if it is his N1 product that competes with toxic 
PrPΔ32-134 for the internalization ligand, the end result is that a non-functional 
molecule competes with a pathogenic one, and this process should partially lead to a 
rescue of the toxicity of PrPΔ32-134. 
On the other hand, given the low abundance of PrPΔ94-134 in transgenic mice 
(Baumann et al. 2007), the coexpression of secreted PrPΔ232-254 would not be 
sufficient to saturate the ligands for the PrP N-terminus polybasic region. In this 
scenario, the function of PrPΔ232-254 or of its N1 product would add to the high toxicity 
of PrPΔ94-134. But given the non-functionality of the former molecules, coexpression of 
these two constructs in transgenic mice would show no difference in toxicity, when 
compared to PrPΔ94-134 expressed alone.  
 
2.2.3. Model predictions: molecular mechanism of toxicity of PrPSc 
 
Assuming that PrPSc has a low cleavage rate, with no α-cleavage (Jimenez-Huete 
et al. 1998; Caughey et al. 1989; Chen et al. 1995), it is predictable by this model that 
an accumulation of uncleavable PrPSc in the cell membrane, or a PrPC cleavage 
inhibition by interacting with PrPSc, would considerably increase the internalization of 
the full length form of PrP, and diminish the intake of N1 cleavage product (Figure 2.1 
F). The end result is that PrPSc should induce systemic stress and toxicity in a very 
slow pace, and that it would only be toxic to cells expressing membrane bound PrPC, 
which corroborates with existing published data (Büeler et al. 1993; Brandner et al. 
1996a; Aguzzi et al. 2007a). 
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2.2.4. Model predictions: overexpression of normal PrPC 
 
In conditions where overexpression of PrPC would be so high that would saturate 
the availability of PrPC α-cleavage protease complex, there would be an 
accumulation of unprocessed PrPC. According to the proposed model, such 
accumulation would saturate the coated-pits endocytic ligand for the N-terminus of 
PrPC. As consequence, there would be a strong diminishment on regulation of the 
activatory signalling of PrPC, which could result in cell toxicity (Figure 2.1 G). Indeed 
is has already been reported such an effect in brain and in other organs, in mice 
over-expressing PrPC (Westaway et al. 1994b; Jouvin-Marche et al. 2006). 
Furthermore, an increase of cell activation in PrPC overexpressing conditions also 
explains the results suggesting that there is a higher incidence of tumours in mice 
overexpressing PrPC (P. Schwarz and A. Aguzzi, unpublished results), for the reason 
that it has been widely known that forced cell activation increases the probability of 
tumourgenesis (Tlsty and Coussens 2006; Tibes et al. 2005). Therefore, if 
overexpression of PrPC indeed induces activation, which can lead to toxicity, it is also 
expected that it will increase the probability of generating tumours in aged mice. 
 
2.3. Discussion 
 
As described previously, there have already been proposed models describing the 
molecular mechanisms of toxicity of modified PrP molecules (Shmerling et al. 1998; 
Hegde et al. 1998; Baumann et al. 2007; Li et al. 2007; Stefani and Dobson 2003; 
Brown 2002). However, the vast majority of them only attempt to elucidate either the 
toxic mechanisms of prionopathies in mice, or of PrPSc. Moreover, from the ones that 
address the noxious effect of PrPC deletion mutants and Dpl, only Baumann 
incorporated the complex network of toxic effects when PrPΔ114-121 is coexpressed 
with PrPΔ32-134 or with PrPΔ94-134 (Baumann et al. 2007). Together, this indicates that 
despite the high likelihood that the same principles govern the effects of PrPC, PrPSc 
and all PrP-like proteins, there have been very few attempts to incorporate toxicity of 
PrPSc and prionopathies in one single mechanistic model. It may probably be 
possible to incorporate all the toxicity of the prion field into an adapted version of 
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Baumann’s framework (Baumann et al. 2007), however this would most likely 
increase the amount of assumptions and the rigidity of the model, which would be a 
clear challenge to the law of parsimony. 
The proposed model therefore aimed to unify all the toxicity of PrPSc, PrPC mutants 
and its homolog Dpl, into one single mechanistically framework. And this may be the 
most simplistic and flexible set of explanations from all the prion-unifying models. The 
assumptions supporting it are: 
i) The PrPC N-terminus polybasic region binds to a ligand that targets a specific 
signal, which most likely is a coated-pit mediated internalization pathway. This 
suggestion is supported by findings from different labs (Sunyach et al. 2003; Shyng 
et al. 1995; Taylor et al. 2005), and one of the strongest evidences resulted from 
showing that incorporating this domain in GPI-linked Thy-1 was sufficient to induce a 
coated-pit dependent endocytosis (Sunyach et al. 2003), like the one shown for PrPC, 
and deletion of this domain or from PrPC would inhibit this endocytosis (Shyng et al. 
1995). 
ii) The carboxy-product of cleavage of the N-terminus positively charged amino acids 
is unable to be internalized by the same pathway as normal full length PrPC, and 
enters the cell in a very slow manner. Experimentally this has been successfully 
achieved in the N2a cell model (Shyng et al. 1995; Nunziante et al. 2003), which is a 
neuroblastoma cell line. 
iii)  Internalization of the C-proximal globular domain of PrP or of Dpl, via the coated-
pit endocytic pathway, generates a cell activation signal. This is the strongest 
assumption and there is not enough data to support it. On one hand there has been a 
strong body of evidence suggesting that PrPC participates in cell activation (Aguzzi et 
al. 2008a; Hu et al. 2008; Zomosa-Signoret et al. 2008; Mazzoni et al. 2005), 
however, given the innumerous functions and interacting partners attributed to PrPC 
(Aguzzi et al. 2008a; Zomosa-Signoret et al. 2008), this data lacks further support.  
Moreover, there has been little data restricting the cellular activation with the globular 
domain of PrP, maybe because it would demand to use a construct with only the C1 
and the N-terminus polybasic domain to target it to the right internalization pathway. 
The best examples of such molecules are PrPΔ32-134 and Dpl. While there have been 
few cell activation studies done with the former protein, the finding that Dpl is highly 
expressed in development tissues, including brain of newborn mice (Li et al. 2000), 
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may indicate for activatory role, and thence that the globular domain participates in 
cell activation. However this statement lacks further verification. 
iv) Another fundamental assumption is that the amount of the ligand for the PrP N-
terminus polybasic domain is limited. Because such a ligand has not been identified 
so far, it is difficult to support this assumption. However, it is already established that 
such endocytic pathways are strictly regulated (Mellman 1996; Kaplan and Ward 
1990; Ward and Kaplan 1990). This assumption goes further, by assuming that 
expression of the most toxic constructs is bellow saturation of this ligand, and that the 
availability of PrPΔ32-134 is so high that saturates the binding for the ligand of the N-
terminal positively charged domain. Although lacking experimental data, these 
assumptions are very reasonable, given the very low and the very high expression of 
the most toxic and the less toxic constructs, respectively (Shmerling et al. 1998; Li et 
al. 2007; Baumann et al. 2007). 
v) The regulation of the amount of α-cleaving protease available to cleave PrPC is 
another assumption. This is expectable given the fact that proteolytic pathways are 
usually strictly regulated (Ehrmann and Clausen 2004). The consequent result is that 
in high PrPC overexpressing conditions, it is possible that occasionally the amount of 
this protein would saturate the available proteases. 
vi) The assumption that molecules with a long N-proximal tail are more stable in 
terms of providing activatory signals or binding with the endocytic ligand, also 
remains to be proved. However, the most parsimonic explanation for the difference in 
toxicity between the highly toxic PrPC mutants with deletions restricted to the CC and 
HC (Baumann et al. 2007; Li et al. 2007), and the lower toxicity of constructs with 
almost all N-proximal domain deleted (Shmerling et al. 1998), may be the higher 
stability of the formers. 
vii) In order to incorporate unpublished results obtained from experiments with 
mutants expressing only the N-proximal PrPC domain linked with a C-terminus GPI 
(PrPΔ141-131; C. Bridel and A. Aguzzi, unpublished data), It is proposed that such a 
flexible and highly amyloidogenic molecule  (Kourie 2001) targeted to the same 
membrane microdomains of PrPC would generate an association between the N-
proximal part of these two molecules, and consequently impair accessibility to the 
PrPC α-cleavage site. 
viii) The other postulation necessary to incorporate unpublished data from F. 
Baumann, B. Chesebro and A. Aguzzi, is that a PrPC molecule needs to be 
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membrane bound by the GPI anchor, in order to exert its function. F. Baumann and 
A. Aguzzi showed already that PrPΔ94-134,232-254, which is the anchorless version of the 
highly toxic PrPΔ94-134, has no toxicity, and this supports the proposed hypothesis. 
ix) The final consideration is that the anchorless versions of PrPC (Chesebro et al. 
2005) and the N1 product of its α-cleavage (Walmsley et al. 2008) can be in such a 
concentration and proximity to the membrane, that allows them to be internalized by 
binding the ligand for the PrPC N-terminus polybasic residues. The parallel of this 
mechanism with the specific binding of several extracellular proteins to its cellular 
receptor suggests that the secretion of PrPC does not inhibit the ligation of this 
molecule to certain interacting partners at the membrane. 
Given all these assumptions, particularly the first three, the natural conclusion is 
that α-cleavage of PrPC is a crucial way to regulate the function of this protein, and as 
a result, to modulate its own potential toxicity. 
 
2.4. Outlook 
 
As discussed above, from all the assumptions of this model, the most critical one is 
the cellular activatory property of PrPC (assumption “iii”). Although extensively studied 
(Aguzzi et al. 2008a; Hu et al. 2008; Zomosa-Signoret et al. 2008; Mazzoni et al. 
2005), this question demands further analysis, and new scientific approaches. This 
issue is addressed in more detail in section 4 of this dissertation. 
The main regulating mechanism of this model is the cleavability of the PrP-related 
proteins, and the toxicity that results from cleavage impairment. Therefore this 
question deserves further detail. For that purpose section 3 aims to discuss the 
physiological relevance of α-cleavage of PrPC, and suggests further studies that will 
add to the present knowledge in the field. Moreover, a careful study to elucidate the 
sequence domains in PrPC sequence and the main biochemical factors that regulate 
α-cleavage has been attempted. 
Additionally, there is also the plan to further validate experimentally these 
assumptions, and the model itself. However, the most important step to verify this 
model is to identify the main variables and the mathematical relations that link them, 
so that it could be possible to numerically predict the degree of toxicity of further 
constructs. This is an on going study. 
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3. Candidate approach study for the main domains in PrP 
sequence that regulate its cleavage at 109KH110 
3.1. Introduction 
3.1.1. Aim of the study 
 
As illustrated in the model described ahead in this document (Figure 2.1), all the 
mechanisms of toxicity of PrP and PrP-related proteins can be explained by an 
impairment of α-cleavage and consequent lack of regulation of PrP dependent cell 
activation signalling. The main support for this idea comes from work that has been 
performed on the coated-pit dependent endocytic pathway that internalizes PrPC by 
interaction with its N-terminal polybasic region (Sunyach et al. 2003; Shyng et al. 
1995; Taylor et al. 2005). Hence, given the probably crucial role of α-cleavage in 
regulating the toxicity of PrP-derived molecules, an analysis of α-cleavage was 
performed. The main focus was to assess the domains in PrPC sequence which are 
important for its cleavage. Because the α-cleavage occurs in the flexible “unfolded” 
region of PrPC, it is reasonable to rationalize that the recognition domain for this 
proteolysis should be a continuous region in the vicinity of the cleavage site. 
Therefore, the identification of such continuous unfolded recognition region, together 
with the already available knowledge of the localization of the α-cleavage site (Chen 
et al. 1995; Kornblatt et al. 2003), may be a crucial tool for biochemically design 
molecules that should enhance or block α-cleavage. Because the cleavage products 
of α-cleavage do not appear to be convertible to PrPSc (Shmerling et al. 1998; Aguzzi 
et al. 2008a; Caughey et al. 1989), the identification of a substance that could 
specifically cleave PrPC would be of important clinical value as anti-PrPSc therapy. In 
addition, the identification of the binding domain in PrPC for its α-cleavage protease 
complex, here called PrPase, would allow to structurally screen for specific 
interacting partners and for consequently identify the molecules responsible for this 
physiological cleavage, and hopefully to gain insights on the pathways involved in 
PrPC function. 
 For this purpose several PrPC constructs were designed, with several mutations 
predominantly in the PrPC CC and HC domains, which are the regions that flank the 
α-cleavage site. Each one of these new molecules was used to address a question 
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about the principal domains in PrPC and its main biochemical features, which are 
responsible for modulating the physiological proteolysis of PrPC. The degree of 
cleavage of these constructs was assessed mainly in Hpl cells, a cell line purified 
from the hippocampus of a Prnp-/- mouse (Kuwahara et al. 1999). 
 
3.1.2. Previous studies performed on α-cleavage of PrPC mutants 
 
Though the need to assess the main domains in PrPC molecule that are 
responsible for modulating its cleavage may be one of the priority questions in the 
prion field, studies assessing α-cleavage of PrPC mutants are very scarce. From the 
experiments performed in mouse model, it is noteworthy that all constructs that were 
not cleaved were shown to be toxic when transgenically expressed in mice 
(Shmerling et al. 1998; Baumann et al. 2007; Li et al. 2007). 
Although not highlighted by the authors, Shmerling and coworkers were the first to 
show a correlation between absence of α-cleavage, and neurotoxicity of PrPC 
constructs in Prnp0/0 background (Shmerling et al. 1998). In this pioneer study of α-
cleavage of PrPC mutants in mice, many transgenic lines were created expressing 
PrPC deletion mutants conserving the C-proximal globular domain, the N-terminus 
polybasic region, and varied portion of the N-proximal domain. The authors showed 
that PrPΔ32-134 and PrPΔ32-121 were toxic in Prnp0/0 background, and were not cleaved. 
Another construct, PrPΔ32-106 had a partial impairment in its cleavage, and did not 
cause toxicity during the experimental time. Finally, PrPΔ32-93 and other shorter 
deletions within these amino acids were normally processed and showed no toxicity.  
Apart from that report, only two other studies accessed cleavage of constructs with 
deletions around the α-cleavage site. PrPΔ94-134 and PrPΔ105-125 had a complete 
cleavage inhibition and were highly toxic in Prnp0/0 background (Baumann et al. 
2007; Li et al. 2007), and PrPΔ114-121 was proteolyticaly processed with low efficiency 
and showed very mild toxicity (Baumann et al. 2007).  
Concerning cell culture systems, the data available is not more abundant. There is 
one study assessing α-cleavage of PrPC in constructs with mutations in the 
palindromic region in the N2a cell culture system (Wegner et al. 2002). It was 
concluded that PrPGG113,118AA was normally cleaved, but PrPA112,114-117,119G and 
PrPΔ105-125 were not or very weakly cleaved, a finding that according to the authors, 
was “highly significant and reproducible” (Wegner et al. 2002). 
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In human neuroblastoma SH-SY5Y cells, it was assessed the cleavage of murine 
PrPC constructs with deleted octarepeat region PrPΔ51-90 or with insertion of more 
repeats in that region (Watt et al. 2005). There was no apparent difference in C1 
generation comparing with unmutated PrPC. These results were reproduced in Hpl 
cells (Sakudo et al. 2005) using a similar murine PrPΔ53-94, which also has the 
octarepeats removed. In this same study, the authors also showed that PrPΔ95-132 
was not cleaved in Hpl cells (Sakudo et al. 2005), agreeing with the uncleavability of 
PrPΔ94-134 in mouse brain (Baumann et al. 2007). 
The last relevant study assessing α-cleavage of PrPC mutants was performed in a 
cell culture system expressing ovine PrP (ovPrP) constructs with GFP insertion in the 
N-proximal region (Tveit et al. 2005). In this system, ovPrPK113R, ovPrPK113D, 
ovPrPK113A and ovPrPKHV113-115AAA, all fused with GFP, were cleaved in a similar 
fashion as unmutated ovPrPC with GFP insertion. 
These are the few studies that assessed the domains in PrPC molecule that are 
important for α-cleavage. In spite of the high in vivo correlation between toxicity and 
cleavage impairment, the work performed in this area is very limited, and always on a 
small scale, which adds importance to this study. 
 
3.2. Results 
3.2.1. Characterization of α-cleavage of PrPC 
 
To characterize the processing of PrPC, glycosylation and α-cleavage were 
assessed in various murine cell lines transfected with a construct coding for PrPC and 
for the mutant PrPΔ(32-134), which is reported to have an electrophoretic mobility 
similar to C1 (Shmerling et al. 1998) (Figure 3.1 A-B). The cell lines used were N2a-
PK1 cells, a murine neuroblastoma cell line (Klohn et al. 2003); NIH3T3, a murine 
fibroblastic cell line (Todaro and Green 1963); Npl cells, a neuronal cell line derived 
from Prnp0/0 mice, which do not express PrP (Nishimura et al. 2007); Hpl cells, a cell 
line derived from hippocampus of Prnp-/- mice, which do not express PrP, but express 
the Doppel protein linked to the Prnp promoter (Kuwahara et al. 1999). In all these 
cell lines PrPC and PrPΔ(32-134) appeared to be normally glycosylated (Figure 3.1 A). 
Also, upon removal of the glycosyl groups with PNGase treatment, it was detectable 
in all cell lines a strong band with similar electrophoretic mobility as PrPΔ(32-134), and 
 therefore corresponding to the C1 fragment of PrPC (Figure 3.1 B). To assess the 
efficiency of PrPC cleavage in other cell models, PrPC and PrPΔ(111-120) were 
transfected into human HeLa cells (Gey et al. 1952) (Figure 3.1 C), and into murine 
primary embryonic fibroblasts (MEFs) derived from Prnp0/0 mice (Figure 3.1D). This 
mutant PrPΔ(111-120) is a molecule that lacks the PrPC palindromic region which flanks 
the α-cleavage site, and that for this reason was expected to have an impairment in 
C1 generation. In both HeLa and MEFs the murine PrPC molecule was efficiently 
cleaved (Figure 3.1 C-D). In addition, α-cleavage of the mutant PrPΔ(111-120) was 
impaired in both cell systems. Together, these observations indicate that α-cleavage 
of murine PrPC is a process common to many cell systems which include murine- and 
human-derived cell lines and murine primary cells. 
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Figure 3.1: Proteolysis of PrPC in various biological models. A) and B) Western blot of cell lysates 
of various cell lines (N2a-PK1, Npl, NIH3T3, Hpl) untreated A) or treated  B) with PNGase. Cells were 
transfected with a plasmid coding for PrPC (lane 1-4) or PrPΔ(32-134) that lacks the most part of the N-
proximal domain (lane 5-6). Detection was done with POM1, which binds the C-proximal region of 
PrP. C) Western blot of PNGase treated cell lysates of human HeLa cells transfected with murine PrPC 
molecule and with murine PrPΔ(111-120). Detection was done with POM19, which is an anti-PrP C-
proximal domain antibody that does not react whit human PrP. D) Western blot of PNGase treated cell 
lysates of mouse primary embryonic fibroblasts from Prnp-/- mice. Cells were transfected with murine 
PrPC molecule and with murine PrPΔ(111-120). Uncleaved PrP is the band around 25KDa; C1 is the band 
around 15KDa. 
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3.2.2. Evaluation of the role of the charged residues neighbouring the α-
cleavage site, in the modulation cleavage of PrPC 
 
Because changes on the proteic secondary structure pattern may correspond to 
sites for protein binding, cleavage, or for other biochemical alteration, we decided to 
evaluate the role on α-cleavage of the PrPC domains localized in the region of the α 
site. This PrPC α-cleavage site is located between CC and HC. It is flanked by 
positively charged residues that extend upstream and has palindrome in the 
downstream neighbouring region. 
I started by evaluating if the positive charges at the α-cleavage site would be a 
determinant for defining the proteolytic site. For this purpose a series of PrPC mutants 
were designed with substitutions of these basic amino-acids. PrPKH109-110AA had the 
two charged amino acids mutated to small neutral alanine residues, and PrPKH109-
110DD had the charges inverted to negative ones, by mutation to aspartic acid (Figure 
3.2 A). As control, the mutant PrPΔ(32-134), that has a C1-resembling electrophoretic 
mobility (Shmerling et al. 1998; Baumann et al. 2007), was used. The cleavability of 
these constructs was determined by assessing the C1 generation on Hpl and Npl 
cells (Figure 3.2 B). For this, cell lysates of these cell lines transfected with PrPC 
mutants and PrPC were collected. PrPC glycosylation and proteolytic processing were 
then assessed in PNGase untreated and treated samples respectively. In both cell 
lines, PrPKH109-110AA and PrPKH109-110DD and the large deletion mutant PrPΔ(32-134) were 
glycosylated in a similar fashion as PrPC. This data suggests that charge inversion or 
large deletions in the flexible N-proximal domain of PrPC do not have a strong impact 
in PrPC glycosylation (Figure 3.2 B), as in accordance with other studies (Baumann et 
al. 2007; Shmerling et al. 1998; Li et al. 2007). In addition, in both Hpl and Npl cells 
the degree of α-cleavage of PrPKH109-110AA and PrPKH109-110DD was comparable to 
unmutated PrPC (Figure 3.2 B). This indicates that abolishment and even inversion of 
the positive charges at the α-cleavage site do not appear to inhibit α-cleavage. 
Furthermore, it suggests that the pattern of proteolytic processing of PrPC that is 
seen in Hpl cells is reproducible in other cell types, as Npl cells. For this reason, this 
study focused mainly in only one cell system, which was the Hpl cells derived from 
hippocampus of Prnp-/- mice. 
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To further explore the observation that suggests that α-cleavage is independent of 
the charges and sequence of the cleavage site, I designed a construct that had 
removed the five charges in the region of the α-cleavage site. For this, the mutant 
PrPK100,103,105,109A H110A was constructed, which had five positive histidine and lysine 
residues mutated to uncharged alanines (Figure 3.2 A). In addition I evaluated if 
swapping the position of the α-cleavage site would alter the proteolytic processing of 
PrPC. For this, the mutant PrPKHVA109-112VAKH was elaborated, which had the α-
cleavage site shifted downstream by two amino-acids (Figure 3.2 A). As with the 
previously assessed constructs, PrPK100,103,105,109A H110A and PrPKHVA109-112VAKH 
generated C1 in a frequency comparable to the one shown by unmutated PrPC.  
The next step was to assess the degree of α-cleavage upon stronger alterations on 
the CC. For this purpose two constructs were designed. PrPH95,110E; K100,103,105,109E had 
all positive six residues from the CC mutated to negative glutamic acid, resulting in a 
complete inversion of all the charges (Figure 3.2 A). PrPK100,103,105,109E had the four 
positive lysines from the CC reversed to glutamic acid residues, and therefore these 
mutated acidic residues were mixed with two basic histidines (Figure 3.2 A). 
Simultaneously it was tested again the construct PrPK100,103,105,109A; H110A, which had 
removed the charges in the region of the α-cleavage site, and replaced to uncharged 
alanines (Figure 3.2 A). Comparison of the proportion of C1 generated in these 
constructs, with the C1 generated in unmutated PrPC suggested that, as discussed 
before, removal of the five positive charges from the α-cleavage site and in the 
neighbouring region had no remarkable effect on the proteolytic processing of PrPC 
(Figure 3.2 D,F). In addition, a strong modification as the inversion into negative, of 
four or even the six positive charges of the α-cleavage site region, resulted in only 
about 38% impairment on proteolysis of PrPC (Figure 3.2 D,F). These results suggest 
that the positive charges of the α-cleavage site and from its neighbouring regions 
play no important role in modulating proteolysis of PrPC. However, the overall polarity 
of the CC appears to have a partial impact in α-cleavage, because inversion of the 
charges resulted in about 38% impairment of PrPC cleavage. Furthermore, this data 
shows that α-cleavage of PrPC is strongly sequence independent, because amino-
acid shift, charge removal, and charge inversion of the amino-acids reported to flank 
the α-cleavage site (Chen et al. 1995; Kornblatt et al. 2003) had no dramatic effect on 
α-cleavage. 
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Figure 3.2: Proteolysis of PrPC constructs with mutations in the palindrome and in the positive 
charges neighbouring the α-cleavage site. A) Amino-acid sequence alignment of the region (90-
124), of the PrPC constructs used. The arrow indicates the α-cleavage site. Negatively charged amino 
acids are represented in blue, other mutations are in red. B) Western blots of cell lysates of Hpl and 
Npl cells transfected with the various PrPC mutants. Samples in the lower blot were PNGase treated. 
C) and D) Western blot of PNGase treated cell lysates of Hpl cells transfected with the various PrPC 
mutants. All lanes in D) belong to the same blot. Detection was done with POM1. E) Western blot of 
PNGase treated cell lysates of HeLa cells transfected with various PrPC mutants. Detection was done 
with POM19. F) Quantification of the percentage of α-cleavage of the various PrPC mutants, based on 
densitometry of Western Blots. Quantifications were calculated in the linear range of the densitometric 
signal of independent experiments. Values refer to the amount of C1 generation comparing to total 
abundance of PrPC, and are normalized to cleavage of unmutated PrPC (wtPrP), which was assessed 
in the same blot. Error bars represent the SEM. In PNGase treated samples, C1 is the band at 15KDa 
and uncleaved PrPC is the band at 25KDa. 
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3.2.3. Evaluation on the role of the PrPC palindromic region (111-120) in 
α-cleavage 
 
Given the observation of the strong independence of PrPC proteolysis from the 
charged amino acids in and upstream the α-cleavage site, I decided to study the 
region downstream the cleavage site. In this region there is a palindrome at primary 
sequence level, which marks the border of the HC. This region was already mutated 
in a study using the N2a cell model. There, it was shown that substitution of all 
palindromic glycines for alanines as in the construct PrPA(112,114-117,119)G, resulted in 
no or very weakly detectable C1 cleavage product (Wegner et al. 2002). Following 
this suggestion that exchange of alanines for glycines had a strong  impact on α-
cleavage, I assessed in the Prnp-/- Hpl cell model (Kuwahara et al. 1999) the 
cleavability of the same PrPA(112,114-117,119)G construct, and of PrPA112,115,117G which 
was a mutant bearing only three residue substitutions (Figure 3.2 A). In this setup, 
quantification of C1 generated by these palindromic mutants in Hpl cells, revealed 
that they were proteolytic processed in a fashion similar to the α-cleavage of PrPC 
(Figure 3.2 D,F). In order to evaluate the robustness of these results, the proteolytic 
processing of these constructs was also assessed in the human-derived HeLa cell 
model. The palindromic mutants PrPA(112,114-117,119)G, PrPA112,115,117G  and PrPΔ(111-120), 
and the control PrPK100,103,105,109A; H110A, were transfected into HeLa cells, and the 
detection was done with the antibody POM19, which recognizes the globular domain 
of murine PrPC but not human PrPC (Polymenidou et al. 2008). Comparison of 
proteolytic processing of PrPC and of these PrPC mutants showed no major 
differences between proteolysis in HeLa cells (Figure 3.2 E), and in Hpl cells (Figure 
3.2 D,F). Furthermore, PrPA(112,114-117,119)G and PrPA112,115,117G proteolysis did not 
appear to be strongly reduced comparing to unmutated PrPC (Figure 3.2 E). Thence, 
in my setup the substitution of the palindrome downstream of the α-cleavage site, for 
a total or a partial poly-glycine chain, did not have a strong impact in the α-cleavage 
of PrPC.  
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3.2.4. Evaluation of the role of hydrophobicity in PrPC sequence in 
modulating α-cleavage 
 
Another candidate biochemical feature of PrPC sequence for modulation of α-
cleavage was the high hydrophobicity neighbouring the cleavage site. My rationale 
was that the HC could be cell membrane associated, and that α-cleavage could 
depend mainly on the distance between the cleavage site and the cell membrane. 
This rationale implies that reduction of the hydrophobicity of the HC may impair its 
putative interaction with the cell membrane, and therefore decrease the rate of α-
cleavage. To assess this, three PrPC constructs were designed, bearing substitutions 
of hydrophobic amino acids for non-polar hydrophilic residues that had a similar size 
as the original ones. The small glycines (G) replaced alanines (A), and glutamines 
(Q) replaced the leucines (L) and valines (V) (Figure 3.3 A). The maximum amino-
acid difference between each construct was four residues. The mutant PrPA115-116G 
L124,129Q had only a slight reduction of hydrophobicity and therefore was expected to 
be cleaved almost as efficiently as unmutated PrPC (Figure 3.3 A-B). PrPV120-121Q 
L124,129Q had already a strong diminishment of hydrophobicity (Figure 3.3 A-B). 
Finally, with an almost no positive hydrophobic integral, PrPA115-116G V120-121Q L124,129Q 
was expected not to be digested if it would be confirmed the hypothesis that 
hydrophobicity on PrPC sequence plays a role in modulation of α-cleavage (Figure 
3.3 A-B). Quantification of C1 generation in all these three constructs showed that 
none of these mutations resulted in impairment on proteolysis of PrPC (Figure 3.3 
D,E). There may even have been a slight increase in proteolysis of PrPC, but given 
the fact that this increase was similar within the three mutants, it suggested that the 
changes were independent on the hydrophobicity. Thus, reduction of hydrophobicity 
in the region neighbouring the α-cleavage site appears to play no significant role in 
the proteolytic processing of PrPC. 
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Figure 3.3: Evaluation of the role in modulating α-cleavage, of the hydrophobicity in the α-
cleavage site region. A) Amino-acid sequence alignment of the region (101-134), of the PrPC 
constructs used. The arrow indicates the α-cleavage site. Point-mutations are in red. B) Superimposed 
hydrophobicity plots of the region (90-153) of PrPC in green, and the mutants PrPA115-116G L124,129Q in 
black, PrPV120-121Q L124,129Q in blue and PrPA115-116G V120-121Q L124,129Q in red. C) Hydrophobicity plot of the 
region (90-153) of PrPΔ(118-125) in the upper panel and PrPΔ(111-125) in the lower panel. Vertical line 
represents the site of the deletion, and the numbers next to it indicate the amino acid residue that 
flanks the deletion. D) Western blot of PNGase treated cell lysates of Hpl cells transfected with the 
various PrPC deletion constructs used in the current study. Detection was done with POM1. C1 is the 
band around 15KDa; Uncleaved PrPC is the band around 25KDa. E) Quantification of the percentage 
of α-cleavage of the various PrPC mutants, based on densitometry of Western Blots. Quantifications 
were calculated in the linear range of the densitometric signal of independent experiments. Values 
refer to the amount of C1 generation comparing to total abundance of PrPC, and are normalized to 
cleavage of unmutated PrPC (wtPrP), which was assessed in the same blot. Error bars represent the 
SEM. 
 
In a more extreme approach, large deletions were made in the HC, which resulted 
in two constructs with medium and strong reduction of hydrophobicity respectively. 
PrPΔ(118-125) had an eight amino-acid deletion, which changed mildly the 
hydrophobicity around the α-cleavage site (Figure 3.3 A,C). In contrast, PrPΔ(111-125) 
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had a larger deletion that extended upstream to the beginning of the HC, which 
conferred a strong reduction in hydrophobicity (Figure 3.3 A,C). Measures of C1 
production in these constructs (Figure 3.3 D-E) showed that α-cleavage was strongly 
inhibited in the construct PrPΔ(111-125), which had a larger deletion and a strong 
decrease in hydrophobicity. In contrast, the shorter deletion PrPΔ(118-125), which had a 
higher degree of hydrophobicity, had a milder impairment in PrPC proteolysis (Figure 
3.3 D-E). Therefore, using a deletion approach α-cleavage could be inhibited in 
mutants with low hydrophobicity in the HC. However, this inhibition could be merely 
dependent on the size of the deletion. 
 
3.2.5. Assessment of the existence of a defined domain in PrPC that 
regulates its α-cleavage 
 
Because the strategy of inhibiting PrPC proteolysis using a point-mutation approach 
was inefficient, and because I observed an α-cleavage impairment upon large 
deletions in the HC, I proceeded in this study using a deletion approach. I firstly 
assessed the cleavage efficiency of a construct with an almost complete deletion of 
the CC and the HC, PrPΔ(100-129), which are the regions that flank the α-cleavage site 
(Figure 3.4 A). In this paradigm PrPΔ(100-129), with 30 amino-acids deleted, generated 
virtually no C1 product in transfected Hpl cells (Figure 3.4 B,C). This suggested that 
there is a region within amino-acids (100-129) that is essential for modulating α-
cleavage of PrPC. 
To further identify the region within the PrPC domain (100-129) that modulates α-
cleavage, the rate of C1 generation was assessed in PrPC constructs with small 
deletions encompassing the totality of this (100-129) domain. PrPΔ(100-110) and 
PrPΔ(105-110) had a deletion in the α-cleavage site and further upstream residues 
(Figure 3.4 A). PrPΔ(111-120) had the full palindrome downstream of the α-cleavage site 
deleted and PrPΔ(121-129) had a deletion downstream of the palindrome (Figure 3.4 A). 
In respect to α-cleavage of these mutants, no differences were detected between PrP 
Δ(100-110), PrPΔ(121-129) and unmutated PrPC (Figure 3.4 B-C). In contrast, PrPΔ(105-110) 
and PrPΔ(111-120) showed about 50% impairment in C1 generation (Figure 3.4 B-C). 
This suggests that the PrPC domain (105-120), which refers to the union of the 
deleted domains [(105-110) + (111-120)], is important for α-cleavage of PrPC. These 
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results are in agreement with the observation that PrPΔ(105-125) does not appear to be 
cleaved when transgenically expressed in brain of mice (Li et al. 2007). In addition, 
although point mutations in the palindromic region had no remarkable influence in α-
cleavage (Figure 3.3 C,F), deletion of the full palindromic region in PrPΔ(111-120) 
resulted in a partial cleavage inhibition (Figure 3.4 B-C). Another important 
observation is that though PrPΔ(100-110) was normally processed, the shorter deletion 
PrPΔ(105-110) resulted in about 50% inhibition of α-cleavage. By analyzing the amino 
acids that compose the residue (100-104), which is present in PrPΔ(105-110) and is 
deleted in PrPΔ(100-110), it is noticeable the presence of two positively charged lysines 
and two prolines (Figure 3.4 A). The presence in the flank of the deletion of rigidity 
enhancer proline residues and of charged amino-acids may contribute to a decrease 
in the flexibility of the region. Such rigid structure may enhance the antagonistic 
effects that a deletion may have in the degree of α-cleavage. This may also apply to 
the other deletion that showed impairment in PrPC proteolysis, PrPΔ(111-120), with 
removal of palindromic region, which was also flanked by the charged amino-acids of 
the α-cleavage site (Figure 3.4 A-C). 
Because PrPC domain (105-120) appeared to be important for α-cleavage, I 
decided to identify the minimal region within this domain that would be involved in 
modulating the proteolytic processing of PrPC. For this purpose, it was assessed the 
degree of C1 generation in constructs bearing deletions of different sizes, centred in 
the region of the α-cleavage site, and within the domain (105-120). The designed 
mutants, PrPΔ(106-119), PrPΔ(106-114), and PrPΔ(109-112), had deletions of 14, 9, and 4 
amino acids respectively (Figure 3.4 A). Quantification of the degree of PrPC 
proteolysis on these constructs revealed already an impairment of about 28% of α-
cleavage on the construct PrPΔ(106-119), with 4 amino-acids deleted from the α-
cleavage site (Figure 3.4 B-C). This impairment increased at a rate that was 
proportional to the increase on the size of the deletion (Figure 3.4 B-C). Plotting the 
α-cleavage inhibition in relation with the number of amino-acids deleted (Figure 3.4 
D) revealed that α-cleavage impairment was dose dependent on the size of PrPC 
deletion, with the deletion being centred in the region of the α-cleavage site, and 
being within the PrPC domain (106-119). In this setup, the estimated 50% cleavage 
inhibition is expected to be achieved with a deletion of six amino-acids (Figure 3.4 D). 
The large deletion PrPΔ(100-129) was used as control for total α-cleavage impairment. 
 Together, this suggests that there is no specific short domain in the vicinity of the 
PrPC α-cleavage site that modulates the degree of proteolysis. 
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Figure 3.4: Assessment of the existence of a defined domain in PrPC that regulates its α-
cleavage. A) Amino-acid sequence alignment of the region (93-134), of the PrPC constructs used. The 
arrow indicates the α-cleavage site. B) Western blot of PNGase treated cell lysates of Hpl cells 
transfected with the various PrPC deletion constructs used in the current study. Detection was done 
with POM1. C1 is the band around 15KDa; Uncleaved PrPC is the band around 25KDa. C) 
Quantification of the percentage of α-cleavage of the various PrPC mutants, based on densitometry of 
Western Blots. Quantifications were calculated in the linear range of the densitometric signal of 
independent experiments. Values refer to the amount of C1 generation comparing to total abundance 
of PrPC, and are normalized to cleavage of unmutated PrPC (wtPrP), which was assessed in the same 
blot. Error bars represent the SEM. D) Graphic illustrating the percentage of α-cleavage impairment of 
PrPC deletion mutants. Points correspond to the average value illustrated in C), for the samples PrPC, 
PrPΔ(109-112), PrPΔ(106-114), PrPΔ(106-119), PrPΔ(100-129), which have 0, 4, 9, 14 and 30 amino-acids deleted, 
respectively. In x-axis are plotted the size of the deletion of each of these constructs. Dashed line 
refers to the estimated deletion size that would result in 50% inhibition of α-cleavage. 
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3.2.6. α-cleavage in PrP molecules with PrPSc-generating point mutations 
 
There is a model for PrPSc toxicity suggesting that an increase of hydrophobicity in 
the HC may result in increased generation of a transmembrane species of PrP, the 
CtmPrP, which may be the toxic agent of PrPSc form (Hegde et al. 1999). This was 
mainly supported by a study where toxicity and PrPSc replication were assessed in a 
transgenic mouse model that highly overexpressed PrPKH109-110II in Prnp0/0 
background (Hegde et al. 1999). This PrPC mutant had the two charged amino acids 
of the α-cleavage site substituted by the highly hydrophobic isoleucines. Data 
suggested that enhanced hydrophobicity on the PrP molecule led to higher CtmPrP 
formation and increased PrPSc accumulation (Hegde et al. 1999). Here I wanted to 
assess if the toxicity of this mutant could be explained by inhibition of α-cleavage. For 
this purpose the proteolysis of PrPKH109-110II was assessed in the Hpl cell model. 
Quantification of α-cleavage suggested that this may be partially inhibited (Figure 3.5 
A,C), although the values ranged from only 11% to 30% inhibition, plus one sample 
with 86% inhibition. This cleavage inhibition thus provides another explanation for the 
neurotoxicity observed in transgenic mice expressing PrPKH109-110II in high doses. 
In order to further test the hypothesis that a slight impairment on PrPC cleavage 
could be mildly toxic and therefore be translated into human diseases, the degree of 
proteolysis of constructs carrying mutations linked to human prion diseases was 
quantified. PrPP101L is associated with Gerstmann-Sträussle-Syndrome (GSS) (Hsiao 
et al. 1989), PrPD177L replicated Fatal Familial Insomnia (FFI) (Medori et al. 1992), 
and PrPE199K is found in familiar CJD cases (Hsiao et al. 1991; Goldfarb et al. 1991). 
As control, the proteolysis of PrPQ218K was assessed, which is a construct reported to 
be a dominant negative of PrPSc replication (Kaneko et al. 1997b). Quantification of 
C1 generation in Hpl cells expressing these mutants showed that PrPE199K, but 
specially PrPD177N, had inhibited PrPC cleavage (Figure 3.5 B-C). Also, PrPP101L 
showed a high variability in terms of α-cleavage rate, with low values of C1 
generation observed sporadically (Figure 3.5 B-C). Finally, the PrPSc dominant 
negative PrPQ218K was cleaved in a similar fashion as normal PrPC (Figure 3.5 A,C). 
Together, this data suggests a link between toxicity of inherited human prion 
diseases, and inhibition of α-cleavage of PrP.  
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Figure 3.5:  α-cleavage of PrPC mutants with PrPSc-generating point mutations. A) and B), 
Western blots of PNGase treated cell lysates of Hpl cells transfected with various PrPC mutants. All 
lanes in A) belong to the same blot. Detection was done with POM1. C1 is the band around 15KDa; 
Uncleaved PrPC is the band around 25KDa. C) Quantification of the percentage of α-cleavage of the 
various PrPC mutants, based on densitometry of Western Blots. Quantifications were calculated in the 
linear range of the densitometric signal of independent experiments. Values refer to the amount of C1 
generation comparing to total abundance of PrPC, and are normalized to cleavage of unmutated PrPC 
(wtPrP), which was assessed in the same blot. Error bars represent the SEM. 
 
3.3. Discussion 
 
Data here suggest that PrPC has the uncommon property of despite being 
proteolytic digested in the α-cleavage site, is highly independent of the sequence of 
the cleavage site region. Manipulations like small deletions of the cleavage site, 
inversion of all charges, manipulation of the hydrophobicity, alteration of domains like 
the palindrome, all had only partial or no effect in α-cleavage of PrPC. However, 
deletion of the PrPC domain (106-119) virtually blocked α-cleavage, while shorter 
deletions within this region had only a partial blocking effect. This effect increased 
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gradually, in function of the size of the deletion with centre in the region of the α-
cleavage site.  
Using the Hpl cell model system derived from the brain of Prnp-/- mice, the data in 
this dissertation suggested that first, substitution of positively charged residues of the 
α-cleavage site have no major effect on the degree of PrPC proteolysis. This is in 
agreement with previous studies performed using GFP-fused ovine PrPC mutants, in 
the N2a cell system (Tveit et al. 2005). Second, a complete inversion to negative, of 
the six positive charges of the CC, including the ones of the α-cleavage site, resulted 
only in a partial inhibition of C1 generation. Third, even total or partial substitution of 
the alanines of the palindrome that flanks the α-cleavage site, for glycines, had no or 
little impact in the normal proteolysis of PrPC. This observation is based on the data 
from this dork, which was obtained in the murine Hpl and in the human HeLa cell 
models, and did not replicate previous findings in murine N2a cells (Wegner et al. 
2002). Fourth, amino-acid substitutions that intended to decrease at different levels 
the degree of hydrophobicity of the region in the vicinity of the α-cleavage site also 
failed to reduce the proteolysis of PrPC. However, an impairment of α-cleavage was 
observed upon the substitution of the charged residues of the cleavage site for two 
highly hydrophobic isoleucines. Fifth, deletions in the vicinity of the α-cleavage site, 
as the domains (100-110) and (121-129), had no impact in proteolysis of PrPC. And 
deletions in the domains (105-110) and (111-120) resulted in only about 50% 
impairment on α-cleavage. The later result is in agreement with previous data 
indicating that a PrPC mutant lacking the domain (114-121) had partial inhibition of α-
cleavage when transgenically expressed in mice (Baumann et al. 2007). The 
observation that deletion of the region (100-110) had no apparent effect on the 
proteolysis of PrPC, but the shorter deletion (105-110) partially blocked α-cleavage, 
can be explained by the residues in the region (100-104). These include two rigidity-
conferring proline amino-acids, and two charged lysines. Thus, it suggests that 
prolines or charged residues flanking a deletion around the α-cleavage site may 
contribute for blocking the access of the PrPase to the PrPC chain. Sixth, in the setup 
of this work α-cleavage was practically abolished only in a deletion as large as the 
removal of the domain (106-119) or larger portions. This reproduces the data 
obtained from transgenic mice expressing PrPΔ(105-125), which did not appear to show 
C1 fragment (Li et al. 2007). However, shorter deletions within the PrPC domain (106-
119) and centred in the α-cleavage site region appeared to only partially block 
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proteolysis of PrPC, in a blockage dependent manner of the size of the deletion. A 
50% blockage of α-cleavage was estimated to be obtained with a six amino-acid 
deletion. Therefore, I can conclude that α-cleavage of PrPC has a strong plasticity 
concerning the amino-acid sequence and the physical and structural patterns on the 
vicinity regions of the α-cleavage site. This strong plasticity may correlate with the 
fact that all reports that refer to transgenic mice expressing a PrPC mutant that had a 
blockage of α-cleavage, have always shown neurotoxicity (Baumann et al. 2007; 
Shmerling et al. 1998; Li et al. 2007). If this correlation holds true, it would be 
expectable that α-cleavage of PrPC would be a process with strong plasticity, 
because its inhibition could result in toxicity. Finally, the cleavage of part of the 
mutants used in this study was assessed using other biological systems, as Prnp-/- 
mouse derived Npl cells (Nishimura et al. 2007), human HeLa cells, and mouse 
embryonic fibroblasts. Together the data suggested that the patterns of α-cleavage of 
PrPC mutants are comparable between the Hpl cell model, and the other biological 
systems addressed.   
The strong plasticity of PrPC α-cleavage can possibly be explained by a high level 
of redundancy in terms of PrPases involved in PrPC cleavage. Alternatively, there are 
proteases that partially replicate the high cleavage plasticity of the putative PrPase. 
One example is the β-amyloid precursor protein (APP) -cleaving γ-secretase. In this 
respect it has been reported that point mutations in APP have the property of shifting 
the amino acid cleavage site, but often do not block the generation of APP cleaved 
fragment (McCarthy et al. 2009; Qi-Takahara et al. 2005; Zhao et al. 2005). γ-
secretase cleaves within a transmembrane region, whose length has been suggested 
to be determinant for definition of the cleavage site (McCarthy et al. 2009). As for 
PrPC, the α-cleavage site is in the interface between a charged and a hydrophobic 
domain, and it is still not resolved if this later region can associate with the lipidic 
bilayer. Therefore, though the proteolytic features of PrPC are very uncommon, there 
are other examples of proteins with a high plasticity at the level of the cleavage site 
sequence. 
In respect to α-cleavage associated with mutations that replicate familial prion 
diseases, there appears to be an impairment of the proteolytic processing of these 
constructs. In addition, α-cleavage appeared to also be impaired in PrPKH109-110II, 
which is a mutant reported to enhance PrPSc replication and to be toxic in transgenic 
mice (Hegde et al. 1999). And in the construct PrPQ218K construct, which dominantly 
  58
inhibits PrPSc replication (Kaneko et al. 1997b), the degree of α-cleavage was similar 
to the one detectable in PrPC. If this PrPC cleavage inhibition is on the basis of the 
toxicity of these mutants, or if it is a consequence of it, remains to be established. 
Together, in this study testing the role on α-cleavage of diverse biochemical 
properties in PrPC sequence, it is shown that α-cleavage is highly independent of the 
primary and secondary structure in the vicinity of the α-cleavage site. It is also shown 
that the PrPC domain (106-119) is important for modulating PrPC proteolysis and that 
inhibition of this proteolysis was dependent on the number of residues removed from 
this domain. 
 
3.4. Outlook 
 
This study provided a very clear vision about the role in α-cleavage of the domains 
in PrPC sequence that are in the neighbouring regions of this proteolytic site. 
However, there are few issues in this domain that remain to be clarified. One of the 
questions is the evaluation of the role for this cleavage that the rigidity of the PrP N-
proximal flexible sequence has. The main reason for this is the observation that the 
presence of rigidity-conferring proline residues in the flanks of a deletion can be 
correlated with the inhibition of α-cleavage. 
Another important point that remains to be evaluated is the cleavability of the PrPC 
constructs with deleted globular domain. I showed that contrary to Hpl, Npl and NIH-
3T3, in N2a-PK1 it is possible to detect N1 cleavage product, but the N1 generation 
of these constructs was only assessed in the Hpl cell model, which does not express 
PrPC. It remains to evaluate the cleavage of these constructs using a model system 
where N1 detectable. Moreover, it would be interesting to evaluate the biological 
significance of the two particularities of the N2a-PK1 cell line, which are PrPSc 
replication and N1 detectability. 
But the most important piece of evidence that has been missing is the direct 
connection between the α-cleavage of PrPC and cell toxicity. It has recently been 
shown an assay that may easily allow the measurement of toxicity of several PrPC 
mutants (Rambold et al. 2008), however this data remains to be confirmed.  
The other important question in the field is the identification of the PrPase. Though 
many players have been suggested (Jimenez-Huete et al. 1998; Cisse et al. 2005; 
  59
Vincent et al. 2001; Shyng et al. 1993; Kornblatt et al. 2003; Vincent et al. 2000; 
Laffont-Proust et al. 2005; Yadavalli et al. 2004), the results remain contradictory and 
the consensus is not yet established. The interaction between the PrPase candidates 
and these mutants could be assessed, in order to identify the interaction site in PrPC 
sequence. In another way, proteomic studies urge to be performed, in order to 
identify proteases or other interactors that associate differently between PrPC and 
PrPC mutants with cleavage impairment.  
There has also been published a fluorimetric assay that should allow the assess α-
cleavage at large scale (Cisse et al. 2006). Though it is still not completely 
established the degree of which this technique replicates the data originated using 
traditional methods, it is unquestionable that this is a good tool for PrPC cleavage 
field. It would be interest to do genetic studies of pooled cell clones that exhibit a high 
degree of PrPC cleavage, and other ones that have this process impaired. Also, it 
would be interesting to do a similar genetic study to identify the special 
characteristics of N2a-PK1 cells within this feature of conserving an intact N1. 
Many other interesting research projects may be raised from this and other reports, 
which would allow to address the most important open questions about α-cleavage, 
and consequently to help solving the big mystery about the physiological function of 
PrPC and the mechanisms of PrP toxicity. Here we aimed to suggest the experiments 
that we considered more pertinent in the field of α-cleavage.  
 
3.5. Materials and methods 
 
3.5.1. Cloning 
 
Murine PrPC was amplified from total brain cDNA, using the primers SY6 and SY7 
(Table 1), which introduces the BamHI and the SalI cleavage sites, respectively. The 
PCR products were digested with BamHI and SalI and the targeted vector, pBMN-I-
EGFP (Addgene, Plasmid  1736), was digested with BamHI and XhoI. Fragments 
were later purified from an agarose gel, using the Amersham GFX PCR DNA and Gel 
Band Purification Kit. The PCR products and the open plasmid were ligated using the 
Roche Rapid DNA Ligation Kit. The products were once again purified using 
Amersham GFX PCR DNA and Gel Band Purification Kit, and transformed into 
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TOP10 competent E. coli (Invitrogen). Other constructs were performed in two PCR 
steps using the primers and templates listed in Table1. In the first step, PCR was 
performed with 1) SY6 (Table1) and the reverse plasmid referred in Table1; 2) SY7 
(Table1) and the forward plasmid referred in Table1. Second step was performed 
with a PCR using 1uL of PCR product 1) and 2), and using SY6 and SY7 to make the 
full construct. PCR product purification, digestion and ligation were done in a similar 
way as described for PrPC. Constructs PrPΔ(118-125) and PrPΔ(111-125) were done using 
the QuikChange kit (Stratagene), using the primers indicated in Table 1. Dv1 
construct originates from previous experiments (Ott et al. 2008).  
 
Table 1: List of the primers used in this study. 
Primer 
name 
sequence 5' ---> 3'  direction Description Code Template  
A5 aaa cca aaa acc aac ctc gat gat gtg gca ggg gct gcg gca  Fw PrP KH109-110DD BOM3 PrPc 
A6 tgc cgc agc ccc tgc cac atc atc gag gtt ggt ttt tgg ttt  Rv PrP KH109-110DD BOM3 PrPc 
A11 aaa cca aaa acc aac ctc gcc gcc gtg gca ggg gct gcg gca Fw PrP KH109-110AA BOM6 PrPc 
A12 tgc cgc agc ccc tgc cac ggc ggc gag gtt ggt ttt tgg ttt  Rv PrP KH109-110AA BOM6 PrPc 
A13 aaa cca aaa acc aac ctc gtg gca aag cat ggg gct gcg gca   Fw PrP KHVA109-112VAKH BOM7 PrPc 
A14 tgc cgc agc ccc atg ctt tgc cac gag gtt ggt ttt tgg ttt  Rv PrP KHVA109-112VAKH BOM7 PrPc 
A15 
ggg ggt acc cat aat cag tgg aac gcc ccc agc gca cca gca acc aac ctc gcc 
gcc gtg gca ggg gc  
Fw 
PrP K100,103,105,109A 
H110A 
BOM8 BOM6 
A16 
gc ccc tgc cac ggc ggc gag gtt ggt tgc tgg tgc gct ggg ggc gtt cca ctg att atg 
ggt acc ccc  
Rv 
PrP K100,103,105,109A 
H110A 
BOM8 BOM6 
A17 
aaa acc aac ctc aag cat gtg gga ggg ggt ggg gga ggt ggg gga gta gtg ggg 
ggc ctt ggt  
Fw PrP A112,114-117,119G BOM9 PrPc 
A18 
acc aag gcc ccc cac tac tcc ccc acc tcc ccc acc ccc tcc cac atg ctt gag gtt 
ggt ttt  
Rv PrP A112,114-117,119G BOM9 PrPc 
A21 
aaa acc aac ctc aag cat gtg gga ggg gct ggg gca ggt ggg gca gta gtg ggg 
ggc ctt  
Fw PrP A112,115,117G BOM11 PrPc 
A22 
aag gcc ccc cac tac tgc ccc acc tgc ccc agc ccc tcc cac atg ctt gag gtt ggt 
ttt  
Rv PrP A112,115,117G BOM11 PrPc 
A23 gtg gca ggg gct gcg gca gct  Fw PrP D(100-110) BOM12 PrPc 
A24 ccc tgc cac gtt cca ctg att atg ggt acc ccc t  Rv PrP D(100-110) BOM12 PrPc 
A23 gtg gca ggg gct gcg gca gct  Fw PrP D(105-110) BOM13 PrPc 
A26 ccc tgc cac tgg ttt gct ggg ctt gtt cca ctg att  Rv PrP D(105-110) BOM13 PrPc 
A27 ggg agc gcc atg agc agg ccc at  Fw PrP D(121-129) BOM14 PrPc 
A28 ggc gct ccc tac tgc ccc agc tgc cgc agc ccc t Rv PrP D(121-129) BOM14 PrPc 
A29 gc aaa cca aaa gca gct ggg gca gta gtg ggg ggc ctt  Fw PrP D(106-114) BOM15 PrPc 
A30 ttt tgg ttt gct ggg ctt gtt  Rv PrP D(106-114) BOM15 PrPc 
A31b aa acc aac ctc gct gcg gca gct ggg gca gta Fw PrP D(109-112) BOM16 PrPc 
A32 gag gtt ggt ttt tgg ttt gct  Rv PrP D(109-112) BOM16 PrPc 
A34 gc aaa cca aaa gta gtg ggg ggc ctt ggt ggc ta Fw PrP D(106-119) BOM17 PrPc 
A30 ttt tgg ttt gct ggg ctt gtt  Rv PrP D(106-119) BOM17 PrPc 
B14 aaa acc aac ctc aag cat ¦ ggc tac atg ctg ggg agc Fw PrP D(111-125) BOM23 PrPc 
B15 gct ccc cag cat gta gcc ¦ atg ctt gag gtt ggt ttt Rv PrP D(111-125) BOM23 PrPc 
B16 gca  ggg gct gcg gca gct ¦ ggc tac atg ctg ggg agc Fw PrP D(118-125) BOM24 PrPc 
B17 gct ccc cag cat gta gcc ¦ agc tgc cgc agc ccc tgc  Rv PrP D(118-125) BOM24 PrPc 
B18 
aag cat gtg gca ggg gct ggg gga gct ggg gca caa cag ggg ggc cag ggt ggc 
tac atg cag ggg agc gcc atg agc agg 
Fw 
PrP A115-116G V120-
121Q L124,129Q 
BOM25 PrPc 
B19 
cct gct cat ggc gct ccc ctg cat gta gcc acc ctg gcc ccc ctg ttg tgc ccc agc 
tcc ccc agc ccc tgc cac atg ctt 
Rv 
PrP A115-116G V120-
121Q L124,129Q 
BOM25 PrPc 
B20 
aag cat gtg gca ggg gct ggg gga gct ggg gca gta gtg ggg ggc cag ggt ggc 
tac atg cag ggg agc gcc atg agc agg 
Fw PrP A115-116G L124,129Q BOM26 PrPc 
B21 
cct gct cat ggc gct ccc ctg cat gta gcc acc ctg gcc ccc cac tac tgc ccc agc 
tcc ccc agc ccc tgc cac atg ctt 
Rv PrP A115-116G L124,129Q BOM26 PrPc 
B22 
gct gcg gca gct ggg gca caa cag ggg ggc cag ggt ggc tac atg cag ggg agc 
gcc atg agc agg 
Fw PrP V120-121Q L124,129Q BOM27 PrPc 
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Primer 
name 
sequence 5' ---> 3'  direction Description Code Template  
B23 
cct gct cat ggc gct ccc ctg cat gta gcc acc ctg gcc ccc ctg ttg tgc ccc agc 
tgc cgc agc 
Rv PrP V120-121Q L124,129Q BOM27 PrPc 
BAUF95 t cag tgg aac gag ccc agc gaa cca gaa acc aac ctc gag cat gtg gc Fw PrP K100,103,105,109E FBOM1 PrPc 
BAUF96 gc cac atg ctc gag gtt ggt ttc tgg ttc gct ggg ctc gtt cca ctg a  Rv PrP K100,103,105,109E FBOM1 PrPc 
BAUF97 ga ggg ggt acc gag aat cag tgg aac gag ccc agc gaa cca aaa ac Fw PrP H95E K100,103E FBOM2 PrPc 
BAUF98 gt ttt tgg ttc gct ggg ctc gtt cca ctg att ctc ggt acc ccc tc   Rv PrP H95E K100,103E FBOM2 PrPc 
BAUF99 ccc agc gaa cca gaa acc aac ctc gag gag gtg gca ggg g Fw 
PrP H95,110E 
K100,103,105,109E 
FBOM3 FBOM2 
BAUF100 c ccc tgc cac ctc ctc gag gtt ggt ttc tgg ttc gct ggg Rv 
PrP H95,110E 
K100,103,105,109E 
FBOM3 FBOM2 
DOM2f gtg cgt cac cca gta caa gaa gga gtc cca ggc Fw PrP Q218K Dv1 PrPc 
DOM2r gcc tgg gac tcc ttc ttg tac tgg gtg acg cac Rv PrP Q218K Dv1 PrPc 
Bauf5 gca aac caa aaa cca acc tca tca tcg tgg cag ggg ctg cgg cag Fw PrP KH109-110II C12 PrPc 
Bauf6 ctg ccg cag ccc ctg cca cga tga tga ggt tgg ttt ttg gtt tgc Rv PrP KH109-110II C12 PrPc 
SY71 cag tgg aac aag ctc agc aaa cca aaa Fw PrP P101L C32 PrPc 
SY72 ttt tgg ttt gct gag ctt gtt cca ctg Rv PrP P101L C32 PrPc 
SY73 aac ttc gtg cac aac tgc gtc aat atc Fw PrP D177N C33 PrPc 
SY74 gat att gac gca gtt gtg cac gaa gtt Rv PrP D177N C33 PrPc 
SY75 gag aac ttc acc aag acc gat gtg aag Fw PrP E199K C34 PrPc 
SY76 ctt cac atc ggt ctt ggt gaa gtt ctc Rv PrP E199K C34 PrPc 
SY6 cgc gga tcc aat tta gga gag cca agc aga      
SY7 acg cgt cga cca cga gaa tgc gaa gga aca     
 
3.5.2. Analysis of the constructs 
 
Most of the work was performed in Hpl cells (Kuwahara et al. 1999). Other cell lines 
used were N2a-Pk1 (Klohn et al. 2003), NIH-3T3 (Todaro and Green 1963), Npl 
(Nishimura et al. 2007), Hela (Gey et al. 1952) and primary embryonic fibroblasts 
obtained from E12,5 Prnp-/- embryos. 
Transfection was performed using Lipofectamine (Invitrogen) and Plus Reagent 
(Invitrogen), into 80% confluent cells. Cells were harvested using 10mM EDTA, 2 
days after transfection. Cell lysis was performed on ice for 1h, using 1% Triton-X-100 
and 1% NP-40, in Tris buffer at pH7.5, with NaCl and protease inhibitors (Complete; 
Roche). Lysate supernatant was collected after centrifugation for 30 min at 16000g at 
4°C. Supernatant was then treated with PNGase (NEB), and loaded onto 12% SDS-
polyacrylamide gels. After electrophoresis, proteins were transferred to nitrocellulose 
membranes (Schleicher & Schuell) by wet blotting. Primary antibody was anti PrPC 
POM1 (Polymenidou et al. 2008), and POM19 (Polymenidou et al. 2008) in case of 
human derived Hela cells, diluted 1:10’000 from a 1ug/ul stock. Peroxidise-labelled 
anti-mouse IgG1 diluted 1:10’000 (Zymed) was used as secondary antibody. 
Antibodies were probed for 1h at room temperature or over-night at 4°C in a 1% Top-
Block solution (FLUKA) in PBS-Tween 20. For membrane blocking, a 5% Top-Block 
solution was used. Development was done using ECL detection system (Pierce). 
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Densitometry of the PrP bands was done using TINA v2.09g (raytest 
Isotopenmessgeräte), in the linear range of the band intensity. 
 
3.5.3. Hydrophobicity plots 
 
Hydrophobicity plots were calculated for using DNAMAN software (Lynnon BioSoft, 
Canada), for window intervals of nine residues.  
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4. The physiological function of PrPC in the immune system 
4.1. Introduction  
4.1.1. Aim of the study 
 
As discussed in section 2, one of the crucial assumptions in the model proposed in 
this dissertation is that PrP contributes for cell activation, and that miss-regulation of 
this cell activation can lead to cell death. As refereed, though there are many studies 
that support this statement (Aguzzi et al. 2008a; Hu et al. 2008; Zomosa-Signoret et 
al. 2008; Mazzoni et al. 2005), this question is still far from being resolved. Therefore, 
I decided to put efforts in evaluating if modulation of cell activation is a feature of the 
physiological function of PrPC.   
Lymphocytes are very intensely studied cells whose development includes positive 
and negative selection steps which are important to eliminate hypo- and hyper-
responsive cells respectively. These steps are well described and are crucial to 
assure that the individual is not immunodeficient, in case of hypo-responsiveness, 
nor allergic, in case of hyper-responsiveness. Given these characteristics, and if the 
assumption aforedescribed is correct, it is expectable that manipulation of PrPC 
expression in different lymphocytes would lead to altered threshold of cell activation, 
and therefore would induce or inhibit apoptosis in different developmental stages. 
The final deduction is that abnormal PrPC expression profiles should result in 
detectable changes in lymphocyte homeostasis. 
For this purpose, I decided to analyse the frequencies of various lymphocyte 
populations in mice that transgenically expressed PrPC in different doses and in 
distinct cellular subsets, and to assess the effect of PrPC expression in lymphocyte 
homeostasis. The working hypothesis was that PrPC overexpressing mice would 
have diminished cell populations that were more sensitive to over-activation. Also, I 
expected to find a decreased expression of costimulatory molecules involved in the 
cellular activation pathways, in order to compensate for transgenic PrPC 
overexpression.  
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4.1.2. Brief overview about murine B-cell development 
 
B-cells development starts with the migration to the bone marrow of multipotent 
lymphoid precursors (CLP), which derived form hematopoietic stem cells (HSC).  In 
bone marrow, they start expressing B220, also named CD45R, together with low 
levels of the heat stable antigen (HSA) also called CD24, and CD43, and are named 
pre-pro-B-cells (Figure 4.1), or Fraction A, according to Hardy’s nomenclature (Hardy 
et al. 1991; Hardy 2003). The next stage is Fraction B, or early pro-B-cell, when the 
immunoglobulin (Ig) heavy chain D-J rearrangements occur (Hardy et al. 1991). 
Here, cells express at the surface high levels of CD24 and CD19. This is followed by 
heavy chain V-DJ rearrangement and membrane expression of BP-1 and the pre-
BCR (pre B-cell receptor) Igα-Igβ heterodimer in association with calnexin (Nagata et 
al. 1997), at Fraction C or late pro-B-cell stage. During this pro-B-cell stages, 
progression in development depends mainly on activation of transcription factors like 
EBF (Lin and Grosschedl 1995), E12 and E47 (Bain et al. 1994), and on extrinsic 
factors like IL7-R signalling (Miller et al. 2002), and are fairly independent of pre-BCR 
signalling (Hagman and Lukin 2006). But to advance to the pre-B-cell phase, cell 
need to successfully pass the pro- to pre-B-cell checkpoint which depends mainly on 
pre-BCR efficient signalling (Kitamura et al. 1991; Wang and Clark 2003). The pre-B-
cell stage proceeds with an increase in cell size, followed by 2 to 5 mitotic cycles 
(Rolink et al. 2000) and an augment of IL-7 responsiveness (Marshall et al. 1998). 
The step that follows is the small pre-B cell stage, where light chain Ig 
rearrangements initiate, and CD24, CD43 and IL-7R are downreagulated (Hardy et 
al. 1991). The successful rearrangement of the light chain, and is detected by de 
membrane deposition of newly formed IgM, together with the CD79 complex (CD79a, 
also termed Igα, associated with CD79b, also known as Igβ). It fallows a strict 
process of negative selection, which eliminates by anergy the cells that bind with low 
avidity to the antigen (Fulcher and Basten 1994), and by deletion the autoreactive 
ones (Erikson et al. 1991; Hartley et al. 1991). These last high affinity antigen binding 
cells can also undergo secondary Ig gene rearrangements, in order to produce a less 
autoreactive receptor and escape deletion (Gay et al. 1993; Tiegs et al. 1993). The 
cells that manage to be approved in all these checkpoints maturate and leave the 
bone marrow. Although there are many possible paths that can follow, the selected 
cells eventually enter the splenic red pulp, as T1 transitional cells. For the transition 
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from immature B-cell to T1 it is crucial the presence of an activation signal mediated 
by CD79b molecule (Reichlin et al. 2001). These lymphocytes start expressing the 
FcεRII CD23 molecule and the complement receptor CR2, also known as CD21, 
together with the high expression of IgD in the membrane, by alternative RNA 
splicing, in conjunction with high IgM, which move them to the T2 transitional 
category (Loder et al. 1999; Wang and Clark 2003). In a Burton’s tyrosine kinase 
(Btk) dependent manner, T2 cells need to get enough B-cell receptor (BCR) -antigen 
signalling in order to proceed to the Follicular (FO) B-cell stage (Fang et al. 1998), 
where IgM is downregulated, and the cell can enter into the germinal centres and 
give rise do plasma and memory cells. Alternatively, if the BCR-antigen signal is 
weaker, B-cells move to the Marginal Zone (MZ) of the splenic follicules, maintain 
high IgM expression and decrease IgD, and turn into MZ B-cells (Cariappa et al. 
2001). 
Other important cell populations are the B1a and B1b cells. These are long-lived 
self-renewing B-cells, located mainly in pleural and the peritoneal cavities, which are 
maintained or selected by high avidity interaction with self antigens (Hayakawa et al. 
1999). B1a cells develop from the fetal liver and therefore lack the Terminal 
Deoxynucleotidyl Transferase (TdT) DNA polymerase which is important for the DNA 
VDJ recombination of Ig heavy chain. In contrast B1b, which are a very low fraction 
of the B1 cells and yet, are originated by bone-marrow derived stem cells and 
phonotypically are distinguished by B1a cells, by the absence of CD5, a negative 
regulator of lymphocyte activation (Tarakhovsky et al. 1995; Bikah et al. 1996). 
These B1 B-cells are the major source of secretion of natural antibodies and depend 
on a strong TCR-antigen signalling to develop or to be maintained (Pillai et al. 2004). 
 
  
Figure 4.1: B-cell development. CLP – Common Lymphoid Precursor; T1 – Transitional 1 immature 
B-cells; MZ – Marginal Zone B-cell; MZP – Progenitor of Marginal zone cell; FO – Follicular B-cell; GC 
– Germinal Centre B-cell; Mem. – Memory cell; PC – Plasma cell. From (Wang and Clark 2003). 
 
4.1.3. Brief overview about murine T-cell development 
 
In adult mice, bone marrow hematopoietic stem cells (HSC) give rise to Lin-Thy1.1-
Sca1+c-kit+CD62L+ precursors, known as LSK-CD62L+ (Perry et al. 2003; Perry et al. 
2004), which develop to early lymphoid precursors (ELP) (Medina et al. 2001) that 
can originate the common lymphoid precursors (CLP) (Kondo et al. 1997). Excluding 
this later population, the first two mentioned ones can also be found in the blood, and 
are thought to be the progenitors of the early T lineage progenitors (ETP) that are 
found in the thymus (Schwarz and Bhandoola 2004). These ETP cells (Borghesi et 
al. 2004) may correspond to the DN1a and DN1b populations (Porritt et al. 2004) that 
are CD44+CD25-c-kithiCD24+. In an earlier stage they are Flt3+, and later switch off 
this marker (Sambandam et al. 2005), before they deposit at the membrane the α 
chain of IL-2 receptor named CD25 and advance to the stage DN2 (Figure 4.2). After 
this, cells switch off CD44 and move to the DN3 developmental phase. In the period 
cells spend as DN2 and DN3, cells migrate to the thymic cortex in a CCR7-
dependent process (Witt and Robey 2004; Misslitz et al. 2004), and rearrange the 
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 gene that encodes the β chain of the T-cell receptor (TCRβ). This protein is then 
expressed in the membrane in a complex with an invariant pre-Tα chain, which 
globally constitutes the pre-TCR. At this stage there is a checkpoint for the correct 
functionality of the newly formed pre-TCR, where cells that do not receive efficient 
pre-TCR signals undergo apoptosis (Newton et al. 2000; Mandal et al. 2005). After 
this checkpoint there is the down-regulation of CD25 (DN4 stage), and the switch on 
of CD4 and CD8 expression, accompanied with intense proliferation. The resulting 
CD4+CD8+ cells (DP stage) stop dividing and start rearranging the TCRα, originating 
a mature TCRαβ complex (Figure 4.2). At this stage cells face the second important 
checkpoint, where a functional TCRαβ is positively selected and a hyper-reactive or 
low-reactive one is eliminated (Goldrath and Bevan 1999; Starr et al. 2003). 
Curiously, this selection process takes into account the community effect (Gurdon 
1988), because the presence of cells with non-functional TCR favours the positive 
selection of cells with a functional one (Canelles et al. 2003). Also in this DP phase, 
cells interact with antigen presented by the Major Histocompatibility Complex class I 
(MHC I) or MHC II, and depending of the class of MHC that provided the optimal 
surviving signal, the expression of either CD4 or CD8 respectively is switched off, 
resulting in CD8 SP (single positive) or CD4 SP cells. From the positively selected 
CD4 SP cells, it appears that the fraction of the ones with higher reactivity to the 
presented antigen (Ag) complexed MHC II will end up turning into regulatory T-cells 
(Jordan et al. 2001; Apostolou et al. 2002) which are CD4+CD25+Foxp3+ and play an 
important role in suppressing the activation of naïve T-cells (Sakaguchi et al. 1995). 
These SP cells will down-regulate CD24, and up-regulate CCR7 (Rosen et al. 2003), 
a chemokine receptor that is important for migration from the thymic cortex, go back 
to the medulla (Ueno et al. 2004) and out of the thymus. 
 
 
Figure 4.2: Representation of T-cell development in Thymus. (Zamoyska and Lovatt 2004) 
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Another set of T-cells are the γδT-cells, which are a population mainly located in the 
peritoneal cavity and in the gut mucosa, and that react to various Ag independently of 
its association with MHC. These cells are distinguished from the αβT-cells by having 
a TCR complex composed by a γ and a δ chain, and not the more common α and β. 
The development divergence appears to occur in the DN2 and DN3 developmental 
stages (Ciofani et al. 2006), where it has been suggested that negatively selected 
cells bearing γδTCR may convert into the αβTCR lineage (Haks et al. 2005; Hayes et 
al. 2005), which appears to demand weaker signals for being positively selected 
(Irving et al. 1998; Yamasaki et al. 2006). 
  
4.1.4. Previous studies about function of PrPC in lymphocyte 
homeostasis 
 
One of the pioneering studies at the level of assessing the function of PrPC in the 
immune system was performed by Cashman and colleagues (Cashman et al. 1990) 
where they showed that lymphocyte activation induces increased PrPC expression. 
Other studies followed which confirmed this observation on activated T-cells 
(Mabbott et al. 1997; Bainbridge and Walker 2005), and showed that this could occur 
within 4-8h of in vitro primary culture with Con A (Kubosaki et al. 2003). Another 
important study showed that PrPC on stimulating dendritic cells (DC), but not on T-
cells, is important for efficient T-cell activation (Ballerini et al. 2006). Also at 
lymphocyte development level it was suggested that PrPC is important for the activity 
of long term hematopoietic stem cell in bone marrow (Zhang et al. 2006). At another 
level, Marche and colleagues studied the T-cell development in thymus of mice over-
expressing PrPC and observed a partial arrest in the DN3 phase and a strong Cu2+-
dependent decrease of the DP and SP populations when PrPC was highly over-
expressed (Jouvin-Marche et al. 2006). One intriguing factor on these studies is the 
observation that PrPC expression profiles in immune system differ in a high degree 
between species (Linden et al. 2008), therefore advising for some caution when 
extrapolating results. In addition, the data from Zabel and colleagues showing that 
many putative effects of PrPC can be explained by a transgene insertion artifact in 
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one PrPC overexpressing mouse line adverts for prudence in interpreting results from 
experiments with transgenic animals. 
Few studies have been made available for characterization of various immune cell 
populations in terms of PrPC expression. Liu and colleagues did a detailed analysis 
on PrPC expression of various populations during B-cell development, with high focus 
on bone marrow cells, and found high expression on subpopulations of HSC (Liu et 
al. 2001). This last observation was later confirmed by observation that PrPC is a 
marker for long term HSC in the bone marrow, which are lin-sca-1+Endoglin+ (Zhang 
et al. 2006). The number of studies about PrPC expression during T-cell development 
in murine thymus have also been limited, and have mainly suggested that PrPC 
expression may be higher in DN and in CD4-SP populations (Kubosaki et al. 2001; 
Jouvin-Marche et al. 2006). These results were recently complemented by the 
observation that CD4+CD25+Foxp3+ regulatory T-cells also express high levels of 
PrPC (Isaacs et al. 2008). Finally it has also been shown that splenic follicular 
dendritic cells (FDCs) are PrPhi (Brown et al. 1999b). 
These are the most significant studies focusing on assessing the role PrPC in 
lymphocyte development and homeostasis, and on characterizing its expression 
profiles in different murine lymphocytic populations. 
 
4.2. Results 
4.2.1. PrPC expression increases in cells activated in vitro 
 
The first step for assessing the role of PrPC in lymphocyte activation was to assess 
in vitro the relation of these two parameters. For this purpose, splenocytes from adult 
wilt type (wt) mice were collected and to cultured in vitro, with or without 25ng/mL of 
PMA (phorbol 12-myristate 13-acetate) and 0,5μM of ionomycin, which should induce 
cell activation. The goal was to do a time course analysis of the membrane levels of 
CD69, a marker for early cell activation (Testi et al. 1989), and to evaluate if PrPC 
expression would correlate with the cellular activation status.  
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Figure 4.3: PrPC and CD69 expression profiles on T-cells activated in vitro. Splenocytes from 
C57Bl6 mice (wt) and Prnp-/- mice were collected and cultured in vitro for different time periods, with or 
without 25ng/mL of PMA (phorbol 12-myristate 13-acetate) and 0,5μM of ionomycin. Populations were 
gated on TCRβ+ T-cells. A) Quantification of surface CD69 levels at different time-points after cells 
were put in culture in presence of PMA and ionomycin (left panels) and in the absence of addition of 
stimulatory molecules (right panels). Wt cells were analysed (top panels) and Prnp-/- lymphocytes (low 
panels) were used as negative control. B) Quantification of surface PrPC levels at different time-points 
after cells were put in culture in presence of PMA and ionomycin (left panels) and in the absence of 
addition of stimulatory molecules (right panels). Wt cells were analysed (top panels) and Prnp-/- 
lymphocytes (low panels) were used as negative control. C) Dot-plot of the wt T-cells cultured in 
presence of PMA and ionomycin, for each time-point of our experiment. Data illustrate the covariation 
of PrPC and CD69 surface expressions. 
 
Analysis of surface CD69 levels on TCRβ-gated T-cells suggest that the membrane 
levels of CD69 were highly elevated as early as 40 minutes after lymphocytes were 
put in culture (Figure 4.3 A), and that PrPC levels followed shortly after, with high 
elevation already at 2h after cells were put in culture (Figure 4.3. B). Moreover, the 
kinetics of these two proteins correlated and their expression showed always a 
gradual increase, which lasted all the 24h of the experiment (Figure 4.3 A-C).  
In contrast, on B-cells PrPC appears to have a much different behaviour. While 
membrane levels of CD69 increase strongly on B220+ splenocytes already at 40 
minutes after cells were put in culture with the cell activators PMA and ionomycin 
(Figure 4.4 A), PrPC up-regulation was only detected on these B-cells after 24h of 
culture (Figure 4.4 B-C). 
Together, these results confirm observations reported by others on total human 
peripheral blood cells (Cashman et al. 1990) and on mouse splenocytes (Mabbott et 
al. 1997; Bainbridge and Walker 2005; Kubosaki et al. 2003), and add another level 
to their findings, showing for the first time that surface PrPC can be up-regulated on 
T-cells as early as 2h after lymphocytes were put in culture, with a 20 to 80 minute 
delay of the protein surface up-regulation of CD69, which is one of the earliest 
activation markers known (Testi et al. 1994; Marzio et al. 1999). Moreover, it is to our 
knowledge the first time that such a study is performed on B-cells, illustrating the 
discrepancy of PrPC up-regulation kinetics between T-cells and B-cells. Finally, such 
dramatic PrPC up-regulation dynamics on T-cells suggests that PrPC may be 
functionally linked to a pathway involving CD69. 
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Figure 4.4: PrPC and CD69 expression profiles on B-cells activated in vitro. Splenocytes from 
C57Bl6 mice (wt) and Prnp-/- mice were collected and cultured in vitro for different time periods, with or 
without 25ng/mL of PMA (phorbol 12-myristate 13-acetate) and 0,5μM of ionomycin. Populations were 
gated on B220+ B-cells. A) Quantification of surface CD69 levels at different time-points after cells 
were put in culture in presence of PMA and ionomycin (left panels) and in the absence of addition of 
stimulatory molecules (right panels). Wt cells were analysed (top panels) and Prnp-/- lymphocytes (low 
panels) were used as negative control. B) Quantification of surface PrPC levels at different time-points 
after cells were put in culture in presence of PMA and ionomycin (left panels) and in the absence of 
addition of stimulatory molecules (right panels). Wt cells were analysed (top panels) and Prnp-/- 
lymphocytes (low panels) were used as negative control. C) Dot-plot of the wt B-cells cultured in 
presence of PMA and ionomycin, for each time-point of our experiment. Data illustrate the covariation 
of PrPC and CD69 surface expressions. 
 
4.2.2. PrPC expression in vivo is increased in activated cells 
 
Given the finding that PrPC expression increases when cells are activated in vitro, I 
wanted to assess in vivo if the expression of PrPC was increased in lymphocytes 
expressing activation markers. For this purpose splenocytes and lymph node cells 
expressing the activation marker CD69 were analysed by flow cytometry. As in 
agreement with the in vitro data, T-cells from lymph nodes (Figure 4.5 A-B), and from 
the spleen (Figure 4.5 C-D), as well as splenic B-cells (Figure 4.5 E-F), showed an 
increase in PrPC at the cell surface in CD69+ activated lymphocytes, comparing with 
non-activated CD69- ones. Interestingly, though in lymph nodes this augment was 
about 1log (Figure 4.5 B), in spleen this enhancement of PrPC expression was much 
milder (Figure 4.5 D, F), suggesting that in spleen the levels of PrPC are more tightly 
regulated, or that there may be mechanisms complementary to PrPC function, with 
higher prominence in spleen. 
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Figure 4.5: PrPC expression is increased in activated cells: Lymph node and splenic cells from a 
wt mouse were collected and stained for CD3, a T-cell marker, B220, a B-cell marker, CD69, an early 
cell activation marker, and PrPC. A) Dot-plot for lymph node cells showing activation of CD3+ T-cells. 
B) Histogram for PrPC expression of CD3+ gated lymph node T-cells. CD69+ population is shown in red 
and CD69- in blue. Grey refers to CD3+ Prnp-/- cells. C) Dot-plot for splenocytes showing activation of 
CD3+ T-cells. D) Histogram for PrPC expression of CD3+ gated splenic T-cells. CD69+ population is 
shown in red and CD69- in blue. Grey refers to CD3+ Prnp-/- cells. E) Dot-plot for splenocytes showing 
activation of B220+ B-cells. F) Histogram for PrPC expression of B220+ gated splenic B-cells. CD69+ 
population is shown in red and CD69- in blue. Grey refers to B220+ Prnp-/- cells. 
 
 
4.2.3. Characterization of surface PrPC expression in various T-cell 
populations 
 
Given this observation that PrPC up-regulation in lymphocytes appears to be a 
marker for cell activation, it was then assessed if PrPC expression correlated directly 
with the positive selection phases, and inversely with the phases where exclusion of 
auto-reactive cells occurred. 
The T-cell development was assessed in thymocytes of C57Bl6 mice by comparing 
the expression levels of CD4 and CD8 (Figure 4.6. A), and by measuring the amount 
of CD44 in the DN-gated population (Figure 4.6 B). As described earlier, in the 
thymus the T-cell development phases start with a CD4-CD8- (DN) CD44+ 
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phenotype, then DN CD44- (Figure 4.6 A-B), and it is during this DN stage that the 
TCRβ is rearranged and that positive selection for the pre-TCR occurs. After that, 
cells become CD4+CD8+ (DP) when positive and negative selection of TCRαβ takes 
place, and later become CD4+CD8- or CD4-CD8+ (Figure 4.6 A).  
In this study the average levels of PrPC appeared to be higher in the DN phase, and 
to decrease in the remaining phases (Figure 4.6 C-D). These results are in 
agreement with previous publications that also showed a higher PrPC expression in 
the DN population (Kubosaki et al. 2001), and in line with our rationale, they appear 
to correlate with the positive selection for a functional pre-TCR, which takes place in 
the same phase. 
Given the observation that PrPC expression was higher in DN CD4-CD8- 
thymocytes I wanted to evaluate if this property is also visible in peripheral T-cells. 
For this purpose, the PrPC levels in lymph nodal T-cells were assessed. As observed 
with the thymic T-cells, the higher PrPC expressing population was the CD3+CD4-
CD8-. This subset may belong to the published TCRαβ+CD3+CD4-CD8- double 
negative (DN) regulatory T-cell population (Zhang et al. 2000), which comprises 1-
5% of the peripheral T-cells of human and mice (Thomson et al. 2006).  The 
suggestion that a regulatory T-cell population was high in PrPC expression prompted 
to assess the PrPC levels profile of the classical CD4+CD25+ regulatory T-cell (T-reg) 
population (Sakaguchi et al. 1995). Comparison of the amounts of PrPC in the cell 
membrane of CD4+CD25+ T-regs with the CD4+CD25- population, suggested that this 
type of T-regs also expresses high amounts of PrPC, which is in accordance with 
other publications (Isaacs et al. 2008). In line with the model proposed in this study, 
this observation can be explained by the fact that in the thymic selection process, this 
type of T-regs derives from the non eliminated T-cells that had a highest affinity for 
the Ag-complexed MHC class II (Jordan et al. 2001; Apostolou et al. 2002). 
Taken together, in thymic T-cell development, the highest levels of PrPC expression 
correspond to the positive selection phase for a functional TCRβ. Also, our data as 
well as other publications (Isaacs et al. 2008) suggest that PrPC is present in high 
doses in populations of regulatory T-cells, which classically are selected among the 
T-cells that showed a higher reactivity for self antigens (Jordan et al. 2001; Apostolou 
et al. 2002). Again, this supports the suggestion that PrPC is more expressed in cells 
whose endogenous activatory status appears to be higher. 
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Figure 4.6: PrPC expression in various T-cell populations: Lymphatic tissues from wt mice, and 
Prnp-/- as controls, were collected analysed by flow cytometry for various T-cell populations. A) Dot-
plot for thymic lymphocytes showing expression of CD4 and CD8. B) Dot-plot for thymic CD4-CD8- 
lymphocytes showing expression of CD44 and PrPC. C) Histogram for PrPC expression the Thymic 
populations shown in A) and B). D) Quantification of the average PrPC intensity of the populations 
shown in C) of 4 wt mice (blue) measured in fold increase over the average intensity for the Prnp-/-
(black). Error bars represent the standard error of the mean. E) Dot-plot for CD3+ gated lymph nodal 
lymphocytes with reference for the expression of CD4 and CD8. F) Histogram for PrPC expression the 
Lymph nodal populations shown in E). G) Dot-plot for lymph nodal lymphocytes with reference for the 
expression of CD4 and CD25. H) Histogram for PrPC expression the Lymph nodal populations shown 
in G). 
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4.2.4. Characterization of surface PrPC expression in various B-cell 
populations 
 
Like the T-cell development, B-cell development also has positive and negative 
selection processes. One of the checkpoints is at the end of Pro-B phase, where 
there is a selection for functional pre-BCR complexes. The other important step is at 
immature phase, where another positive and negative selection occurs. In order to 
evaluate if, like in T-cell development, an increase on PrPC expression is correlated 
with states when cellular endogenous activity appears to be higher, the B-cell 
development was characterized in term of PrPC expression. As represented in Figure 
4.7 (A-B) for the bone-marrow of a C57Bl6 mouse, B220-CD19- subset refers to a 
heterogeneous population of precursor cells for various lymphocytic lineages, 
including B-cell precursors. B220+CD19- are the Pro-B-cells, that turn 
B220loCD19+IgM- pre-B-cell, and B220loCD19+IgM+ are immature B-cells. Mature B-
cells are generally represented as B220hiCD19+. Analysis of PrPC expression in all 
these populations showed that PrPC levels are much lower for bone-marrow B-cells, 
than for thymic T-cells (Figure 4.7 C-D). In addition, the subsets showing higher PrPC 
levels are the B220-CD19- heterogeneous population, in agreement with previous 
publications (Liu et al. 2001), and the Pro-B-cells that are in positive selection phase 
for a functional VDJ recombination in the heavy chain of the BCR (Figure 4.7 C-D), 
which agrees with the model the working hypothesis proposed in this study.  
The other phase of B-cell receptor takes place in the spleen. There, transitional B-
cells need to be positively selected for the BCR-Ag interaction, in order to proceed to 
mature follicular B-cells. However, the ones with lower interaction would turn into 
marginal zone cells (Cariappa et al. 2001). Therefore, in line with the observations 
that have been described in this work, it would be expectable a higher PrPC 
expression in transitional B-cells, and low in MZ ones. However, the data suggested 
that the B220+CD21hiCD23int MZ B-cells express the highest levels, and 
B220+CD21loCD23lo transitional, and B220+CD21+CD23hi follicular B-cells express 
the lower levers (Figure 4.7 E-H). But a careful evaluation of the histogram of Figure 
4.7 F shows that transitional B-cells express similar levels of PrPC as MZ, though the 
values of average intensity for this former population were lower than the ones for 
MZ, probably because Transitional B-cell appear to consist of an heterogeneous 
 population, with many PrPC non-expressing B-cells, and with another population with 
higher levels for this protein (Figure 4.7 G-H). This apparent contradiction on PrPC 
enhanced expression in MZ, and low affinity of these cells to the Ag during selection 
process (Cariappa et al. 2001) may be easily explained by the partial activated profile 
of the MZ B-cells (Oliver et al. 1997; Carvalho et al. 2001). 
Taken together, in accordance with my observations with T-cells, in B-cells it also 
appears to exist a correlation between PrPC expression profiles and the endogenous 
activatory status of the B-lymphocytes. 
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Figure 4.7: PrPC expression in various B-cell populations: Lymphatic tissues from wt mice, and 
Prnp-/- as controls, were collected analysed by flow cytometry for various B-cell populations. A) Dot-
plot for bone marrow lymphocytes illustrating various B-cell developmental phases, based on 
expression of B220 and CD19. B) Dot-plot for bone marrow CD19+B220lo lymphocytes showing Pre 
and immature B-cell populations, based on expression of IgM and B220 and PrPC. C) Histogram for 
PrPC expression the bone marrow populations shown in A) and B). D) Quantification of the average 
PrPC intensity of the populations shown in C) of 4 wt mice (blue) measured in fold increase over the 
average intensity for the Prnp-/-(black). Error bars represent the standard error of the mean. E) Dot-plot 
for B-cell final developmental steps in spleen, based on B220+ gated cells with reference for the 
expression of CD21 and CD23. F) Histogram for PrPC expression the splenic populations shown in E). 
G) Quantification of the average PrPC intensity of the populations shown in F) of 2 wt mice (blue) 
measured in fold increase over the average intensity for the Prnp-/-(black). Error bars represent the 
standard error of the mean. 
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4.2.5. Study of the influence of altered expression of PrPC in lymphocyte 
homeostasis 
 
As discussed in the previous sections, PrPC is differentially expressed during 
lymphocyte development, and it appears to be correlated with the activatory status of 
the cell. This observation, together with the model here described, suggests that 
PrPC modulates the activation of lymphocytes. A corollary of this hypothesis is that 
artificial up-regulation of PrPC in lymphocytes may increase their activatory condition 
and therefore induce the autoreactivity and consequently their elimination by 
negative selection, or their positive selection. Given this rationale, a short comparison 
of the lymphocytic homeostasis between wild type (wt), Prnp-/-, and transgenic mice 
overexpressing PrPC was performed. 
The first step was to reproduce previously published data. Jouvin-Marche and 
colleagues made an exhaustive study of the T-cell development of wt mice, and two 
PrPC overexpressing mouse lines: Tg33, which overexpressed PrPC linked to the lck 
promoter (Raeber et al. 1999); and the transgenic Tga20 line that overexpressed 
PrPC earlier in lymphocyte development, because it used the ubiquitous Prnp 
promoter (Fischer et al. 1996). The conclusion of that study was that overexpression 
of PrPC alters T-cell development in the thymus, namely increases the frequency of 
DN cells and decreases DP (Jouvin-Marche et al. 2006). In order to evaluate the 
reproducibility of those results, the T-cell development in Tg33 and Prnp-/- normal 
littermates was assessed. Simultaneously, in order evaluate if the phenotype 
observed was age dependent, two litters of different ages were used: 12 week old, 
and a late age, 19 week old. According to Jouvin-Marche et al. (2006), the thymic 
phenotype of Tg33 appears from 10.5 weeks. 
Analysis of T-cell development in Tg33 and Prnp-/- mice showed no differences in 
the frequency of the various T-cell populations in the thymus of these mice (Figure 
4.8 A-C). It appeared to be a trend for higher frequency of DN (CD4-CD8-) T-cells in 
aged mice (figure 4.8. A-B), but in any of the cases it was not detectable the 
previously reported effect of PrPC overexpression in increasing the proportion of DN 
T-cells and decreasing the DP (CD4+CD8+) ones (Jouvin-Marche et al. 2006). 
Following this study on the Thymus, an effect of PrPC abnormal expression in B-cell 
development in bone marrow was investigated. For this, the late B-cell development 
of Prnp-/-, wt, and the CD19 promoter-linked PrPC overexpressing TgN431 transgenic 
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mouse line (Montrasio et al. 2001) was compared. Because both the transgenic lines 
were in a C57Bl6 and 129Sv mixed background, wt animals of these two 
backgrounds were included. Analysis of the frequencies of the various B-cell 
populations in bone marrow (Figure 4.8 D-E) showed a decrease of IgMhiIgDlo 
immature B-cells, dependent on the PrPC expression. In this experimental setup, 
absence of PrPC increased the proportion on Immature B-cell in about 40%, and its 
overexpression decreased in other 40% the abundance of this IgMhiIgDlo population 
(Figure 4.8 D-E). This observation is in agreement with the predictions that 
manipulation of doses of PrPC expression may alter the activation status of the cell. 
In the Immature phase, lymphocytes are undergoing negative selection, in order to 
eliminate the ones that overreact to self antigens (Erikson et al. 1991; Hartley et al. 
1991). Overexpression of PrPC in high doses, may immediately dictate the 
elimination of these hyper-responsive cells. In contrast, hypo-responsive Prnp-/- 
immature B-cells would be arrested in the development in order do V-J 
rearrangements in the light chain of the immunoglobulin. 
Other cell populations in the periphery were also analysed, namely the CD3+CD4-
CD8- population that was shown previously to be a high PrPC-expressing subset 
(Figure 4.8 F-G). These cells have been referred to include the DN regulatory T-cells 
(Zhang et al. 2000; Ford et al. 2006), which were suggested to comprise 1-5% of the 
peripheral T-cells of human and mice (Thomson et al. 2006). It appeared that in 
lymph nodes, the abundance of these cells may be directly modulated by the amount 
of PrPC expressed, with a very high frequency in Tga20 mice. The particularity of the 
Tga20 phenotype has been suggested by others to be also influenced by the 
insertion site of the Prnp genes (Zabel et al. 2008). This is in agreement with the 
observation that regulatory T-cells are hipper-responsive cells, which are classically 
selected among the T-cells with higher reactivity for self antigens (Jordan et al. 2001; 
Apostolou et al. 2002). 
Taken together, data here suggests that the published effect of PrPC 
overexpression on T-cell development (Jouvin-Marche et al. 2006) is not dependent 
on PrPC expression, given the fact that Prnp-/-, which was not assessed in the original 
publication, and the PrPC overexpressing Tg33 mouse, had no notorious differences 
in T-cell development in thymus. In addition, data suggests that PrPC expression may 
influence the positive and negative BCR selection events on immature B-cells in the 
bone marrow. Finally, it suggests the existence of an expansion of the regulatory T-
 cell compartment in transgenic mice expressing high levels of PrPC. This observed 
inverse correlation between dose of PrPC and percentage of immature B-cells, and 
direct correlation with the abundance of regulatory T-cells is in agreement with the 
results already discussed here and with the working hypothesis that PrPC modulates 
the activatory status of a cell. 
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Figure 4.8: Influence of altered expression of PrPC in lymphocyte homeostasis. A) Dot-plot 
illustrating thymic T-cell developmental populations from Prnp-/- mice (top) and PrPC overexpression 
Tg33 (bottom), with 12 (left) or 19 (right) weeks of age. B) and C) Quantification of the percentage of 
CD4-CD8- DN (B) and CD4+CD8+ DP (C) populations from the dot-plots form A). D) Dot-plot 
illustrating bone marrow B-cell developmental populations from Prnp-/- (first panel), C57Bl6 (second 
panel), 129Sv (third panel) and PrPC overexpressing TgN431 mice (fourth panel). E) Quantification of 
the percentage of IgMhiIgDlo immature B-cell population from the results represented by the dot-plots 
in D). F) Dot-plot illustrating lymph nodal T-cell populations from Prnp-/- (first panel), wt (second panel), 
and PrPC overexpressing Tg33 (third panel) and Tga20 (fourth panel). E) Quantification of the 
percentage of CD3+CD4-CD8- T-cells population from the results represented by the dot-plots in F). 
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4.2.6. Role of PrPC in TCR signalling 
 
Given the data described above, suggesting that PrPC expression alters the 
lymphocytic homeostasis, I decided to evaluate the role of PrPC in modulating the 
intensity of the signals that reach a lymphocyte through its antigen receptor. The 
working hypothesis was that overexpression of PrPC would decrease the lymphocytic 
activation threshold, and therefore promote the positive selection of lymphocytes with 
lower expression of the costimulatory molecules that participate in the antigen 
receptor signalling. A result of this model would be that the positively selected T-cells 
that proliferating in the periphery would have a lower expression of CD3, in order to 
weaken the signal provided to the cell, through interaction of MHC with the Ag (Gil et 
al. 2005; Kuhns et al. 2006). 
In order to test this hypothesis, it was first assessed by flow cytometry the 
expression of surface CD3 in T-cells in lymph nodes, in mouse lines overexpressing 
PrPC, Tg33 and Tga20, and in wt and Prnp-/- mice. A first approach confirmed that 
mature T-cells of mice overexpressing PrPC had lower quantity of the costimulatory 
CD3 molecule at the surface, comparing with wt and Prnp-/- mice (Figure 4.9 A-B). 
The working hypothesis would also predict that absence of PrPC would select for 
lymphocytes with higher expression of CD3, however, there were detected no 
differences between Prnp-/- and wt (Figure 4.9 A-B). This could indicate that T-cells 
are more sensitive to overexpression of PrPC, than to the absence of it. 
These results were later confirmed when it were compared the levels of CD3 
expression in T-cells from the spleen of Prnp-/- mice and PrPC overexpressing Tg33 
normal littermates. In spite of the high variability observed in the Prnp-/- sample, in 
this paradigm it was again observed the trend of detecting lower quantity of CD3 at 
the membrane in mice overexpressing PrPC (Figure 4.9 C-D). Furthermore, it 
appeared that in these transgenic conditions, lymphocytes in older animals were 
more susceptible to the effect of overexpressing PrPC, and showed a more 
pronounced trend for down-regulation CD3 (Figure 4.9 C-D). 
These evidences for a role of PrPC in modulating the cell activation status, 
prompted for a more crucial experiment. I decided to evaluate if overexpression of 
PrPC in thymocytes would partially revert the absence of MHC class II, in the positive 
selection process. For this, the Aa0/Aa0 mice were used. These animals completely 
lacked MHC class II (Kontgen et al. 1993), and were crossed with PrPC 
 overexpressing Tg33 mice. Knocking out MHC class II is not sufficient to abolish CD4 
T-cell development, because there are cases of low affinity interactions of CD4 
molecule with MHC class I, which may allow the positive selection and the 
maintenance of a small population of CD4+ T-cells (Kontgen et al. 1993; Chan et al. 
1998). The working hypothesis was that PrPC up-regulation in mice devoid of MHC 
class II, would result in a decrease of the activation threshold, and therefore allow the 
maintenance of a slightly larger population of CD4 T-cells. 
Analysis of the lymph nodes of Prnp+/- Aa0/Aa0 mice showed a large presence of 
CD8 T-cells, comparing with CD4 T-cells (Figure 4.9 E-F). However, overexpression 
of PrPC resulted in the maintenance of an about 10% larger population of CD4 T-cells 
(Figure 4.9 E-F). Though this increase was not very pronounced, it provides another 
piece of evidence for a role of PrPC in modulating cell activation.  
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Figure 4.9: PrPC influences TCR signalling. A) CD3+ gated histogram for CD3 expression the lymph 
node T-cell populations of Prnp-/-, wt, and PrPC overexpressing Tg33 and Tga20 mice. B) 
Quantification of the median CD3 intensity of the populations shown in A). C) CD3+ gated histogram 
for CD3 expression the splenic T-cell populations of Prnp-/- and PrPC overexpressing Tg33 normal 
littermates of 12 and 19 weeks of age. D) Quantification of the median CD3 intensity of the 
populations shown in C). E) Representative dot-plots for CD4 and CD8 expression on CD3+ gated 
lymph node cells of MHC class II deficient Prnp+/- Aa0/Aa0 mice and PrPC overexpressing MHC class II 
deficient Tg33 Prnp+/- Aa0/Aa0 normal littermates. F) Quantification of the CD4+/CD8+ ratio from the 
dot-plots shown in E), with n=3. 
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4.3. Discussion 
 
The goal for this set of experiments was to test the assumption that overexpression 
of PrPC would modulate cell activation, and that a continuous non-physiological 
maintenance of an activatory status of many cells could lead to toxicity and 
degeneration of a certain system. In fact many functions, properties and interacting 
partners have been already appointed to PrPC, which could all be explained by this 
assumption (Aguzzi et al. 2008a; Hu et al. 2008; Zomosa-Signoret et al. 2008; 
Mazzoni et al. 2005), however there was the need to confirm this paradigm, given the 
central role it played in the general model proposed here, for the role of PrPC in 
neurotoxicity. In this chapter it was shown that PrPC is quickly up-regulated upon T-
cell activation, in a time-frame faster that what has been reported. It also provided for 
the first time evidence for PrPC being up-regulated upon B-cell activation, but in a 
much less pronounced fashion. These results were confirmed in vivo by showing that 
B and T-cell in the periphery, expressing the activation marker CD69, also expressed 
higher levels of PrPC. Furthermore, data also indicated that in B and T-cell 
development, the higher PrPC expresser cells are the ones that are facing positive 
selection and therefore have a higher activatory status, like the Pro-B-cells in bone 
marrow and the DN T-cells in thymus. And this pattern was also detectable in other 
population with a higher activatory status, like regulatory T-cells and marginal zone 
B-cells. 
But more than providing evidence for a correlation between abundance of PrPC and 
the activatory status of a cell, this work aimed to show that altered PrPC expression 
interferes with the lymphocyte developmental stages where positive or negative 
selection are involved. Data suggested that this does not occur during the various 
thymic T-cell developmental stages, therefore contradicting the conclusions achieved 
by others (Jouvin-Marche et al. 2006). In this respect, the results presented here 
indicated that T-cell development in PrPC overexpressing Tg33 mice appears to be 
similar to the one of Prnp-/- mice, and in the studies referred (Jouvin-Marche et al. 
2006), this knockout mouse line was not studied. I propose that the absence in 
previous studies of data relative to the Prnp-/- line (Jouvin-Marche et al. 2006) may 
have been the main reason for this contradiction. But despite of the absence of 
evidence for a role of PrPC in modulating T-cell development in thymus, data here 
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indicated that PrPC expression may modulate other processes in lymphocyte 
development and homeostasis, as the abundance of regulatory T-cells and the 
amount of immature B-cells at the bone marrow. This last population had a lower 
frequency in transgenic mice expressing high doses of PrPC at the cell membrane, 
and was elevated in Prnp-/- animals, which can result from the fact that 
overexpression of PrPC may have induced a higher activatory status on the cell, and 
consequent deletion due to over-reactivity against self antigens. Also, a lower 
activatory status induced by deletion of PrPC should result in an increase of anergy of 
immature B-cells, and consequent arrest at this stage, for BCR recombination. 
Such an effect of PrPC in the activatory status of a lymphocyte would imply that the 
T-cells in the periphery, which would transgenically express high doses of PrPC, 
would have to decrease the expression of the proteins that positively participate in 
the TCR signalling. And in fact this was observed in PrPC overexpressing Tga20 and 
Tg33 mice. Though with a small sample size, it was shown here that in two 
independent experimental setups, there is a trend for a decrease of the expression of 
membrane CD3 in T-cells from mice with high doses of PrPC, both in lymph nodes 
and in spleen. But the most convincing result for demonstrating that PrPC is a 
modulator of the activatory status of a cell was the observation that PrPC 
overexpression could partially revert the CD4 T-cell selection arrest of mice devoid of 
MHC class II. This is the first time that it was shown that overexpression of PrPC can 
compensate the deficiency of MHC molecule and therefore provides strong evidence 
for a participation of PrPC in the TCR signalling pathway, or in a complementary cell 
activation cascade. 
There are however two main arguments that main weaken the certainty of the data 
presented here. One is the low sample size used in some of the experiments, the 
other is the fact that the background differences of the mice used and the transgene 
insertion site on the transgenic lines advise for caution in interpreting the results. On 
the other hand, this work provided a large set of experiments, using in total two wt 
and six transgenic mouse lines, and although the results obtained sufficed to 
disprove previous research works, they never contradicted the main working 
hypothesis of this work, but rather supported it. Furthermore, many of the 
observations presented here, were supported by previous reports. For these 
reasons, the most parsimonic explanation for the data presented here and for the 
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observations done in other reports is that PrPC modulates the activatory status in 
certain lymphocyte populations. 
 
4.4. Outlook 
 
Despite the conclusion described here results from the observation of a large set of 
experiments performed in many different paradigms and using a total of 8 mouse 
lines, this study still has some weaknesses that can be easily overcome. One of the 
actions to be taken is to increase the sample size of these experiments. Another 
important experiment would be to graft lymphocytes from the various mouse lines 
used, into a single recipient mouse, and to evaluate the influence of PrPC expression 
would favour the selection of certain lymphocyte populations. 
 The “Holly Grail” of prionology is to uncover the main physiological function of 
PrPC. For this, one of the approaches is to assess the molecular pathways where 
PrPC is integrated. In this study I described a phenotype of mice with altered PrPC 
expression, and showed that CD3 is down-regulated in transgenic mice 
overexpressing PrPC. Thus, it is important to evaluate the position of PrPC in the 
TCR/CD3 signalling pathway. PrPC is located in the lipid rafts, and therefore it is 
possible that it participates in the immunological synapse. On the other hand, PrPC 
may function internally, upon its internalization. These possibilities urge to be 
clarified. 
Another important experiment is to evaluate if PrPC mutations that result in toxicity 
act on the same pathway as PrPC overexpression. This could be done either using 
the MHC class II deletion model, or by assessing if CD3 and other TCR costimulatory 
molecules, are also down-regulated in mice bearing toxic PrP molecules. As a follow-
up, it would be important to investigate if PrPSc would also act in the same pathway. 
The integration of these 3 PrP features (PrPSc, PrP toxic mutants, and PrPC 
overexpression at very high doses) in a single pathway is another of the main 
assumptions of our model, and for many years has been a central question in the 
field. 
Many other further studies can be done using this system, however, I consider that 
the focus of future work should be in: i) Identifying the main molecular pathways 
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influenced by PrPC expression; ii) Evaluating if PrPSc, PrPC toxic mutants, and PrPC 
abnormal overexpression share the same toxic pathways. 
 
4.5. Materials and methods 
 
4.5.1. Mice used 
 
Tga20 (Fischer et al. 1996), Tg33 (Raeber et al. 1999), and TgN431 (Montrasio et 
al. 2001), are PrPC overexpressing transgenic mice, with the Prnp gene linked to the 
Prnp, Lck, and CD19 promoter, respectively. These mice, together with Prnp-/- mice 
(Büeler et al. 1992) are all in a background mixture of C57Bl6 (Harlan Laboratories) 
and 129Sv (Charles River). Aa0/Aa0 mice (Kontgen et al. 1993) were in C57Bl6 
background, and were crossed with Tg33. F2 Tg33+Prnp+/- Aa0/Aa0 were used. If not 
described, wt designation always referred to C57Bl6 strain. Unless stated otherwise, 
mice were 12 week old. 
 
4.5.2. Flow cytometry 
 
Mouse organs were collected, and cell suspensions were kept on ice, in PBS 2% 
FCS.  
Antibodies used for stainings were PerCP- and PE- labelled CD3 and CD4, PE- 
and APC- CD8, PE- CD69, FITC- and PerCP- B220, FITC- CD44, PE- CD25, FITC- 
CD21, PE- CD23, PE- CD43, PE- CD19, FITC- and PE- IgM, PE- IgD, and FITC- 
IAb, all were obtained from BD Biosciences. Anti PrP POM2 antibody (Polymenidou 
et al. 2008) was labelled with Cy5. 
Data was analysed using FlowJo software. 
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4.5.3. in vitro lymphocyte culture 
 
Splenocytes were obtained from C57Bl6 and Prnp-/- mice. Cells were cultured with 
RPMI, 10%FCS, 1mM NaPiruvate, and 0.05mM 2-ME, in presence or absence of 
25ng/ml PMA (phorbol 12-myristate 13-acetate) and 0.5uM ionomycin (ionophore). 
Cells were harvested at the various time-points and kept on ice. All samples were 
stained and analysed at the same time.  
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5. Final considerations 
 
The term “Prion” has more than 25 years old (Prusiner 1982), and the fundaments 
of the protein-only hypothesis are from the 60’s (Griffith 1967). But in spite of the big 
effort put in prion research in all these years, the main fundamental questions are still 
unanswered: The physiological function of PrPC remains elusive; the published data 
about interacting partners of PrPC is largely contradictory; the mechanisms of PrP-
dependent toxicity are still an enigma; and there is even no certainty about the 
number of mechanisms on how an altered PrPC molecule can result in toxicity. 
The main aim for this work was to draw a model that would conciliate all the 
information available on PrPC function and toxicity. This was obviously a very 
ambitious goal, but nevertheless I elaborated a model on the function of PrPC and on 
the mechanisms of PrP-dependent toxicity induced by PrPSc, PrPC mutants, and 
probably abnormal PrPC overexpression (Westaway et al. 1994b). I believe that the 
model presented in this dissertation is the one that congregates more data and has 
the higher parsimony. 
The step was to investigate the mechanism that I proposed to the driving one for 
regulating the function of PrPC. I rationalised that α-cleavage of PrPC was the most 
significant process by which PrP could be regulated, and the main factor that would 
explain the PrP-dependent toxicity. Therefore, I dedicated my efforts in 
understanding the way α-cleavage is regulated. My results provided a 
characterization of the PrPC domains and factors involved in modulating this 
cleavage, which illustrated for the first time the exceptional features of this proteolytic 
process. α-cleavage appears to be largely sequence independent, charge 
independent, hydrophobicity independent, of the region of cleavage site. These 
characteristics are not common in the literature, but may find a certain degree of 
parallelism in the cleavage plasticity of γ-secretase. 
Following the study on the characterization of the main player in the conceptual 
model proposed here, I decided to validate the main assumption on this system. I 
assumed that PrPC internalization would lead to cell activation, and that a miss-
regulation of this process could be the basis of PrP-dependent toxicity. For this, I 
chose to use the immune system as a biological model for cell activation, mainly 
because lymphocytes undergo positive and negative selection during its 
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development, and therefore may be used to test situations of cell hypo- and hyper-
reactivity. Data indicated that PrPC is up-regulated upon lymphocyte activation and 
that the populations with more elevated levels of PrPC expression are generally the 
ones that are activated or that have a higher reactivity or activatory status. It also 
suggested that altered expression of PrPC results in an alteration of the lymphocytic 
homeostasis, favouring the elimination of lymphocytes undergoing negative selection 
for hyper-reactivity, in case of overexpression of PrPC, and the inverse if PrPC was 
knocked-out. Finally, data provided evidence for an influence of PrPC in the TCR 
signalling pathway: positively selected lymphocytes overexpressing PrPC had a 
reduction in CD3 expression, and additionally, high levels of PrPC partially reverted 
the phenotype of mice devoid of MHC class II, by enhancing the positive selection of 
CD4 T-cells. 
Globally this work provides a unified model of PrPC function and of the PrP-
dependent mechanisms of toxicity. It also characterizes the α-cleavage of PrPC, 
which is the main driving force of the model here proposed, and provides data 
supporting the main assumption of the model, which is that PrPC expression 
modulates cell activation.  
 
  91
6. References 
 
Aguzzi, A. 2004. Understanding the diversity of prions. Nat Cell Biol 6 (4):290-292. 
———. 2006. Prion diseases of humans and farm animals: epidemiology, genetics, and 
pathogenesis. J Neurochem 97 (6):1726-1739. 
Aguzzi, A., F. Baumann, and J. Bremer. 2008a. The prion's elusive reason for being. Annu 
Rev Neurosci 31:439-477. 
Aguzzi, A., M. Heikenwalder, and M. Polymenidou. 2007a. Insights into prion strains and 
neurotoxicity. Nat Rev Mol Cell Biol 8 (7):552-561. 
Aguzzi, A., C. Sigurdson, and M. Heikenwaelder. 2008b. Molecular mechanisms of prion 
pathogenesis. Annu Rev Pathol 3:11-40. 
Aguzzi, A., C. Sigurdson, and M. Heikenwalder. 2007b. Molecular Mechanisms of Prion 
Pathogenesis. Annu Rev Pathol. 
Aguzzi, A., and C. J. Sigurdson. 2004. Antiprion immunotherapy: to suppress or to stimulate? 
Nat Rev Immunol. 4 (9):725-736. 
Aguzzi, A., and C. Weissmann. 1997. Prion research: the next frontiers. Nature 389:795-798. 
Alper, T., W. A. Cramp, D. A. Haig, and M. C. Clarke. 1967. Does the agent of scrapie 
replicate without nucleic acid? Nature 214 (90):764-766. 
Alper, T., D. A. Haig, and M. C. Clarke. 1966. The exceptionally small size of the scrapie 
agent. Biochem Biophys Res Commun 22 (3):278-284. 
Apostolou, I., A. Sarukhan, L. Klein, and H. von Boehmer. 2002. Origin of regulatory T cells 
with known specificity for antigen. Nat Immunol 3 (8):756-763. 
Bain, G., E. C. Maandag, D. J. Izon, D. Amsen, A. M. Kruisbeek, B. C. Weintraub, I. Krop, 
M. S. Schlissel, A. J. Feeney, M. van Roon, and et al. 1994. E2A proteins are required 
for proper B cell development and initiation of immunoglobulin gene rearrangements. 
Cell 79 (5):885-892. 
Bainbridge, J., and K. B. Walker. 2005. The normal cellular form of prion protein modulates 
T cell responses. Immunol Lett 96 (1):147-150. 
Ballerini, C., P. Gourdain, V. Bachy, N. Blanchard, E. Levavasseur, S. Gregoire, P. Fontes, P. 
Aucouturier, C. Hivroz, and C. Carnaud. 2006. Functional implication of cellular 
prion protein in antigen-driven interactions between T cells and dendritic cells. J 
Immunol 176 (12):7254-7262. 
Bareggi, S. R., D. Braida, M. Gervasoni, G. Carcassola, C. Pollera, C. Verzoni, and M. Sala. 
2003. Neurochemical and behavioural modifications induced by scrapie infection in 
golden hamsters. Brain Res 984 (1-2):237-241. 
Basler, K., B. Oesch, M. Scott, D. Westaway, M. Walchli, D. F. Groth, M. P. McKinley, S. B. 
Prusiner, and C. Weissmann. 1986. Scrapie and cellular PrP isoforms are encoded by 
the same chromosomal gene. Cell 46 (3):417-428. 
Bassant, M. H., M. Picard, D. Olichon, F. Cathala, and L. Court. 1986. Changes in the 
serotonergic, noradrenergic and dopaminergic levels in the brain of scrapie-infected 
rats. Brain Res 367 (1-2):360-363. 
Baumann, F., M. Tolnay, C. Brabeck, J. Pahnke, U. Kloz, H. H. Niemann, M. Heikenwalder, 
T. Rulicke, A. Burkle, and A. Aguzzi. 2007. Lethal recessive myelin toxicity of prion 
protein lacking its central domain. Embo J 26 (2):538-547. 
Bendheim, P. E., H. R. Brown, R. D. Rudelli, L. J. Scala, N. L. Goller, G. Y. Wen, R. J. 
Kascsak, N. R. Cashman, and D. C. Bolton. 1992. Nearly ubiquitous tissue 
distribution of the scrapie agent precursor protein. Neurology 42 (1):149-156. 
Berndt, R. M. 1981. In the steps of kuru [letter]. Lancet 1:381. 
  92
Bikah, G., J. Carey, J. R. Ciallella, A. Tarakhovsky, and S. Bondada. 1996. CD5-mediated 
negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 
274 (5294):1906-1909. 
Bolton, D. C., M. P. McKinley, and S. B. Prusiner. 1982. Identification of a protein that 
purifies with the scrapie prion. Science 218 (4579):1309-1311. 
Bolton, D. C., S. J. Seligman, G. Bablanian, D. Windsor, L. J. Scala, K. S. Kim, C. M. Chen, 
R. J. Kascsak, and P. E. Bendheim. 1991. Molecular location of a species-specific 
epitope on the hamster scrapie agent protein. J Virol 65 (7):3667-3675. 
Borchelt, D. R., M. Scott, A. Taraboulos, N. Stahl, and S. B. Prusiner. 1990. Scrapie and 
cellular prion proteins differ in their kinetics of synthesis and topology in cultured 
cells. J Cell Biol 110 (3):743-752. 
Borghesi, L., L. Y. Hsu, J. P. Miller, M. Anderson, L. Herzenberg, M. S. Schlissel, D. 
Allman, and R. M. Gerstein. 2004. B lineage-specific regulation of V(D)J 
recombinase activity is established in common lymphoid progenitors. J Exp Med 199 
(4):491-502. 
Brandel, J. P., N. Delasnerie-Laupretre, J. L. Laplanche, J. J. Hauw, and A. Alperovitch. 
2000. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence 
estimates [In Process Citation]. Neurology 54 (5):1095-1099. 
Brandner, S., S. Isenmann, A. Raeber, M. Fischer, A. Sailer, Y. Kobayashi, S. Marino, C. 
Weissmann, and A. Aguzzi. 1996a. Normal host prion protein necessary for scrapie-
induced neurotoxicity. Nature 379 (6563):339-343. 
Brandner, S., A. Raeber, A. Sailer, T. Blattler, M. Fischer, C. Weissmann, and A. Aguzzi. 
1996b. Normal host prion protein (PrPC) is required for scrapie spread within the 
central nervous system. Proc Natl Acad Sci U S A 93 (23):13148-13151. 
Brown, D. R. 2002. Mayhem of the multiple mechanisms: modelling neurodegeneration in 
prion disease. J Neurochem 82 (2):209-215. 
Brown, D. R., B. S. Wong, F. Hafiz, C. Clive, S. J. Haswell, and I. M. Jones. 1999a. Normal 
prion protein has an activity like that of superoxide dismutase [published erratum 
appears in Biochem J 2000 Feb 1;345 Pt 3:767]. Biochem J 344 Pt 1:1-5. 
Brown, K. L., K. Stewart, D. L. Ritchie, N. A. Mabbott, A. Williams, H. Fraser, W. I. 
Morrison, and M. E. Bruce. 1999b. Scrapie replication in lymphoid tissues depends on 
prion protein- expressing follicular dendritic cells. Nat Med 5 (11):1308-1312. 
Brown, P., and D. C. Gajdusek. 1991. Survival of scrapie virus after 3 years' interment. 
Lancet 337 (8736):269-270. 
Bruce, M. E., and A. G. Dickinson. 1987. Biological evidence that scrapie agent has an 
independent genome. J Gen Virol 68 (Pt 1):79-89. 
Bruce, M. E., I. McConnell, H. Fraser, and A. G. Dickinson. 1991. The disease characteristics 
of different strains of scrapie in Sinc congenic mouse lines: implications for the nature 
of the agent and host control of pathogenesis. J Gen Virol 72 (Pt 3):595-603. 
Büeler, H. R., A. Aguzzi, A. Sailer, R. A. Greiner, P. Autenried, M. Aguet, and C. 
Weissmann. 1993. Mice devoid of PrP are resistant to scrapie. Cell 73 (7):1339-1347. 
Büeler, H. R., M. Fischer, Y. Lang, H. Bluethmann, H. P. Lipp, S. J. DeArmond, S. B. 
Prusiner, M. Aguet, and C. Weissmann. 1992. Normal development and behaviour of 
mice lacking the neuronal cell-surface PrP protein. Nature 356:577-582. 
Campana, V., D. Sarnataro, and C. Zurzolo. 2005. The highways and byways of prion protein 
trafficking. Trends Cell Biol 15 (2):102-111. 
Canelles, M., M. L. Park, O. M. Schwartz, and B. J. Fowlkes. 2003. The influence of the 
thymic environment on the CD4-versus-CD8 T lineage decision. Nat Immunol 4 
(8):756-764. 
  93
Cariappa, A., M. Tang, C. Parng, E. Nebelitskiy, M. Carroll, K. Georgopoulos, and S. Pillai. 
2001. The follicular versus marginal zone B lymphocyte cell fate decision is regulated 
by Aiolos, Btk, and CD21. Immunity 14 (5):603-615. 
Carvalho, T. L., T. Mota-Santos, A. Cumano, J. Demengeot, and P. Vieira. 2001. Arrested B 
lymphopoiesis and persistence of activated B cells in adult interleukin 7(-/)- mice. J 
Exp Med 194 (8):1141-1150. 
Cashman, N. R., R. Loertscher, J. Nalbantoglu, I. Shaw, R. J. Kascsak, D. C. Bolton, and P. 
E. Bendheim. 1990. Cellular isoform of the scrapie agent protein participates in 
lymphocyte activation. Cell 61 (1):185-192. 
Castilla, J., P. Saa, C. Hetz, and C. Soto. 2005. In vitro generation of infectious scrapie prions. 
Cell 121 (2):195-206. 
Caughey, B. 2003. Prion protein conversions: insight into mechanisms, TSE transmission 
barriers and strains. Br Med Bull 66:109-120. 
Caughey, B., R. E. Race, D. Ernst, M. J. Buchmeier, and B. Chesebro. 1989. Prion protein 
biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol 63 
(1):175-181. 
Chan, S., M. Correia-Neves, C. Benoist, and D. Mathis. 1998. CD4/CD8 lineage 
commitment: matching fate with competence. Immunol Rev 165:195-207. 
Chatelain, J., F. Cathala, P. Brown, S. Raharison, L. Court, and D. C. Gajdusek. 1981. 
Epidemiologic comparisons between Creutzfeldt-Jakob disease and scrapie in France 
during the 12-year period 1968-1979. J Neurol Sci 51 (3):329-337. 
Checler, F., and B. Vincent. 2002. Alzheimer's and prion diseases: distinct pathologies, 
common proteolytic denominators. Trends Neurosci 25 (12):616-620. 
Chen, S., A. Mange, L. Dong, S. Lehmann, and M. Schachner. 2003. Prion protein as trans-
interacting partner for neurons is involved in neurite outgrowth and neuronal survival. 
Mol Cell Neurosci 22 (2):227-233. 
Chen, S. G., D. B. Teplow, P. Parchi, J. K. Teller, P. Gambetti, and L. Autilio Gambetti. 
1995. Truncated forms of the human prion protein in normal brain and in prion 
diseases. J Biol Chem 270 (32):19173-19180. 
Chesebro, B., M. Trifilo, R. Race, K. Meade-White, C. Teng, R. LaCasse, L. Raymond, C. 
Favara, G. Baron, S. Priola, B. Caughey, E. Masliah, and M. Oldstone. 2005. 
Anchorless prion protein results in infectious amyloid disease without clinical scrapie. 
Science 308 (5727):1435-1439. 
Chiarini, L. B., A. R. Freitas, S. M. Zanata, R. R. Brentani, V. R. Martins, and R. Linden. 
2002. Cellular prion protein transduces neuroprotective signals. EMBO J 21 
(13):3317-3326. 
Ciofani, M., G. C. Knowles, D. L. Wiest, H. von Boehmer, and J. C. Zuniga-Pflucker. 2006. 
Stage-specific and differential notch dependency at the alphabeta and gammadelta T 
lineage bifurcation. Immunity 25 (1):105-116. 
Cisse, M. A., C. Gandreuil, J. F. Hernandez, J. Martinez, F. Checler, and B. Vincent. 2006. 
Design and characterization of a novel cellular prion-derived quenched fluorimetric 
substrate of alpha-secretase. Biochem Biophys Res Commun 347 (1):254-260. 
Cisse, M. A., C. Sunyach, S. Lefranc-Jullien, R. Postina, B. Vincent, and F. Checler. 2005. 
The disintegrin ADAM9 indirectly contributes to the physiological processing of 
cellular prion by modulating ADAM10 activity. J Biol Chem 280 (49):40624-40631. 
Coitinho, A. S., R. Roesler, V. R. Martins, R. R. Brentani, and I. Izquierdo. 2003. Cellular 
prion protein ablation impairs behavior as a function of age. Neuroreport 14 
(10):1375-1379. 
Colchester, A. C., and N. T. Colchester. 2005. The origin of bovine spongiform 
encephalopathy: the human prion disease hypothesis. Lancet 366 (9488):856-861. 
  94
Colling, S. B., J. Collinge, and J. G. R. Jefferys. 1996. Hippocampal Slices From Prion 
Protein Null Mice - Disrupted Ca2+-Activated K+ Currents. Neuroscience Letters 209 
(1):49-52. 
Colling, S. B., M. Khana, J. Collinge, and J. G. Jefferys. 1997. Mossy fibre reorganization in 
the hippocampus of prion protein null mice. Brain Res 755 (1):28-35. 
Collinge, J. 1997. Human prion diseases and bovine spongiform encephalopathy (BSE). Hum 
Mol Genet 6 (10):1699-1705. 
Collinge, J., J. Brown, J. Hardy, M. Mullan, M. N. Rossor, H. Baker, T. J. Crow, R. 
Lofthouse, M. Poulter, R. Ridley, and e. al. 1992. Inherited prion disease with 144 
base pair gene insertion. 2. Clinical and pathological features. Brain 115:687-710. 
Collinge, J., and M. Rossor. 1996. A new variant of prion disease. Lancet 347 (9006):916-
917. 
Collinge, J., K. C. Sidle, J. Meads, J. Ironside, and A. F. Hill. 1996. Molecular analysis of 
prion strain variation and the aetiology of 'new variant' CJD. Nature 383 (6602):685-
690. 
Collinge, J., M. A. Whittington, K. C. Sidle, C. J. Smith, M. S. Palmer, A. R. Clarke, and J. 
G. Jefferys. 1994. Prion protein is necessary for normal synaptic function. Nature 370 
(6487):295-297. 
Couzin, J. 2004. Biomedicine. An end to the prion debate? Don't count on it. Science 305 
(5684):589. 
Creutzfeldt, H. G. 1920. Über eine eigenartige herdförmige Erkrankung des 
Zentralnervensystems. Z. ges. Neurol. Psychiatr. 57:1-19. 
Criado, J. R., M. Sanchez-Alavez, B. Conti, J. L. Giacchino, D. N. Wills, S. J. Henriksen, R. 
Race, J. C. Manson, B. Chesebro, and M. B. Oldstone. 2005. Mice devoid of prion 
protein have cognitive deficits that are rescued by reconstitution of PrP in neurons. 
Neurobiol Dis 19 (1-2):255-265. 
Crozet, C., F. Beranger, and S. Lehmann. 2008. Cellular pathogenesis in prion diseases. Vet 
Res 39 (4):44. 
Cuille, J., and P. L. Chelle. 1939. Experimental transmission of trembling to the goat. C R 
Seances Acad Sci 208:1058-1160. 
Cunningham, C., R. Deacon, H. Wells, D. Boche, S. Waters, C. P. Diniz, H. Scott, J. N. 
Rawlins, and V. H. Perry. 2003. Synaptic changes characterize early behavioural signs 
in the ME7 model of murine prion disease. Eur J Neurosci 17 (10):2147-2155. 
de Almeida, C. J., L. B. Chiarini, J. P. da Silva, E. S. PM, M. A. Martins, and R. Linden. 
2005. The cellular prion protein modulates phagocytosis and inflammatory response. J 
Leukoc Biol 77 (2):238-246. 
Deleault, N. R., B. T. Harris, J. R. Rees, and S. Supattapone. 2007. Formation of native prions 
from minimal components in vitro. Proc Natl Acad Sci U S A 104 (23):9741-9746. 
Dickinson, A. G., and V. M. Meikle. 1971. Host-genotype and agent effects in scrapie 
incubation: change in allelic interaction with different strains of agent. Mol Gen Genet 
112 (1):73-79. 
Diez, M., D. Groth, S. J. DeArmond, S. B. Prusiner, and T. Hokfelt. 2007. Changes in 
neuropeptide expression in mice infected with prions. Neurobiol Aging 28 (5):748-
765. 
Duffy, P., J. Wolf, G. Collins, A. G. DeVoe, B. Streeten, and D. Cowen. 1974. Possible 
person-to-person transmission of Creutzfeldt-Jakob disease. N Engl J Med 290 
(12):692-693. 
Eckroade, R. J., G. M. ZuRhein, and R. P. Hanson. 1973. Transmissible mink encephalopathy 
in carnivores: clinical, light and electron microscopic studies in raccons, skunks and 
ferrets. J Wildl Dis 9 (3):229-240. 
  95
Ehrmann, M., and T. Clausen. 2004. Proteolysis as a regulatory mechanism. Annu Rev Genet 
38:709-724. 
Erikson, J., M. Z. Radic, S. A. Camper, R. R. Hardy, C. Carmack, and M. Weigert. 1991. 
Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature 
349 (6307):331-334. 
Fang, W., B. C. Weintraub, B. Dunlap, P. Garside, K. A. Pape, M. K. Jenkins, C. C. 
Goodnow, D. L. Mueller, and T. W. Behrens. 1998. Self-reactive B lymphocytes 
overexpressing Bcl-xL escape negative selection and are tolerized by clonal anergy 
and receptor editing. Immunity 9 (1):35-45. 
Field, E. J. 1966. Transmission experiments with multiple sclerosis: an interim report. Br Med 
J 2 (513):564-565. 
Fischer, M., T. Rülicke, A. Raeber, A. Sailer, M. Moser, B. Oesch, S. Brandner, A. Aguzzi, 
and C. Weissmann. 1996. Prion protein (PrP) with amino-proximal deletions restoring 
susceptibility of PrP knockout mice to scrapie. EMBO J 15 (6):1255-1264. 
Ford, M. J., L. J. Burton, R. J. Morris, and S. M. Hall. 2002. Selective expression of prion 
protein in peripheral tissues of the adult mouse. Neuroscience 113 (1):177-192. 
Ford, M. S., Z. X. Zhang, W. Chen, and L. Zhang. 2006. Double-negative T regulatory cells 
can develop outside the thymus and do not mature from CD8+ T cell precursors. J 
Immunol 177 (5):2803-2809. 
Fraser, E., A. M. McDonagh, M. Head, M. Bishop, J. W. Ironside, and D. M. Mann. 2003. 
Neuronal and astrocytic responses involving the serotonergic system in human 
spongiform encephalopathies. Neuropathol Appl Neurobiol 29 (5):482-495. 
Fuhrmann, M., T. Bittner, G. Mitteregger, N. Haider, S. Moosmang, H. Kretzschmar, and J. 
Herms. 2006. Loss of the cellular prion protein affects the Ca2+ homeostasis in 
hippocampal CA1 neurons. J Neurochem 98 (6):1876-1885. 
Fulcher, D. A., and A. Basten. 1994. Reduced life span of anergic self-reactive B cells in a 
double-transgenic model. J Exp Med 179 (1):125-134. 
Gabriel, J. M., B. Oesch, H. Kretzschmar, M. Scott, and S. B. Prusiner. 1992. Molecular 
cloning of a candidate chicken prion protein. Proc Natl Acad Sci U S A 89 (19):9097-
9101. 
Gajdusek, D., and V. Zigas. 1959. Clinical, pathological and epidemiological study of an 
acute progressive degenerative disease of the central nervous system among natives of 
the eastern higlands of New Guinea. Am J Med 26:442-469. 
Gajdusek, D. C. 1988. Transmissible and non-transmissible amyloidoses: autocatalytic post-
translational conversion of host precursor proteins to beta-pleated sheet 
configurations. J Neuroimmunol 20 (2-3):95-110. 
Gambetti, P., Q. Kong, W. Zou, P. Parchi, and S. G. Chen. 2003. Sporadic and familial CJD: 
classification and characterisation. Br Med Bull 66:213-239. 
Gay, D., T. Saunders, S. Camper, and M. Weigert. 1993. Receptor editing: an approach by 
autoreactive B cells to escape tolerance. J Exp Med 177 (4):999-1008. 
Gerstmann, J., E. Straussler, and I. Scheinker. 1935. On a peculiar hereditary-congenital 
disease of the central nervous system - Along with an article on the question of 
premature ageing. Zeitschrift Fur Die Gesamte Neurologie Und Psychiatrie 154:736-
762. 
Gey, G. O., W. D. Coffman, and M. T. Kubicek. 1952. Tissue Culture Studies of the 
Proliferative Capacity of Cervical Carcinoma and Normal Epithelium. Cancer 
Research 12 (4):264-265. 
Gil, D., A. G. Schrum, B. Alarcon, and E. Palmer. 2005. T cell receptor engagement by 
peptide-MHC ligands induces a conformational change in the CD3 complex of 
thymocytes. J Exp Med 201 (4):517-522. 
  96
Goldfarb, L. G. 2002. Genetics and infectious disease: convergence at the prion. 
Epidemiology 13 (4):379-381. 
Goldfarb, L. G., P. Brown, E. Mitrova, L. Cervenakova, L. Goldin, A. D. Korczyn, J. 
Chapman, S. Galvez, L. Cartier, R. Rubenstein, and e. al. 1991. Creutzfeldt-Jacob 
disease associated with the PRNP codon 200Lys mutation: an analysis of 45 families. 
Eur.J.Epidemiol. 7:477-486. 
Goldrath, A. W., and M. J. Bevan. 1999. Selecting and maintaining a diverse T-cell 
repertoire. Nature 402 (6759):255-262. 
Goudsmit, J., R. G. Rohwer, E. K. Silbergeld, and D. C. Gajdusek. 1981. Hypersensitivity to 
central serotonin receptor activation in scrapie-infected hamsters and the effect of 
serotonergic drugs on scrapie symptoms. Brain Res 220 (2):372-377. 
Griffith, J. S. 1967. Self-replication and scrapie. Nature 215 (105):1043-1044. 
Gurdon, J. B. 1988. A community effect in animal development. Nature 336 (6201):772-774. 
Hadlow, W. J. 1999. Reflections on the transmissible spongiform encephalopathies. Vet 
Pathol 36 (6):523-529. 
Hadlow, W. J., R. C. Kennedy, and R. E. Race. 1982. Natural infection of Suffolk sheep with 
scrapie virus. J Infect Dis 146 (5):657-664. 
Hagman, J., and K. Lukin. 2006. Transcription factors drive B cell development. Curr Opin 
Immunol 18 (2):127-134. 
Haks, M. C., J. M. Lefebvre, J. P. Lauritsen, M. Carleton, M. Rhodes, T. Miyazaki, D. J. 
Kappes, and D. L. Wiest. 2005. Attenuation of gammadeltaTCR signaling efficiently 
diverts thymocytes to the alphabeta lineage. Immunity 22 (5):595-606. 
Haraguchi, T., S. Fisher, S. Olofsson, T. Endo, D. Groth, A. Tarentino, D. R. Borchelt, D. 
Teplow, L. Hood, A. Burlingame, and e. al. 1989. Asparagine-linked glycosylation of 
the scrapie and cellular prion proteins. Arch.Biochem.Biophys. 274:1-13. 
Hardy, R. R. 2003. B-cell commitment: deciding on the players. Curr Opin Immunol 15 
(2):158-165. 
Hardy, R. R., C. E. Carmack, S. A. Shinton, J. D. Kemp, and K. Hayakawa. 1991. Resolution 
and characterization of pro-B and pre-pro-B cell stages in normal mouse bone 
marrow. J Exp Med 173 (5):1213-1225. 
Hartley, S. B., J. Crosbie, R. Brink, A. B. Kantor, A. Basten, and C. C. Goodnow. 1991. 
Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes 
recognizing membrane-bound antigens. Nature 353 (6346):765-769. 
Hayakawa, K., M. Asano, S. A. Shinton, M. Gui, D. Allman, C. L. Stewart, J. Silver, and R. 
R. Hardy. 1999. Positive selection of natural autoreactive B cells. Science 285 
(5424):113-116. 
Hayes, S. M., L. Li, and P. E. Love. 2005. TCR signal strength influences 
alphabeta/gammadelta lineage fate. Immunity 22 (5):583-593. 
Hegde, R. S., and V. R. Lingappa. 1997. Membrane protein biogenesis: regulated complexity 
at the endoplasmic reticulum. Cell 91 (5):575-582. 
Hegde, R. S., J. A. Mastrianni, M. R. Scott, K. A. DeFea, P. Tremblay, M. Torchia, S. J. 
DeArmond, S. B. Prusiner, and V. R. Lingappa. 1998. A transmembrane form of the 
prion protein in neurodegenerative disease. Science 279 (5352):827-834. 
Hegde, R. S., P. Tremblay, D. Groth, S. J. DeArmond, S. B. Prusiner, and V. R. Lingappa. 
1999. Transmissible and genetic prion diseases share a common pathway of 
neurodegeneration Nature 402 (6763):822-826. 
Heikenwalder, M., N. Zeller, H. Seeger, M. Prinz, P. C. Klohn, P. Schwarz, N. H. Ruddle, C. 
Weissmann, and A. Aguzzi. 2005. Chronic lymphocytic inflammation specifies the 
organ tropism of prions. Science 307 (5712):1107-1110. 
  97
Hornemann, S., C. Korth, B. Oesch, R. Riek, G. Wider, K. Wuthrich, and R. Glockshuber. 
1997. Recombinant full-length murine prion protein, mPrP(23-231): purification and 
spectroscopic characterization. FEBS Lett 413 (2):277-281. 
Hsiao, K., H. F. Baker, T. J. Crow, M. Poulter, F. Owen, J. D. Terwilliger, D. Westaway, J. 
Ott, and S. B. Prusiner. 1989. Linkage of a prion protein missense variant to 
Gerstmann-Sträussler syndrome. Nature 338 (6213):342-345. 
Hsiao, K., Z. Meiner, E. Kahana, C. Cass, I. Kahana, D. Avrahami, G. Scarlato, O. Abramsky, 
S. B. Prusiner, and R. Gabizon. 1991. Mutation of the prion protein in Libyan Jews 
with Creutzfeldt-Jakob disease. N Engl J Med 324 (16):1091-1097. 
Hu, W., B. Kieseier, E. Frohman, T. N. Eagar, R. N. Rosenberg, H. P. Hartung, and O. Stuve. 
2008. Prion proteins: physiological functions and role in neurological disorders. J 
Neurol Sci 264 (1-2):1-8. 
Irving, B. A., F. W. Alt, and N. Killeen. 1998. Thymocyte development in the absence of pre-
T cell receptor extracellular immunoglobulin domains. Science 280 (5365):905-908. 
Isaacs, J. D., O. A. Garden, G. Kaur, J. Collinge, G. S. Jackson, and D. M. Altmann. 2008. 
The cellular prion protein is preferentially expressed by CD4+ CD25+ Foxp3+ 
regulatory T cells. Immunology 125 (3):313-319. 
Jakob, A. 1921. Über eigenartige Erkrankungen des Zentralnervensystems mit 
bemerkenswertem anatomischem Befunde. (Spastische Pseudosklerose-
Encephalomyelopathie mit disseminierten Degenerationsherden). Z. ges. Neurol. 
Psychiatr. 64:147-228. 
Jamieson, E., M. Jeffrey, J. W. Ironside, and J. R. Fraser. 2001. Apoptosis and dendritic 
dysfunction precede prion protein accumulation in 87V scrapie. Neuroreport 12 
(10):2147-2153. 
Jarrett, J. T., and P. T. Lansbury, Jr. 1993. Seeding "one-dimensional crystallization" of 
amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73 
(6):1055-1058. 
Jimenez-Huete, A., P. M. Lievens, R. Vidal, P. Piccardo, B. Ghetti, F. Tagliavini, B. 
Frangione, and F. Prelli. 1998. Endogenous proteolytic cleavage of normal and 
disease-associated isoforms of the human prion protein in neural and non-neural 
tissues. Am J Pathol 153 (5):1561-1572. 
Jordan, M. S., A. Boesteanu, A. J. Reed, A. L. Petrone, A. E. Holenbeck, M. A. Lerman, A. 
Naji, and A. J. Caton. 2001. Thymic selection of CD4+CD25+ regulatory T cells 
induced by an agonist self-peptide. Nat Immunol 2 (4):301-306. 
Jouvin-Marche, E., V. Attuil-Audenis, C. Aude-Garcia, W. Rachidi, M. Zabel, V. Podevin-
Dimster, C. Siret, C. Huber, M. Martinic, J. Riondel, C. L. Villiers, A. Favier, P. 
Naquet, J. Y. Cesbron, and P. N. Marche. 2006. Overexpression of cellular prion 
protein induces an antioxidant environment altering T cell development in the thymus. 
J Immunol 176 (6):3490-3497. 
Kane, M. D., W. J. Lipinski, M. J. Callahan, F. Bian, R. A. Durham, R. D. Schwarz, A. E. 
Roher, and L. C. Walker. 2000. Evidence for seeding of beta -amyloid by intracerebral 
infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic 
mice. J Neurosci 20 (10):3606-3611. 
Kaneko, K., M. Vey, M. Scott, S. Pilkuhn, F. E. Cohen, and S. B. Prusiner. 1997a. COOH-
terminal sequence of the cellular prion protein directs subcellular trafficking and 
controls conversion into the scrapie isoform. Proc Natl Acad Sci U S A 94 (6):2333-
2338. 
Kaneko, K., L. Zulianello, M. Scott, C. M. Cooper, A. C. Wallace, T. L. James, F. E. Cohen, 
and S. B. Prusiner. 1997b. Evidence for protein X binding to a discontinuous epitope 
on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci U S 
A 94 (19):10069-10074. 
  98
Kaplan, J., and D. M. Ward. 1990. Movement of receptors and ligands through the endocytic 
apparatus in alveolar macrophages. Am J Physiol 258 (6 Pt 1):L263-270. 
Khosravani, H., Y. Zhang, S. Tsutsui, S. Hameed, C. Altier, J. Hamid, L. Chen, M. 
Villemaire, Z. Ali, F. R. Jirik, and G. W. Zamponi. 2008. Prion protein attenuates 
excitotoxicity by inhibiting NMDA receptors. J Cell Biol 181 (3):551-565. 
Kitamura, D., J. Roes, R. Kuhn, and K. Rajewsky. 1991. A B cell-deficient mouse by targeted 
disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350 
(6317):423-426. 
Klohn, P. C., L. Stoltze, E. Flechsig, M. Enari, and C. Weissmann. 2003. A quantitative, 
highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc Natl Acad 
Sci U S A 100 (20):11666-11671. 
Knaus, K. J., M. Morillas, W. Swietnicki, M. Malone, W. K. Surewicz, and V. C. Yee. 2001. 
Crystal structure of the human prion protein reveals a mechanism for oligomerization. 
Nat Struct Biol 8 (9):770-774. 
Kondo, M., I. L. Weissman, and K. Akashi. 1997. Identification of clonogenic common 
lymphoid progenitors in mouse bone marrow. Cell 91 (5):661-672. 
Kontgen, F., G. Suss, C. Stewart, M. Steinmetz, and H. Bluethmann. 1993. Targeted 
disruption of the MHC class II Aa gene in C57BL/6 mice. Int Immunol 5 (8):957-964. 
Kornblatt, J. A., S. Marchal, H. Rezaei, M. J. Kornblatt, C. Balny, R. Lange, M. P. Debey, G. 
Hui Bon Hoa, M. C. Marden, and J. Grosclaude. 2003. The fate of the prion protein in 
the prion/plasminogen complex. Biochem Biophys Res Commun 305 (3):518-522. 
Kourie, J. I. 2001. Mechanisms of prion-induced modifications in membrane transport 
properties: implications for signal transduction and neurotoxicity. Chem Biol Interact 
138 (1):1-26. 
Kranich, J., N. J. Krautler, E. Heinen, M. Polymenidou, C. Bridel, A. Schildknecht, C. Huber, 
M. H. Kosco-Vilbois, R. Zinkernagel, G. Miele, and A. Aguzzi. 2008. Follicular 
dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. J Exp Med 
205 (6):1293-1302. 
Kretzschmar, H. A., L. E. Stowring, D. Westaway, W. H. Stubblebine, S. B. Prusiner, and S. 
J. DeArmond. 1986. Molecular cloning of a human prion protein cDNA. DNA 5:315-
324. 
Kubosaki, A., Y. Nishimura-Nasu, T. Nishimura, S. Yusa, A. Sakudo, K. Saeki, Y. 
Matsumoto, S. Itohara, and T. Onodera. 2003. Expression of normal cellular prion 
protein (PrP(c)) on T lymphocytes and the effect of copper ion: Analysis by wild-type 
and prion protein gene-deficient mice. Biochem Biophys Res Commun 307 (4):810-
813. 
Kubosaki, A., S. Yusa, Y. Nasu, T. Nishimura, Y. Nakamura, K. Saeki, Y. Matsumoto, S. 
Itohara, and T. Onodera. 2001. Distribution of cellular isoform of prion protein in T 
lymphocytes and bone marrow, analyzed by wild-type and prion protein gene-
deficient mice. Biochem Biophys Res Commun 282 (1):103-107. 
Kuhns, M. S., M. M. Davis, and K. C. Garcia. 2006. Deconstructing the form and function of 
the TCR/CD3 complex. Immunity 24 (2):133-139. 
Kuwahara, C., A. M. Takeuchi, T. Nishimura, K. Haraguchi, A. Kubosaki, Y. Matsumoto, K. 
Saeki, T. Yokoyama, S. Itohara, and T. Onodera. 1999. Prions prevent neuronal cell-
line death. Nature 400 (6741):225-226. 
Laffont-Proust, I., B. A. Faucheux, R. Hassig, V. Sazdovitch, S. Simon, J. Grassi, J. J. Hauw, 
K. L. Moya, and S. Haik. 2005. The N-terminal cleavage of cellular prion protein in 
the human brain. FEBS Lett. 
Laine, J., M. E. Marc, M. S. Sy, and H. Axelrad. 2001. Cellular and subcellular 
morphological localization of normal prion protein in rodent cerebellum. Eur J 
Neurosci 14 (1):47-56. 
  99
Lampert, P. W., D. C. Gajdusek, and C. J. Gibbs. 1972. Subacute spongiform virus 
encephalopathies. Scrapie, Kuru and Creutzfeldt-Jakob disease: a review. 
Am.J.Pathol. 68:626-652. 
Lazarus, L. 1985. Suspension of the Australian human pituitary hormone programme 
[editorial]. Med J Aust 143 (2):57-59. 
Le Pichon, C. E., M. T. Valley, M. Polymenidou, A. T. Chesler, B. T. Sagdullaev, A. Aguzzi, 
and S. Firestein. 2009. Olfactory behavior and physiology are disrupted in prion 
protein knockout mice. Nat Neurosci 12 (1):60-69. 
Legname, G., I. V. Baskakov, H. O. Nguyen, D. Riesner, F. E. Cohen, S. J. DeArmond, and 
S. B. Prusiner. 2004. Synthetic mammalian prions. Science 305 (5684):673-676. 
Li, A., H. Christensen, L. Stewart, K. Roth, R. Chiesa, and D. Harris. 2007. Neonatal lethality 
in transgenic mice expressing prion protein with a deletion of residues 105-125 
EMBO J 26 
 (2):548-558. 
Li, A., S. Sakaguchi, K. Shigematsu, R. Atarashi, B. C. Roy, R. Nakaoke, K. Arima, N. 
Okimura, J. Kopacek, and S. Katamine. 2000. Physiological expression of the gene for 
PrP-like protein, PrPLP/Dpl, by brain endothelial cells and its ectopic expression in 
neurons of PrP-deficient mice ataxic due to Purkinje cell degeneration. Am J Pathol 
157 (5):1447-1452. 
Liao, Y. C., R. V. Lebo, G. A. Clawson, and E. A. Smuckler. 1986. Human prion protein 
cDNA: molecular cloning, chromosomal mapping, and biological implications. 
Science 233 (4761):364-367. 
Lin, H., and R. Grosschedl. 1995. Failure of B-cell differentiation in mice lacking the 
transcription factor EBF. Nature 376 (6537):263-267. 
Linden, R., V. R. Martins, M. A. Prado, M. Cammarota, I. Izquierdo, and R. R. Brentani. 
2008. Physiology of the prion protein. Physiol Rev 88 (2):673-728. 
Liu, T., R. Li, B. S. Wong, D. Liu, T. Pan, R. B. Petersen, P. Gambetti, and M. S. Sy. 2001. 
Normal cellular prion protein is preferentially expressed on subpopulations of murine 
hemopoietic cells. J Immunol 166 (6):3733-3742. 
Llewelyn, C. A., P. E. Hewitt, R. S. Knight, K. Amar, S. Cousens, J. Mackenzie, and R. G. 
Will. 2004. Possible transmission of variant Creutzfeldt-Jakob disease by blood 
transfusion. Lancet 363 (9407):417-421. 
Loder, F., B. Mutschler, R. J. Ray, C. J. Paige, P. Sideras, R. Torres, M. C. Lamers, and R. 
Carsetti. 1999. B cell development in the spleen takes place in discrete steps and is 
determined by the quality of B cell receptor-derived signals. J Exp Med 190 (1):75-89. 
Lu, K., W. Wang, Z. Xie, B. S. Wong, R. Li, R. B. Petersen, M. S. Sy, and S. G. Chen. 2000. 
Expression and structural characterization of the recombinant human doppel protein(,) 
[In Process Citation]. Biochemistry 39 (44):13575-13583. 
Lundmark, K., G. T. Westermark, S. Nystrom, C. L. Murphy, A. Solomon, and P. 
Westermark. 2002. Transmissibility of systemic amyloidosis by a prion-like 
mechanism. Proc Natl Acad Sci U S A 99 (10):6979-6984. 
Mabbott, N. A., K. L. Brown, and M. E. Bruce. 1997. T lymphocyte activation and the 
cellular form of the prion protein, PrPc. Biochem Soc Trans 25 (2):307S. 
Mallucci, G., A. Dickinson, J. Linehan, P. C. Klohn, S. Brandner, and J. Collinge. 2003. 
Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. 
Science 302 (5646):871-874. 
Mallucci, G. R., M. D. White, M. Farmer, A. Dickinson, H. Khatun, A. D. Powell, S. 
Brandner, J. G. Jefferys, and J. Collinge. 2007. Targeting cellular prion protein 
reverses early cognitive deficits and neurophysiological dysfunction in prion-infected 
mice. Neuron 53 (3):325-335. 
  100
Mandal, M., C. Borowski, T. Palomero, A. A. Ferrando, P. Oberdoerffer, F. Meng, A. Ruiz-
Vela, M. Ciofani, J. C. Zuniga-Pflucker, I. Screpanti, A. T. Look, S. J. Korsmeyer, K. 
Rajewsky, H. von Boehmer, and I. Aifantis. 2005. The BCL2A1 gene as a pre-T cell 
receptor-induced regulator of thymocyte survival. J Exp Med 201 (4):603-614. 
Manderson, A. P., M. Botto, and M. J. Walport. 2004. The role of complement in the 
development of systemic lupus erythematosus. Annu Rev Immunol 22:431-456. 
Mange, A., F. Beranger, K. Peoc'h, T. Onodera, Y. Frobert, and S. Lehmann. 2004. Alpha- 
and beta- cleavages of the amino-terminus of the cellular prion protein. Biol Cell 96 
(2):125-132. 
Manson, J. C., A. R. Clarke, M. L. Hooper, L. Aitchison, I. McConnell, and J. Hope. 1994. 
129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are 
developmentally normal. Mol Neurobiol 8 (2-3):121-127. 
Manson, J. C., J. Hope, A. R. Clarke, A. Johnston, C. Black, and N. MacLeod. 1995. PrP gene 
dosage and long term potentiation. Neurodegeneration 4 (1):113-114. 
Marciano, P. G., J. Brettschneider, E. Manduchi, J. E. Davis, S. Eastman, R. Raghupathi, K. 
E. Saatman, T. P. Speed, C. J. Stoeckert, Jr., J. H. Eberwine, and T. K. McIntosh. 
2004. Neuron-specific mRNA complexity responses during hippocampal apoptosis 
after traumatic brain injury. J Neurosci 24 (12):2866-2876. 
Marsh, R. F., D. Burger, R. Eckroade, G. M. Zu Rhein, and R. P. Hanson. 1969. A 
preliminary report on the experimental host range of the transmissible mink 
encephalopathy agent. J Infect Dis 120 (6):713-719. 
Marshall, A. J., H. E. Fleming, G. E. Wu, and C. J. Paige. 1998. Modulation of the IL-7 dose-
response threshold during pro-B cell differentiation is dependent on pre-B cell 
receptor expression. J Immunol 161 (11):6038-6045. 
Marzio, R., J. Mauel, and S. Betz-Corradin. 1999. CD69 and regulation of the immune 
function. Immunopharmacol Immunotoxicol 21 (3):565-582. 
Mattei, V., T. Garofalo, R. Misasi, A. Circella, V. Manganelli, G. Lucania, A. Pavan, and M. 
Sorice. 2004. Prion protein is a component of the multimolecular signaling complex 
involved in T cell activation. FEBS Lett 560 (1-3):14-18. 
Mazzoni, I. E., H. C. Ledebur Jr, E. Paramithiotis, and N. Cashman. 2005. Lymphoid signal 
transduction mechanisms linked to cellular prion protein. Biochem Cell Biol 83 
(5):644-653. 
McCarthy, J. V., C. Twomey, and P. Wujek. 2009. Presenilin-dependent regulated 
intramembrane proteolysis and gamma-secretase activity. Cell Mol Life Sci. 
Medina, K. L., K. P. Garrett, L. F. Thompson, M. I. Rossi, K. J. Payne, and P. W. Kincade. 
2001. Identification of very early lymphoid precursors in bone marrow and their 
regulation by estrogen. Nat Immunol 2 (8):718-724. 
Medori, R., P. Montagna, H. J. Tritschler, A. LeBlanc, P. Cortelli, P. Tinuper, E. Lugaresi, 
and P. Gambetti. 1992. Fatal familial insomnia: a second kindred with mutation of 
prion protein gene at codon 178. Neurology 42 (3 Pt 1):669-670. 
Mellman, I. 1996. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 12:575-625. 
Meslin, F., A. Hamai, P. Gao, A. Jalil, N. Cahuzac, S. Chouaib, and M. Mehrpour. 2007. 
Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to 
TRAIL-mediated cell death. Cancer Res 67 (22):10910-10919. 
Meyer, R. K., M. P. McKinley, K. A. Bowman, M. B. Braunfeld, R. A. Barry, and S. B. 
Prusiner. 1986. Separation and properties of cellular and scrapie prion proteins. Proc 
Natl Acad Sci U S A 83 (8):2310-2314. 
Miller, J. P., D. Izon, W. DeMuth, R. Gerstein, A. Bhandoola, and D. Allman. 2002. The 
earliest step in B lineage differentiation from common lymphoid progenitors is 
critically dependent upon interleukin 7. J Exp Med 196 (5):705-711. 
  101
Misslitz, A., O. Pabst, G. Hintzen, L. Ohl, E. Kremmer, H. T. Petrie, and R. Forster. 2004. 
Thymic T cell development and progenitor localization depend on CCR7. J Exp Med 
200 (4):481-491. 
Miura, T., A. Hori-i, H. Mototani, and H. Takeuchi. 1999. Raman spectroscopic study on the 
copper(II) binding mode of prion octapeptide and its pH dependence. Biochemistry 38 
(35):11560-11569. 
Mo, H., R. C. Moore, F. E. Cohen, D. Westaway, S. B. Prusiner, P. E. Wright, and H. J. 
Dyson. 2001. Two different neurodegenerative diseases caused by proteins with 
similar structures. Proc Natl Acad Sci U S A 98 (5):2352-2357. 
Montrasio, F., A. Cozzio, E. Flechsig, D. Rossi, M. A. Klein, T. Rulicke, A. J. Raeber, C. A. 
Vosshenrich, J. Proft, A. Aguzzi, and C. Weissmann. 2001. B lymphocyte-restricted 
expression of prion protein does not enable prion replication in prion protein knockout 
mice. Proc Natl Acad Sci U S A 98 (7):4034-4037. 
Moore, R. C., I. Y. Lee, G. L. Silverman, P. M. Harrison, R. Strome, C. Heinrich, A. 
Karunaratne, S. H. Pasternak, M. A. Chishti, Y. Liang, P. Mastrangelo, K. Wang, A. 
F. Smit, S. Katamine, G. A. Carlson, F. E. Cohen, S. B. Prusiner, D. W. Melton, P. 
Tremblay, L. E. Hood, and D. Westaway. 1999. Ataxia in prion protein (PrP)-deficient 
mice is associated with upregulation of the novel PrP-like protein doppel [In Process 
Citation]. J Mol Biol 292 (4):797-817. 
Morris, R. J., C. J. Parkyn, and A. Jen. 2006. Traffic of prion protein between different 
compartments on the neuronal surface, and the propagation of prion disease. FEBS 
Lett. 
Muller-Eberhard, U., H. H. Liem, A. Hanstein, and P. A. Saarinen. 1969. Studies on the 
disposal of intravascular heme in the rabbit. J Lab Clin Med 73 (2):210-218. 
Nagata, K., T. Nakamura, F. Kitamura, S. Kuramochi, S. Taki, K. S. Campbell, and H. 
Karasuyama. 1997. The Ig alpha/Igbeta heterodimer on mu-negative proB cells is 
competent for transducing signals to induce early B cell differentiation. Immunity 7 
(4):559-570. 
Newton, K., A. W. Harris, and A. Strasser. 2000. FADD/MORT1 regulates the pre-TCR 
checkpoint and can function as a tumour suppressor. EMBO J 19 (5):931-941. 
Nico, P. B., F. de-Paris, E. R. Vinade, O. B. Amaral, I. Rockenbach, B. L. Soares, R. 
Guarnieri, L. Wichert-Ana, F. Calvo, R. Walz, I. Izquierdo, A. C. Sakamoto, R. 
Brentani, V. R. Martins, and M. M. Bianchin. 2005. Altered behavioural response to 
acute stress in mice lacking cellular prion protein. Behav Brain Res 162 (2):173-181. 
Nilsson, K. P., A. Herland, P. Hammarstrom, and O. Inganas. 2005. Conjugated 
polyelectrolytes: conformation-sensitive optical probes for detection of amyloid fibril 
formation. Biochemistry 44 (10):3718-3724. 
Nishimura, T., A. Sakudo, Y. Hashiyama, A. Yachi, K. Saeki, Y. Matsumoto, M. Ogawa, S. 
Sakaguchi, S. Itohara, and T. Onodera. 2007. Serum withdrawal-induced apoptosis in 
ZrchI prion protein (PrP) gene-deficient neuronal cell line is suppressed by PrP, 
independent of Doppel. Microbiol Immunol 51 (4):457-466. 
Nunziante, M., S. Gilch, and H. M. Schatzl. 2003. Essential role of the prion protein N 
terminus in subcellular trafficking and half-life of cellular prion protein. J Biol Chem 
278 (6):3726-3734. 
Oesch, B., D. Westaway, M. Walchli, M. P. McKinley, S. B. Kent, R. Aebersold, R. A. Barry, 
P. Tempst, D. B. Teplow, L. E. Hood, and C. Weissmann. 1985. A cellular gene 
encodes scrapie PrP 27-30 protein. Cell 40 (4):735-746. 
Oliver, A. M., F. Martin, G. L. Gartland, R. H. Carter, and J. F. Kearney. 1997. Marginal zone 
B cells exhibit unique activation, proliferative and immunoglobulin secretory 
responses. Eur J Immunol 27 (9):2366-2374. 
  102
Ott, D., C. Taraborrelli, and A. Aguzzi. 2008. Novel dominant-negative prion protein mutants 
identified from a randomized library. Protein Eng Des Sel 21 (10):623-629. 
Paitel, E., R. Fahraeus, and F. Checler. 2003. Cellular Prion Protein Sensitizes Neurons to 
Apoptotic Stimuli through Mdm2-regulated and p53-dependent Caspase 3-like 
Activation. J Biol Chem 278 (12):10061-10066. 
Pan, K. M., M. Baldwin, J. Nguyen, M. Gasset, A. Serban, D. Groth, I. Mehlhorn, Z. Huang, 
R. J. Fletterick, F. E. Cohen, and et al. 1993. Conversion of alpha-helices into beta-
sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S 
A 90 (23):10962-10966. 
Parchi, P., R. Castellani, S. Capellari, B. Ghetti, K. Young, S. G. Chen, M. Farlow, D. W. 
Dickson, A. A. F. Sima, J. Q. Trojanowski, R. B. Petersen, and P. Gambetti. 1996. 
Molecular Basis of Phenotypic Variability in Sporadic Creutzfeldt-Jakob Disease. 
Annals of Neurology 39 (6):767-778. 
Parchi, P., A. Giese, S. Capellari, P. Brown, W. Schulz-Schaeffer, O. Windl, I. Zerr, H. 
Budka, N. Kopp, P. Piccardo, S. Poser, A. Rojiani, N. Streichemberger, J. Julien, C. 
Vital, B. Ghetti, P. Gambetti, and H. Kretzschmar. 1999. Classification of sporadic 
Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. 
Ann Neurol 46 (2):224-233. 
Pattison, I. H., and G. C. Millson. 1961. Scrapie produced experimentally in goats with 
special reference to the clinical syndrome. J Comp Pathol 71:101-108. 
Peden, A. H., M. W. Head, D. L. Ritchie, J. E. Bell, and J. W. Ironside. 2004. Preclinical 
vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364 
(9433):527-529. 
Perry, S. S., L. J. Pierce, W. B. Slayton, and G. J. Spangrude. 2003. Characterization of 
thymic progenitors in adult mouse bone marrow. J Immunol 170 (4):1877-1886. 
Perry, S. S., H. Wang, L. J. Pierce, A. M. Yang, S. Tsai, and G. J. Spangrude. 2004. L-selectin 
defines a bone marrow analog to the thymic early T-lineage progenitor. Blood 103 
(8):2990-2996. 
Peters, P. J., A. Mironov, Jr., D. Peretz, E. van Donselaar, E. Leclerc, S. Erpel, S. J. 
DeArmond, D. R. Burton, R. A. Williamson, M. Vey, and S. B. Prusiner. 2003. 
Trafficking of prion proteins through a caveolae-mediated endosomal pathway. J Cell 
Biol 162 (4):703-717. 
Pillai, S., A. Cariappa, and S. T. Moran. 2004. Positive selection and lineage commitment 
during peripheral B-lymphocyte development. Immunol Rev 197:206-218. 
Polymenidou, M., R. Moos, M. Scott, C. Sigurdson, Y. Z. Shi, B. Yajima, I. Hafner-
Bratkovic, R. Jerala, S. Hornemann, K. Wuthrich, A. Bellon, M. Vey, G. Garen, M. N. 
James, N. Kav, and A. Aguzzi. 2008. The POM monoclonals: a comprehensive set of 
antibodies to non-overlapping prion protein epitopes. PLoS ONE 3 (12):e3872. 
Porritt, H. E., L. L. Rumfelt, S. Tabrizifard, T. M. Schmitt, J. C. Zuniga-Pflucker, and H. T. 
Petrie. 2004. Heterogeneity among DN1 prothymocytes reveals multiple progenitors 
with different capacities to generate T cell and non-T cell lineages. Immunity 20 
(6):735-745. 
Priola, S. A., B. Caughey, K. Wehrly, and B. Chesebro. 1995. A 60-kDa prion protein (PrP) 
with properties of both the normal and scrapie-associated forms of PrP. J Biol Chem 
270 (7):3299-3305. 
Prusiner, S. B. 1982. Novel proteinaceous infectious particles cause scrapie. Science 216 
(4542):136-144. 
———. 1991. Molecular biology of prion diseases. Science 252 (5012):1515-1522. 
Prusiner, S. B., D. Groth, A. Serban, R. Koehler, D. Foster, M. Torchia, D. Burton, S. L. 
Yang, and S. J. DeArmond. 1993. Ablation of the prion protein (PrP) gene in mice 
  103
prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci 
U S A 90 (22):10608-10612. 
Prusiner, S. B., M. P. McKinley, K. A. Bowman, D. C. Bolton, P. E. Bendheim, D. F. Groth, 
and G. G. Glenner. 1983. Scrapie prions aggregate to form amyloid-like birefringent 
rods. Cell 35 (2 Pt 1):349-358. 
Qi-Takahara, Y., M. Morishima-Kawashima, Y. Tanimura, G. Dolios, N. Hirotani, Y. 
Horikoshi, F. Kametani, M. Maeda, T. C. Saido, R. Wang, and Y. Ihara. 2005. Longer 
forms of amyloid beta protein: implications for the mechanism of intramembrane 
cleavage by gamma-secretase. J Neurosci 25 (2):436-445. 
Radovanovic, I., N. Braun, O. T. Giger, K. Mertz, G. Miele, M. Prinz, B. Navarro, and A. 
Aguzzi. 2005. Truncated Prion Protein and Doppel Are Myelinotoxic in the Absence 
of Oligodendrocytic PrPC. J. Neurosci. 25 (19):4879-4888. 
Raeber, A. J., A. Sailer, I. Hegyi, M. A. Klein, T. Rülicke, M. Fischer, S. Brandner, A. 
Aguzzi, and C. Weissmann. 1999. Ectopic expression of prion protein (PrP) in T 
lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion 
replication. Proc Natl Acad Sci U S A 96 (7):3987-3992. 
Rambold, A. S., V. Muller, U. Ron, N. Ben-Tal, K. F. Winklhofer, and J. Tatzelt. 2008. 
Stress-protective signalling of prion protein is corrupted by scrapie prions. EMBO J 27 
(14):1974-1984. 
Reichlin, A., Y. Hu, E. Meffre, H. Nagaoka, S. Gong, M. Kraus, K. Rajewsky, and M. C. 
Nussenzweig. 2001. B cell development is arrested at the immature B cell stage in 
mice carrying a mutation in the cytoplasmic domain of immunoglobulin beta. J Exp 
Med 193 (1):13-23. 
Riek, R., S. Hornemann, G. Wider, M. Billeter, R. Glockshuber, and K. Wüthrich. 1996. 
NMR structure of the mouse prion protein domain PrP(121-231). Nature 382 
(6587):180-182. 
Rivera-Milla, E., C. A. Stuermer, and E. Malaga-Trillo. 2003. An evolutionary basis for 
scrapie disease: identification of a fish prion mRNA. Trends Genet 19 (2):72-75. 
Roesler, R., R. Walz, J. Quevedo, F. de-Paris, S. M. Zanata, E. Graner, I. Izquierdo, V. R. 
Martins, and R. R. Brentani. 1999. Normal inhibitory avoidance learning and anxiety, 
but increased locomotor activity in mice devoid of PrP(C). Brain Res Mol Brain Res 
71 (2):349-353. 
Rogers, M., D. Serban, T. Gyuris, M. Scott, T. Torchia, and S. B. Prusiner. 1991. Epitope 
mapping of the Syrian hamster prion protein utilizing chimeric and mutant genes in a 
vaccinia virus expression system. J Immunol 147 (10):3568-3574. 
Rolink, A. G., T. Winkler, F. Melchers, and J. Andersson. 2000. Precursor B cell receptor-
dependent B cell proliferation and differentiation does not require the bone marrow or 
fetal liver environment. J Exp Med 191 (1):23-32. 
Rosen, H., C. Alfonso, C. D. Surh, and M. G. McHeyzer-Williams. 2003. Rapid induction of 
medullary thymocyte phenotypic maturation and egress inhibition by nanomolar 
sphingosine 1-phosphate receptor agonist. Proc Natl Acad Sci U S A 100 (19):10907-
10912. 
Rossi, D., A. Cozzio, E. Flechsig, M. A. Klein, A. Aguzzi, and C. Weissmann. 2001. Onset of 
ataxia and Purkinje cell loss in PrP null mice inversely  correlated with Dpl level in 
brain. EMBO J. 20 (4):1-9. 
Saa, P., J. Castilla, and C. Soto. 2006. Presymptomatic detection of prions in blood. Science 
313 (5783):92-94. 
Safar, J., P. P. Roller, D. C. Gajdusek, and C. J. Gibbs, Jr. 1993. Thermal stability and 
conformational transitions of scrapie amyloid (prion) protein correlate with infectivity. 
Protein Sci 2 (12):2206-2216. 
  104
Sailer, A., H. Büeler, M. Fischer, A. Aguzzi, and C. Weissmann. 1994. No propagation of 
prions in mice devoid of PrP. Cell 77 (7):967-968. 
Sakaguchi, S., S. Katamine, N. Nishida, R. Moriuchi, K. Shigematzu, T. Sugimoto, A. 
Nakatni, Y. Kataoka, H. Houtani, S. Shirabe, H. Okada, S. Hasegawa, T. Myamoto, 
and T. Noda. 1996. Loss of cerebellar Purkinje Cells in aged mice homozygous for a 
disrupted PrP gene. Nature 380:528-531. 
Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-
tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains 
(CD25). Breakdown of a single mechanism of self-tolerance causes various 
autoimmune diseases. J Immunol 155 (3):1151-1164. 
Sakudo, A., D. C. Lee, T. Nishimura, S. Li, S. Tsuji, T. Nakamura, Y. Matsumoto, K. Saeki, 
S. Itohara, K. Ikuta, and T. Onodera. 2005. Octapeptide repeat region and N-terminal 
half of hydrophobic region of prion protein (PrP) mediate PrP-dependent activation of 
superoxide dismutase. Biochem Biophys Res Commun 326 (3):600-606. 
Sambandam, A., I. Maillard, V. P. Zediak, L. Xu, R. M. Gerstein, J. C. Aster, W. S. Pear, and 
A. Bhandoola. 2005. Notch signaling controls the generation and differentiation of 
early T lineage progenitors. Nat Immunol 6 (7):663-670. 
Santuccione, A., V. Sytnyk, I. Leshchyns'ka, and M. Schachner. 2005. Prion protein recruits 
its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite 
outgrowth. J Cell Biol 169 (2):341-354. 
Schneider, K., H. Fangerau, B. Michaelsen, and W. H. Raab. 2008. The early history of the 
transmissible spongiform encephalopathies exemplified by scrapie. Brain Res Bull 77 
(6):343-355. 
Schwarz, B. A., and A. Bhandoola. 2004. Circulating hematopoietic progenitors with T 
lineage potential. Nat Immunol 5 (9):953-960. 
Scott, M., D. Foster, C. Mirenda, D. Serban, F. Coufal, M. Waelchli, M. Torchia, D. Groth, G. 
Carlson, S. J. DeArmond, D. Westaway, and S. B. Prusiner. 1989. Transgenic mice 
expressing hamster prion protein produce species-specific scrapie infectivity and 
amyloid plaques. Cell 59:847-857. 
Shmerling, D., I. Hegyi, M. Fischer, T. Blattler, S. Brandner, J. Gotz, T. Rulicke, E. Flechsig, 
A. Cozzio, C. von Mering, C. Hangartner, A. Aguzzi, and C. Weissmann. 1998. 
Expression of amino-terminally truncated PrP in the mouse leading to ataxia and 
specific cerebellar lesions. Cell 93 (2):203-214. 
Shyng, S. L., J. E. Heuser, and D. A. Harris. 1994. A glycolipid-anchored prion protein is 
endocytosed via clathrin-coated pits. J Cell Biol 125 (6):1239-1250. 
Shyng, S. L., M. T. Huber, and D. A. Harris. 1993. A prion protein cycles between the cell 
surface and an endocytic compartment in cultured neuroblastoma cells. J Biol Chem 
268 (21):15922-15928. 
Shyng, S. L., K. L. Moulder, A. Lesko, and D. A. Harris. 1995. The N-terminal domain of a 
glycolipid-anchored prion protein is essential for its endocytosis via clathrin-coated 
pits. J Biol Chem 270 (24):14793-14800. 
Shyu, W. C., S. Z. Lin, M. F. Chiang, D. C. Ding, K. W. Li, S. F. Chen, H. I. Yang, and H. Li. 
2005. Overexpression of PrPC by adenovirus-mediated gene targeting reduces 
ischemic injury in a stroke rat model. J Neurosci 25 (39):8967-8977. 
Sigurdson, C. J. 2008. A prion disease of cervids: chronic wasting disease. Vet Res 39 (4):41. 
Sigurdson, C. J., K. P. Nilsson, S. Hornemann, G. Manco, M. Polymenidou, P. Schwarz, M. 
Leclerc, P. Hammarstrom, K. Wuthrich, and A. Aguzzi. 2007. Prion strain 
discrimination using luminescent conjugated polymers. Nat Methods 4 (12):1023-
1030. 
Silverman, G. L., K. Qin, R. C. Moore, Y. Yang, P. Mastrangelo, P. Tremblay, S. B. Prusiner, 
F. E. Cohen, and D. Westaway. 2000. Doppel is an N-glycosylated, 
  105
glycosylphosphatidylinositol-anchored protein. Expression in testis and ectopic 
production in the brains of Prnp(0/0) mice predisposed to Purkinje cell loss. J Biol 
Chem 275 (35):26834-26841. 
Simonic, T., S. Duga, B. Strumbo, R. Asselta, F. Ceciliani, and S. Ronchi. 2000. cDNA 
cloning of turtle prion protein. FEBS Lett 469 (1):33-38. 
Smith, P. G., and R. Bradley. 2003. Bovine spongiform encephalopathy (BSE) and its 
epidemiology. Br Med Bull 66:185-198. 
Sparkes, R. S., M. Simon, V. H. Cohn, R. E. Fournier, J. Lem, I. Klisak, C. Heinzmann, C. 
Blatt, M. Lucero, T. Mohandas, and et al. 1986. Assignment of the human and mouse 
prion protein genes to homologous chromosomes. Proc Natl Acad Sci U S A 83 
(19):7358-7362. 
Stahl, N., D. R. Borchelt, K. Hsiao, and S. B. Prusiner. 1987. Scrapie prion protein contains a 
phosphatidylinositol glycolipid. Cell 51 (2):229-240. 
Starr, T. K., S. C. Jameson, and K. A. Hogquist. 2003. Positive and negative selection of T 
cells. Annu Rev Immunol 21:139-176. 
Steele, A. D., J. G. Emsley, P. H. Ozdinler, S. Lindquist, and J. D. Macklis. 2006. Prion 
protein (PrPc) positively regulates neural precursor proliferation during developmental 
and adult mammalian neurogenesis. Proc Natl Acad Sci U S A 103 (9):3416-3421. 
Stefani, M., and C. M. Dobson. 2003. Protein aggregation and aggregate toxicity: new 
insights into protein folding, misfolding diseases and biological evolution. J Mol Med 
81 (11):678-699. 
Stohr, J., N. Weinmann, H. Wille, T. Kaimann, L. Nagel-Steger, E. Birkmann, G. Panza, S. B. 
Prusiner, M. Eigen, and D. Riesner. 2008. Mechanisms of prion protein assembly into 
amyloid. Proc Natl Acad Sci U S A 105 (7):2409-2414. 
Strumbo, B., S. Ronchi, L. C. Bolis, and T. Simonic. 2001. Molecular cloning of the cDNA 
coding for Xenopus laevis prion protein. FEBS Letters 508 (2):170-174. 
Sunyach, C., A. Jen, J. Deng, K. T. Fitzgerald, Y. Frobert, J. Grassi, M. W. McCaffrey, and 
R. Morris. 2003. The mechanism of internalization of glycosylphosphatidylinositol-
anchored prion protein. EMBO J 22 (14):3591-3601. 
Suzuki, T., T. Kurokawa, H. Hashimoto, and M. Sugiyama. 2002. cDNA sequence and tissue 
expression of Fugu rubripes prion protein-like: a candidate for the teleost orthologue 
of tetrapod PrPs. Biochem Biophys Res Commun 294 (4):912-917. 
Taraboulos, A., K. Jendroska, D. Serban, S. L. Yang, S. J. DeArmond, and S. B. Prusiner. 
1992a. Regional mapping of prion proteins in brain. Proc Natl Acad Sci U S A 89 
(16):7620-7624. 
Taraboulos, A., A. J. Raeber, D. R. Borchelt, D. Serban, and S. B. Prusiner. 1992b. Synthesis 
and trafficking of prion proteins in cultured cells. Mol Biol Cell 3 (8):851-863. 
Taraboulos, A., M. Scott, A. Semenov, D. Avrahami, L. Laszlo, S. B. Prusiner, and D. 
Avraham. 1995. Cholesterol depletion and modification of COOH-terminal targeting 
sequence of the prion protein inhibit formation of the scrapie isoform [published 
erratum appears in J Cell Biol 1995 Jul;130(2):501]. J Cell Biol 129 (1):121-132. 
Tarakhovsky, A., S. B. Kanner, J. Hombach, J. A. Ledbetter, W. Muller, N. Killeen, and K. 
Rajewsky. 1995. A role for CD5 in TCR-mediated signal transduction and thymocyte 
selection. Science 269 (5223):535-537. 
Taylor, D. R., N. T. Watt, W. S. Perera, and N. M. Hooper. 2005. Assigning functions to 
distinct regions of the N-terminus of the prion protein that are involved in its copper-
stimulated, clathrin-dependent endocytosis. J Cell Sci 118 (Pt 21):5141-5153. 
Testi, R., D. D'Ambrosio, R. De Maria, and A. Santoni. 1994. The CD69 receptor: a 
multipurpose cell-surface trigger for hematopoietic cells. Immunol Today 15 (10):479-
483. 
  106
Testi, R., J. H. Phillips, and L. L. Lanier. 1989. Leu 23 induction as an early marker of 
functional CD3/T cell antigen receptor triggering. Requirement for receptor cross-
linking, prolonged elevation of intracellular [Ca++] and stimulation of protein kinase 
C. J Immunol 142 (6):1854-1860. 
Thadani, V., P. L. Penar, J. Partington, R. Kalb, R. Janssen, L. B. Schonberger, C. S. Rabkin, 
and J. W. Prichard. 1988. Creutzfeldt-Jakob disease probably acquired from a 
cadaveric dura mater graft. Case report J Neurosurg 69 (5):766-769. 
Thomson, C. W., B. P. Lee, and L. Zhang. 2006. Double-negative regulatory T cells: non-
conventional regulators. Immunol Res 35 (1-2):163-178. 
Tibes, R., J. Trent, and R. Kurzrock. 2005. Tyrosine kinase inhibitors and the dawn of 
molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 45:357-384. 
Tiegs, S. L., D. M. Russell, and D. Nemazee. 1993. Receptor editing in self-reactive bone 
marrow B cells. J Exp Med 177 (4):1009-1020. 
Tlsty, T. D., and L. M. Coussens. 2006. Tumor stroma and regulation of cancer development. 
Annu Rev Pathol 1:119-150. 
Tobler, I., S. E. Gaus, T. Deboer, P. Achermann, M. Fischer, T. Rülicke, M. Moser, B. Oesch, 
P. A. McBride, and J. C. Manson. 1996. Altered circadian activity rhythms and sleep 
in mice devoid of prion protein. Nature 380 (6575):639-642. 
Todaro, G. J., and H. Green. 1963. Quantitative studies of the growth of mouse embryo cells 
in culture and their development into established lines. J Cell Biol 17:299-313. 
Tsutsui, S., J. N. Hahn, T. A. Johnson, Z. Ali, and F. R. Jirik. 2008. Absence of the cellular 
prion protein exacerbates and prolongs neuroinflammation in experimental 
autoimmune encephalomyelitis. Am J Pathol 173 (4):1029-1041. 
Tveit, H., C. Lund, C. M. Olsen, C. Ersdal, K. Prydz, I. Harbitz, and M. A. Tranulis. 2005. 
Proteolytic processing of the ovine prion protein in cell cultures. Biochem Biophys Res 
Commun 337 (1):232-240. 
Ueno, T., F. Saito, D. H. Gray, S. Kuse, K. Hieshima, H. Nakano, T. Kakiuchi, M. Lipp, R. L. 
Boyd, and Y. Takahama. 2004. CCR7 signals are essential for cortex-medulla 
migration of developing thymocytes. J Exp Med 200 (4):493-505. 
Viles, J. H., F. E. Cohen, S. B. Prusiner, D. B. Goodin, P. E. Wright, and H. J. Dyson. 1999. 
Copper binding to the prion protein: structural implications of four identical 
cooperative binding sites [In Process Citation]. Proc Natl Acad Sci U S A 96 (5):2042-
2047. 
Vincent, B., E. Paitel, Y. Frobert, S. Lehmann, J. Grassi, and F. Checler. 2000. Phorbol ester-
regulated cleavage of normal prion protein in HEK293 human cells and murine 
neurons. J Biol Chem 275 (45):35612-35616. 
Vincent, B., E. Paitel, P. Saftig, Y. Frobert, D. Hartmann, B. De Strooper, J. Grassi, E. Lopez-
Perez, and F. Checler. 2001. The disintegrins ADAM10 and TACE contribute to the 
constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. 
J Biol Chem 276 (41):37743-37746. 
Walker, L. C., M. J. Callahan, F. Bian, R. A. Durham, A. E. Roher, and W. J. Lipinski. 2002. 
Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice. 
Peptides 23 (7):1241-1247. 
Walmsley, A. R., N. T. Watt, D. R. Taylor, W. S. Perera, and N. M. Hooper. 2008. alpha-
cleavage of the prion protein occurs in a late compartment of the secretory pathway 
and is independent of lipid rafts. Mol Cell Neurosci. 
Walz, R., O. B. Amaral, I. C. Rockenbach, R. Roesler, I. Izquierdo, E. A. Cavalheiro, V. R. 
Martins, and R. R. Brentani. 1999. Increased sensitivity to seizures in mice lacking 
cellular prion protein. Epilepsia 40 (12):1679-1682. 
Wang, L. D., and M. R. Clark. 2003. B-cell antigen-receptor signalling in lymphocyte 
development. Immunology 110 (4):411-420. 
  107
Ward, D. M., and J. Kaplan. 1990. The rate of internalization of different receptor-ligand 
complexes in alveolar macrophages is receptor-specific. Biochem J 270 (2):369-374. 
Watt, N. T., D. R. Taylor, A. Gillott, D. A. Thomas, W. S. Perera, and N. M. Hooper. 2005. 
Reactive Oxygen Species-mediated {beta}-Cleavage of the Prion Protein in the 
Cellular Response to Oxidative Stress. J Biol Chem 280 (43):35914-35921. 
Wegner, C., A. Romer, R. Schmalzbauer, H. Lorenz, O. Windl, and H. A. Kretzschmar. 2002. 
Mutant prion protein acquires resistance to protease in mouse neuroblastoma cells. J 
Gen Virol 83 (Pt 5):1237-1245. 
Weise, J., R. Sandau, S. Schwarting, O. Crome, A. Wrede, W. Schulz-Schaeffer, I. Zerr, and 
M. Bahr. 2006. Deletion of cellular prion protein results in reduced Akt activation, 
enhanced postischemic caspase-3 activation, and exacerbation of ischemic brain 
injury. Stroke 37 (5):1296-1300. 
Weissmann, C. 1991. A 'unified theory' of prion propagation. Nature 352 (6337):679-683. 
———. 1999. Molecular genetics of transmissible spongiform encephalopathies. J Biol Chem 
274 (1):3-6. 
Weissmann, C., and A. Aguzzi. 1997. Bovine spongiform encephalopathy and early onset 
variant Creutzfeldt- Jakob disease. Curr Opin Neurobiol 7 (5):695-700. 
Westaway, D., C. Cooper, S. Turner, M. Da Costa, G. A. Carlson, and S. B. Prusiner. 1994a. 
Structure and polymorphism of the mouse prion protein gene. Proc Natl Acad Sci U S 
A 91 (14):6418-6422. 
Westaway, D., S. J. DeArmond, J. Cayetano Canlas, D. Groth, D. Foster, S. L. Yang, M. 
Torchia, G. A. Carlson, and S. B. Prusiner. 1994b. Degeneration of skeletal muscle, 
peripheral nerves, and the central nervous system in transgenic mice overexpressing 
wild-type prion proteins. Cell 76 (1):117-129. 
Westaway, D., P. A. Goodman, C. A. Mirenda, M. P. McKinley, G. A. Carlson, and S. B. 
Prusiner. 1987. Distinct prion proteins in short and long scrapie incubation period 
mice. Cell 51 (4):651-662. 
Westaway, D., C. A. Mirenda, D. Foster, Y. Zebarjadian, M. Scott, M. Torchia, S. L. Yang, 
H. Serban, S. J. DeArmond, C. Ebeling, and et al. 1991. Paradoxical shortening of 
scrapie incubation times by expression of prion protein transgenes derived from long 
incubation period mice. Neuron 7 (1):59-68. 
Whittington, M. A., K. C. Sidle, I. Gowland, J. Meads, A. F. Hill, M. S. Palmer, J. G. 
Jefferys, and J. Collinge. 1995. Rescue of neurophysiological phenotype seen in PrP 
null mice by transgene encoding human prion protein. Nat Genet 9 (2):197-201. 
Will, R. G., J. W. Ironside, M. Zeidler, S. N. Cousens, K. Estibeiro, A. Alperovitch, S. Poser, 
M. Pocchiari, A. Hofman, and P. G. Smith. 1996. A new variant of Creutzfeldt-Jakob 
disease in the UK. Lancet 347 (9006):921-925. 
Williams, E. S., and S. Young. 1980. Chronic wasting disease of captive mule deer: a 
spongiform encephalopathy. J Wildl Dis 16 (1):89-98. 
———. 1982. Spongiform encephalopathy of Rocky Mountain elk. J Wildl Dis 18 (4):465-
471. 
Witt, C. M., and E. A. Robey. 2004. The ins and outs of CCR7 in the thymus. J Exp Med 200 
(4):405-409. 
Wroe, S. J., S. Pal, D. Siddique, H. Hyare, R. Macfarlane, S. Joiner, J. M. Linehan, S. 
Brandner, J. D. Wadsworth, P. Hewitt, and J. Collinge. 2006. Clinical presentation and 
pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood 
transfusion: a case report. Lancet 368 (9552):2061-2067. 
Wu, C., W. Pang, J. Yang, X. Zhou, and D. Zhao. 2006a. Amino acid sequence of the 
Pekingese dog prion protein gene. Xenotransplantation 13 (5):471-474. 
  108
Wu, C. D., W. Y. Pang, J. M. Yang, X. M. Zhou, and D. M. Zhao. 2006b. Amino acid 
sequence of the Pekingese dog prion protein gene. Xenotransplantation 13 (5):471-
474. 
Xing, Y., A. Nakamura, T. Chiba, K. Kogishi, T. Matsushita, F. Li, Z. Guo, M. Hosokawa, M. 
Mori, and K. Higuchi. 2001. Transmission of mouse senile amyloidosis. Lab Invest 81 
(4):493-499. 
Xing, Y., A. Nakamura, T. Korenaga, Z. Guo, J. Yao, X. Fu, T. Matsushita, K. Kogishi, M. 
Hosokawa, F. Kametani, M. Mori, and K. Higuchi. 2002. Induction of protein 
conformational change in mouse senile amyloidosis. J Biol Chem 277 (36):33164-
33169. 
Yadavalli, R., R. P. Guttmann, T. Seward, A. P. Centers, R. A. Williamson, and G. C. Telling. 
2004. Calpain-dependent endoproteolytic cleavage of PrPSc modulates scrapie prion 
propagation. J Biol Chem. 
Yamasaki, S., E. Ishikawa, M. Sakuma, K. Ogata, K. Sakata-Sogawa, M. Hiroshima, D. L. 
Wiest, M. Tokunaga, and T. Saito. 2006. Mechanistic basis of pre-T cell receptor-
mediated autonomous signaling critical for thymocyte development. Nat Immunol 7 
(1):67-75. 
Zabel, M., C. Greenwood, A. M. Thackray, B. Pulford, W. Rens, and R. Bujdoso. 2008. 
Perturbation of T-cell development by insertional mutation of a PrP transgene. 
Immunology. 
Zahn, R., A. Liu, T. Luhrs, R. Riek, C. von Schroetter, F. Lopez Garcia, M. Billeter, L. 
Calzolai, G. Wider, and K. Wuthrich. 2000. NMR solution structure of the human 
prion protein. Proc Natl Acad Sci U S A 97 (1):145-150. 
Zamoyska, R., and M. Lovatt. 2004. Signalling in T-lymphocyte development: integration of 
signalling pathways is the key. Curr Opin Immunol 16 (2):191-196. 
Zanata, S. M., M. H. Lopes, A. F. Mercadante, G. N. Hajj, L. B. Chiarini, R. Nomizo, A. R. 
Freitas, A. L. Cabral, K. S. Lee, M. A. Juliano, E. De Oliveira, S. G. Jachieri, A. 
Burlingame, L. Huang, R. Linden, R. R. Brentani, and V. R. Martins. 2002. Stress-
inducible protein 1 is a cell surface ligand for cellular prion that triggers 
neuroprotection. EMBO J 21 (13):3307-3316. 
Zhang, C. C., A. D. Steele, S. Lindquist, and H. F. Lodish. 2006. Prion protein is expressed on 
long-term repopulating hematopoietic stem cells and is important for their self-
renewal. Proc Natl Acad Sci U S A 103 (7):2184-2189. 
Zhang, Z. X., L. Yang, K. J. Young, B. DuTemple, and L. Zhang. 2000. Identification of a 
previously unknown antigen-specific regulatory T cell and its mechanism of 
suppression. Nat Med 6 (7):782-789. 
Zhao, G., M. Z. Cui, G. Mao, Y. Dong, J. Tan, L. Sun, and X. Xu. 2005. gamma-Cleavage is 
dependent on zeta-cleavage during the proteolytic processing of amyloid precursor 
protein within its transmembrane domain. J Biol Chem 280 (45):37689-37697. 
Zomosa-Signoret, V., J. D. Arnaud, P. Fontes, M. T. Alvarez-Martinez, and J. P. Liautard. 
2008. Physiological role of the cellular prion protein. Vet Res 39 (4):9. 
 
 
 
  109
Acknowledgements 
 
In these years at the Institute of Neuropathology there have been major 
transformations in my personality. From these transformations I highlight a high gain 
in scientific and professional maturity, which should be credited to the positive 
influence of Prof. Adriano Aguzzi. In addition, I thank Prof. Adriano Aguzzi for his 
supervision, support and important advice. 
 
During this PhD, my major peaks of learning, enthusiasm, and happiness at work 
correlated with the periods of closer interaction with Dr. Sei-Ichi Yusa. I therefore 
thank Dr. Sei-Ichi Yusa for his help, patience, discussions, ideas, and for his 
friendship. 
 
I thank all lab colleagues for their help and friendship, with special relevance to 
Claire Bridel, Frank Baumann, Sophorn Chip, David Ott, Anna Maria Calella, Jan 
Kranich, Nike Kräutler, Lena Stallmach, Dimitri Goriounov, Rita Moos, Petra Schwarz 
 
I thank the important support of my family and friends. 
 
I thank the Instituto Gulbenkian de Ciência and the PGDB directors, with special 
reference to Dr. Sukalyan Chatergee, for accepting me in the PGDB. I also thank 
Instituto Gulbenkian de Ciência and Fundação para a Ciência e Tecnologia for 
funding this PhD. 
 
I thank all the people that helped me professionally, with special reference to Dr. M. 
Gabriela M. Gomes. 
 
Finally I thank the support of the members of my PhD committee Prof. Annette 
Oxenius and Prof. Burkhard Becher. 
  110
Curriculum Vitae 
IDENTITY: 
 
BIRTH 
NATIONALITY 
 
1980-12-08 - Portugal 
Portuguese 
 
ACADEMIC DEGREES: 
 
 2003 - Degree in Biology at University of Évora – Portugal 
Graduation Thesis: “Modeling Epidemiology and Evolution of Influenza A Virus” 
AWARDS: 
 
 2002 - Merit scholarship for best student of Biology of University of Évora – Portugal 
– in the year 2000/01. 
FELLOWSHIPS: 
 
 2004-2008 – PhD Fellowship from Portuguese Foundation for Science and 
Technology  
 2003-2004 – Gulbenkian Foundation Fellowship for Gulbenkian PhD Program in 
Biomedicine 
 2003 – PRODEP Fellowship awarded via University of Évora - Portugal, for training 
at Gulbenkian Institute of Science - Portugal  
PUBLICATIONS: 
 
  In preparation: José B. Oliveira-Martins, Sei-ichi Yusa, Anna Maria Calella, Claire 
Bridel, Frank Baumann and Adriano Aguzzi: Alpha-Cleavage of the Prion Protein 
tolerates sequence degeneration and is controlled by length of domain 106-119. 
 2006 - Dinis Gökaydin, José B. Oliveira-Martins, Isabel Gordo and M. Gabriela M. 
Gomes: The reinfection threshold regulates pathogen diversity: the case of Influenza. 
J. R. Soc. Interface 
REFEREE REPORTS: 
   Refereed for the journal “Biology Letters” from the Royal Society of London. 
WORKING EXPERIENCE: 
 
  Since Jan 2005: Researcher at the Institute for Neuropathology of the University 
Hospital of Zurich – Switzerland, supervised by Adriano Aguzzi. 
Project Title: Candidate approach study of the main areas in PrPC Central Domain 
involved in regulation of PrPC cleavage at 109KH110.  
Project Title: Study the physiological function of PrPC in Lymphocyte homeostasis 
 May 2004 - Dec 2004: Researcher at the Lymphocyte Physiology Group of Instituto 
Gulbenkian de Ciência – Portugal, supervised by Jocelyne Demengeot. 
    Project Title: Live imaging of lymphocyte motility by intravital microscopy 
 Sep 2002 - Sep 2003: Researcher at the Theoretical Epidemiology Group of Instituto 
Gulbenkian de Ciência – Portugal, supervised by M Gabriela M Gomes. 
Project Title: Mathematical Modeling of Epidemiology and Evolution of Influenza A 
Virus 
  Apr 2001 - Oct 2001: Researcher at the Arachnology Group of University of Évora – 
Portugal, supervised by Carola Meierrose  
Project Title: Biodiversity studies in fallows of varied duration in the area of Castro 
Verde (Southern Alentejo, Portugal) – Spider fauna 
  111
 
